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The basic leucine zipper transcription factor E4bp4 is essential for various immunological 
processes, most notably the development of natural killer (NK) cells.  E4bp4 is required at 
the point of lineage commitment when NK cell progenitors develop from common lymphoid 
progenitors. E4bp4 promotes NK cell development by directly regulating the expression of 
other transcription factors, including Eomes and Id2. Despite its critical role, little is known 
about how the functions of the E4bp4 protein are regulated within the cellular environment. 
This study demonstrates that E4bp4 is post translationally modified by phosphorylation and 
SUMOylation and that these modifications directly regulate the protein’s function.  In the 
absence of either modification, E4bp4 is both a more potent transcriptional activator and 
transcriptional repressor. In NK cells, the absence of post translational modifications on 
E4bp4 promotes the expression of target genes Notch1 and E2A. Most strikingly, when 
expressed in hematopoietic progenitor cells, versions of E4bp4 lacking phosphorylation or 
SUMOylation sites, promote the development of up to three times more NK cells than the 
wild type form of E4bp4. This work has implications for the production of NK cells for use in 
immunotherapy and provides the first evidence that SUMOylation of an individual 
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1.1 Natural Killer cells 
Natural Killer (NK) cells are large granular lymphocytes that sit at the interface between 
innate and adaptive immunity. NK cells were first identified nearly forty years ago by their 
ability to kill certain target cells in vitro without prior sensitisation and were described as 
‘cytolytic effector lymphocytes’ (Herberman et al., 1975) (Kiessling et al., 1975). NK cells 
were distinguished from B and T lymphocytes by their lack of B and T cell surface antigens 
and their ability to develop in mice and humans that were unable to rearrange their antigen 
receptor genes (Hackett et al., 1986). NK cells rely on a collection of germline encoded 
activating and inhibitory receptors that recognise target cells and determine whether NK cell 
effector functions are triggered, killing the target cell (Vivier et al., 2008). 
 
NK cells are classically part of the innate immune system, where they represent one of the 
first lines of defence against infection and are important for tumour immunosurveillance, graft 
rejection and during pregnancy (Di Santo, 2008).  NK cells produce an array of cytokines 
and chemokines, often in response to interactions with antigen-presenting cells, and these 
can influence and augment adaptive immune responses (Vivier et al., 2011). Some studies 
have shown that NK cells can also mount antigen-specific memory responses and long-lived 
‘memory’ NK cells can arise following encounters with certain pathogens (Sun et al., 2011) 
(Sun et al., 2012). Therefore, NK cells have a unique biological niche covering both innate 
and adaptive halves of the immune system. NK cells have been extensively studied in mice, 




1.1.1 NK cell functions 
NK cells are characterised by a number of effector functions. Most notably, NK cells can 
spontaneously lyse susceptible target cells by the exocytosis of perforin and cytoplasmic 
granules containing numerous granzymes. Perforins create holes in the cell surface of target 
cells, whilst granzymes activate apoptosis pathways in the targeted cell (Topham and Hewitt, 
2009). NK cells can also eliminate targets via Fas-L and Trail-mediated apoptosis pathways, 
which are stimulated following ligand binding, receptor oligomersiation and recruitment of 
adaptor proteins to death domain receptors (Warren and Smyth, 1999). 
 
Kärre et al. performed pioneering early work into the activities of NK cells, demonstrating 
that NK cells are able to lyse cells that lack expression of major histocompatibility complex 
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class I (MHC-I) (Karre et al., 1986). This work led to the formation of the ‘missing self’ 
hypothesis, where the predominant targets for NK cell cytolytic activity are cells which down 
regulate MHC-I, such as virally infected cells and tumours (Karre et al., 1986). Inhibitory 
receptors (such as Ly49 receptors in mice and killer cell immunoglobulin-like receptors 
(KIRs) in humans) on the surface of NK cells recognise MHC-I ligands on healthy cells. 
Upon interaction with MHC ligands, inhibitory receptors recruit tyrosine phosphatases (SHP-
1 and SHP-2) to their cytoplasmic domains and these are able to block activation signals, 
therefore preventing a target cell from being killed (Cooper et al., 2001) (Pegram et al., 
2011). Different subsets of NK cells express different inhibitory receptors, including many 
non-MHC-binding inhibitory receptors, with most cells expressing more than one, as this 
allows the global pool of NK cells to carefully monitor self-MHC molecules and react when 
MHC expression is perturbed by disease (Cooper et al., 2001) (Pegram et al., 2011). 
 
Inhibitory receptors do not work in isolation but alongside a large collection of activating 
receptors, including NKG2D, NKp46 and the CD94/NKG2C complex (Koch et al., 2013). 
Through a large number of activating receptor-coupled-adapters NK cells are able to achieve 
their diverse number of functional activities (Koch et al., 2013). Not all activating receptor 
ligands have been defined but some are known to be unregulated on stressed cells, e.g. 
MICA and MICB on tumour cells, which are recognised by NKG2D (Weiss-Steider et al., 
2011). The activating receptor CD16 can trigger antibody-dependent cellular cytotoxicity by 
encountering target cells opsonised with IgG (Moretta et al., 2008). NK cell activity is a fine 
balance between activating and inhibitory signals and target cell killing is initiated when this 
balance is perturbed (Topham and Hewitt, 2009) (Vivier et al., 2008). NK cell triggering is not 
only caused by a lack of MHC-I, but can also be caused by cytokine stimulation or the 
presence of large numbers of stimulatory molecules (Colucci et al., 2002). NK cells can 
respond to missing, altered, stressed or non-self situations, and the ‘missing self hypothesis’ 
is now more commonly described as the dynamic equilibrium concept (Vivier et al., 2011). 
 
An equally important function of NK cells is their ability to rapidly produce cytokines, most 
commonly interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α), but also in 
some instances granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-10 
(Perussia et al., 2005). These cytokines can reinforce TH1 differentiation of T cells in 
secondary lymphoid organs and also promote the maturation of dendritic cells (Walzer et al., 
2005). NK cells can also produce a number of chemokines, such as MIP-1α, MIP-1β and 
RANTES, which are used to promote inflammatory responses and attract leukocytes to sites 
of infection or injury (Perussia et al., 2005) (Vivier et al., 2008). Using these functions NK 
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cells can eliminate unwanted target cells, through various non-redundant pathways, and 
promote inflammatory immune responses. 
 
NK cells are formally members of the innate immune response, but recent evidence 
suggests that, in certain situations, NK cells may mediate some long-lived memory-like 
responses, which is a central attribute of the adaptive immune system (Sun et al., 2009). In 
C57BL/6 mice infected with murine cytomegalovirus (MCMV), a population of NK cells 
expressing the activating receptor Ly49H were found to be expanded and these cells were 
long-lived, possibly surviving for up to 70 days (Sun et al., 2009). On secondary challenge 
with MCMV, these cells proliferated in an IL-12-dependent manner, were highly cytotoxic 
and produced large quantities of cytokines, which provided enhanced protection against 
secondary viral challenge (Sun et al., 2009) (Sun et al., 2012). A similar occurrence has 
been observed in human transplant patients, where a mature NKG2C+ memory-like NK cell 
population expands, is long-lived and has enhanced responsiveness to secondary CMV 
infection (Foley et al., 2012) (Lopez-Verges et al., 2011). 
 
NK cells have essential activities in preventing tumour initiation, halting tumour development 
and controlling several types of viral infection, including MCMV and herpes virus in humans 
(Vivier et al., 2008). This is demonstrated by individuals who selectively lack NK cells and 
exhibit increased susceptibility to viral infections, especially herpes viruses and have an 
increased tumour incidence (Orange, 2006). For example, a large cohort study of Japanese 
people aged over 40 indicated a direct correlation between low NK cytotoxicity and elevated 
cancer incidence (Imai et al., 2000). 
 
 
1.1.2 Innate lymphoid cells 
NK cells are the founding members of the recently defined family of leukocytes that are 
collectively known as Innate Lymphoid Cells (ILCs) (Spits et al., 2013). ILCs are a 
functionally diverse collection of cells that have been grouped according to their functional 
characteristics, as well as the transcription factors (TFs) which drive their differentiation and 
cytokine production (Walker et al., 2013). ILCs are clearly differentiated from T and B 
lymphocytes by their inability to undergo somatic rearrangement of T cell receptors or 








Three main subsets of ILCs have now been distinguished (ILC1, ILC2, ILC3) based on 
phenotypic and functional characteristics, mainly the expression of key cytokines and TFs 
(Spits et al., 2013). NK cells are the prototypical members of the ILC1 subset, which are 
defined by their production of type 1 cytokines such as IFN-γ and TNF-α, and their 
expression of the TFs Tbet and/or Eomes (Figure 1.1). ILC2 cells are dependent on the TF 
Gata3 and express the type 2 cytokines IL-5 and IL-13 (Figure 1.1), whilst ILC3 cells 
express RORγT and produce type 17 cytokines including IL-17 and IL-22 (Figure 1.1). ILCs 
are commonly located at barrier surfaces and are important for maintaining tissue 
homeostasis and providing protection against invading pathogens (Diefenbach et al., 2014). 
As well as contributing to immune responses, lymphoid tissue inducer (LTi) cells, part of the 
ILC3 subset, are also essential for lymphorganogenesis (Walker et al., 2013). LTi cells are 
required during fetal life to initially develop lymphoid organs and are present in adult tissues 
where they promote lymphoid follicle formation (Diefenbach et al., 2014). 
 
All lymphocytes of the adaptive immune system and all ILC subsets derive from common 
lymphoid progenitor (CLP) cells in the bone marrow (BM) (Figure 1.1). For many years it 
was postulated whether a lineage restricted progenitor existed, for some or all of the ILC 
subsets, which was downstream of the CLP. Recently, two independent studies have 
identified ILC progenitor populations that give rise to many of the ILC subsets. 
Constantinides et al. first discovered the committed ILC progenitor (CILP) that can give rise 
to all ILC subsets, except for NK cells and LTi cells, and was identified by its expression of 
the TF promyelocytic leukaemia zinc finger (PLZF) (Constantinides et al., 2014) (Figure 
1.1). Subsequently, Klose et al. identified the common helper-like ILC progenitor (CHILP), 
which can give rise to all ILC subsets, except NK cells and was distinguished by its 
expression of integrin α4β7 and the TF Id2 (Klose et al., 2014) (Figure 1.1). A population of 
CHILP cells, present in fetal liver and BM, were discovered to express PLZF (Klose et al., 
2014) and due to their less restricted differentiation potential, current models suggests that 
the α4β7+ Id2+ CHILP gives rise to the PLZF+ CILP cell (Figure 1.1). 
 
There is also evidence for plasticity in the way ILC subsets develop. ILC3s normally display 
no cytotoxic activity and generally secrete IL-17 or IL-22 (Walker et al., 2013). However, it 
has been reported that some ILC3 cells can respond to IL-12 and IL-23, causing them to 
downregulate expression of RORγT and acquire the capacity to produce IFNγ (Vonarbourg 
et al., 2010). These cells were demonstrated to be analogous to ILC1s and contributed to 
the induction of colitis (Vonarbourg et al., 2010). The disappearance of RORγt expression in 
these cells was accompanied by a strong increase in T-bet expression and mice that are 























rs of the p
 TH17 cells















d these can a
n helper-like 
NK cell subs









lso give rise 
innate lympho







ink et al., 




to T and B c
id cell proge






















































1.1.3 NK cells and immunotherapy 
The importance of NK cells for immune responses against virally infected and cancerous 
cells has meant that there is an ever increasing interest in the development NK cell-based 
immunotherapies (Knorr et al., 2014) (Ljunggren and Malmberg, 2007). Numerous studies 
have shown that NK cells have the ability to kill mouse and human tumour cell lines in vitro, 
as well as freshly isolated human tumour cells (Hayakawa and Smyth, 2006b) (Wu and 
Lanier, 2003). Studies in mice have shown that NK cells are able to eliminate grafted mouse 
tumour cells in vivo and NK cells have been shown to be involved in the eradication of 
induced and spontaneously developing tumours (Hayakawa and Smyth, 2006b) (Wu and 
Lanier, 2003). Significantly, a number of studies have now demonstrated that NK cell 
immunotherapy can to be effective in controlling and/or eradicating some human 
haematological tumours (Curti et al., 2011) (Ruggeri et al., 2002). In particular, adoptively 
transferred NK cells have been effective against acute myeloid leukaemia (AML) when given 
to patients in combination with a hematopoietic stem cell transplant (Curti et al., 2011) 
(Ruggeri et al., 2002). The NK cells are able to attack and kill the tumour cells whilst not 
causing any graft-versus-host disease, as observed when using cytotoxic T cells in similar 
approaches (Geller and Miller, 2011). 
 
Numerous advances have been made in understanding how adoptively transferred NK cells 
behave when transfused into a patient and why in some situations they effectively attack 
tumour cells and in others they do not (Geller and Miller, 2011). For example, NK cell killing 
can fail due to inhibitory KIRs recognising self MHC-1 on the surface of tumour cells (Miller 
et al., 2007). Patients and NK cell donors are now routinely screened for their KIR genotype 
or ligand status, so that patients receive KIR-ligand mismatched alloreactive NK cells that 
can more effectively target cancer cells (Miller et al., 2007) (Ruggeri et al., 2002). However, 
before NK cells can be used regularly in the clinic major challenges remain to increase the 
cytotoxic effects of adoptively transferred NK cells, making them consistently expand in vivo 
and making their activity more reliable (Scheper et al., 2014). 
 
Producing the large numbers of highly cytotoxic NK cells required for every patient is difficult, 
especially as most recent clinical studies involved the use of adoptively transferred NK cells, 
isolated from adult donors by lymphapheresis and transfused into patients (Knorr et al., 
2014). Although these cells have been educated in healthy hosts and have high anti-tumour 
activity, this strategy has the major drawback of requiring very large numbers of healthy 
volunteers to donate their NK cells. Strategies have been suggested for expanding these 
cells in vitro before transfusion, but to date no standard procedure has been adopted for 
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achieving this (Gong et al., 2010) (Rujkijyanont et al., 2013). Numerous alternative sources 
of NK cells are now being investigated including the generation of NK cells from 
hematopoietic stem cells (HSCs) derived from BM (Knorr et al., 2013) (Woll et al., 2005) or 
from umbilical cord blood (Luevano et al., 2012) (Spanholtz et al., 2010). Using these 
strategies potentially unlimited numbers of highly cytotoxic NK cells could be produced and 
with correct cryopreservation could be made as an ‘off-the-shelf’ product (Knorr et al., 2014) 
(Luevano et al., 2014). There is also the potential to genetically modify these NK cells 
allowing tailored therapeutic products to be produced expressing tumour-specific receptors 
(Themeli et al., 2013). However, if these or other strategies are to be successful, a greater 
understanding is required of how NK cells naturally develop and how this process is 
controlled and regulated. 
 
 
1.2 NK cell development 
Hematopoiesis is the process by which all mature blood cells develop from HSCs in the BM 
of adult mammals (Orkin and Zon, 2008). Mature blood cells are relatively short lived and so 
self-renewing HSCs are required to replenish multi-lineage progenitors and committed 
precursor cells that give rise to all hematopoietic lineages (Orkin and Zon, 2008). Common 
lymphoid progenitors (CLPs) develop from HSCs and have precursor potential to give rise to 
T, B and NK cells, as well as all other innate lymphoid cells (Papatriantafyllou, 2013)  
(Figure 1.1). 
 
The understanding of NK cell development has mainly derived from studies on human 
peripheral blood and mouse splenic NK cells and these are now commonly referred to as 
conventional NK (cNK) cells. These cNK cells develop in the BM through a number of well-
defined stages to produce mature NK (mNK) cells that are released to the periphery to 
acquire effector functions (Yu et al., 2013a). However, numerous studies have now identified 
NK cell subsets in the liver, uterus, thymus and lymph nodes and these tissue-resident NK 
(trNK) cells have alternative developmental pathways and can perform different roles to cNK 









1.2.1 Murine NK cell development 
NK cell development in the mouse BM requires CLPs, which are lineage marker negative 
(Lin-) and express c-Kit (CD117), Sca-1 (Ly6A/E), IL-7Rα (CD127), 2B4 (CD244), TNF 
receptor (CD27) and Flt3 (CD135) (Figure 1.2). Like T and B cells, NK cells go through an 
ordered and linear maturation process (Figure 1.2), but unlike T and B cells, NK cells do not 
require significant time to develop effector functions and, once produced, can rapidly be 
activated (Huntington et al., 2007). Two reports have defined the earliest NK cell committed 
precursor (NKP) residing within the Lin- population. Fathman et al. used adoptive transfer 
experiments and in vitro assays to define two populations, pre-NKPs (Lin- CD135- CD27+ 
CD244+ CD127+ CD122-) as the earliest committed NK cell stage, which differentiate to 
become refined NKPs (Lin- CD135- CD27+ CD244+ CD127+ CD122+), also referred to as 
rNKPs (Fathman et al., 2011) (Figure 1.2). In the second report, Carotta et al. used an Id2gfp 
reporter mouse to identify similar NK committed precursors, as the TF Id2 is essential for NK 
cell development (Carotta et al., 2011). They identified a pre-pro NK cell population as the 
earliest NK cell committed stage, defined as: Lin- CD122- Id2+ CD127+ CD135- Sca1+ 
CD117+ NKG2Dlow (Carotta et al., 2011). The pre-pro NK cell population seems to largely 
overlap with the pre-NKP population identified by Fathman et al. (Fathman et al., 2011). 
However, it should be noted that immature NK (iNK) cells can develop in the absence of Id2 
(Boos et al., 2007). Therefore the Id2+ pre-pro NK cell population may not include every 
single committed NK cell precursor.  
 
The acquisition of the IL-15 receptor β chain (IL-15Rβ; CD122) at the NKP stage is an 
important step in the development of NK cells, as IL-15 specifically promotes the 
differentiation, maturation and survival of NK cells (Huntington, 2014). Maturing NK cells 
acquire functional receptors in a systematic fashion with iNK cells acquiring NK1.1, CD94 
and NKp46 (Figure 1.2). This is followed by Ly49 receptors, DX5, CD43 and CD11b by fully 
mature NK cells (Figure 1.2). Mature NK cells further differentiate from CD11b- CD27+ NK 
cells, into double positive CD11b+ CD27+ and finally to the most mature CD11b+ CD27- NK 
cells (Kim et al., 2002). Both the double positive and CD11b+ CD27- NK cells have capacity 
to kill target cells and secrete IFN-γ, but the double positive population displays greater 
effector function and responsiveness to chemokines (Hayakawa and Smyth, 2006a). The 
three subsets also differ in tissue distribution, with the CD11b- CD27+ NK cells primarily 
present in the bone marrow and lymph nodes, whilst the CD11b+ CD27- population are more 
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For many years the liver was known to contain large numbers of NK cells, but more recently 
it has been discovered that many of these NK cells are not like cNK cells (Crispe, 2009). Up 
to 50% of the NK cells in the liver have an immature TRAIL+ DX5- phenotype; whereas NK 
cells in most other peripheral organs are TRAIL- DX5+ and are phenotypically mature. Peng 
et al. recently identified that these immature NK cells are a liver-specific trNK cell population 
that exclusively express CD49a, reside in liver sinusoids and are important for antigen-
specific memory-like responses (Peng et al., 2013).  
 
 
1.2.2 Human NK cell development 
It has been suggested that human NK cell development goes through a similar set of 
developmental stages to murine NK cell development, but this is currently less well defined 
(Figure 1.3). Human CLPs are defined as CD34+ CD38+ CD45RA+ CD10+ and are generally 
found in the BM, but similar CLP-like populations have also been identified in extramedullary 
tissues, e.g. the tonsils and lymph nodes (McClory et al., 2012). In these tissues the earliest 
NK progenitors have been identified (stage 1 and stage 2), but these cells also appear to 
retain some potential for T cell and DC development, under certain conditions (Freud et al., 
2006) (Figure 1.3). Therefore these cells may not represent true NK progenitors that are 
committed specially to the NK lineage. Similarly to murine NK cell development, IL-15 is key 
driver of differentiation, and IL-15 responsive CD45RA+ CD117+ CD161+ CD94- cells (stage 2 
cells) are found in secondary lymphoid tissues and these give rise to CD56+ CD94+ CD122+ 
progeny; stages 3 and 4 (Freud et al., 2006) (Figure 1.3). 
 
Peripheral human NK cells are split into CD56bright and CD56dim populations, which differ in 
their functional activity and localisation (Stages 4 and 5) (Figure 1.3). CD56dim NK cells are 
fully mature, highly cytotoxic, produce IFN-γ and perforin and constitute 90% of the NK cells 
in peripheral blood and spleen (Cooper et al., 2001) (Robertson and Ritz, 1990). In contrast, 
CD56bright NK cells are more immature and are considered as cytokine producers and 
commonly found in lymph nodes and tonsils (Cooper et al., 2001). Human NK cells have 
also been discovered in the uterus, liver, intestine and thymus, often with varying 
phenotypes, suggesting different anatomical locations can support specialised NK cell 
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The regulation of murine T and B cell development has been well understood for a number 
of years, and sets of genetic regulators have been identified that consign progeny to each 
particular lineage (Rothenberg, 2014). In T cells, Notch1, E2A and TCF7 work together to 
activate T cell genes and repress non-T cell genes; whilst in B cells Pax5 and Ebf1 performs 
a similar role (Warren and Rothenberg, 2003). In murine NK cell development the picture 
has been less clear and only in recent years have a number of key transcriptional regulators 
been identified (Figure 1.4). Epigenetic regulation is an additional layer of complexity that 
can influence TF access to binding sites (Cichocki et al., 2013). The loci of important 
regulators such as Ebf1 and Pax5 have been found to carry epigenetic marks in HSCs and, 
following lineage commitment, these marks can either change to become activating or 
repressing marks depending on which lineage the cell commits to (Heinz et al., 2010). 
 
The development of NK cells is highly dependent on the cytokine IL-15. Developing NKPs 
express IL-15Rβ, which is required for IL-15 signal transduction and development 
(Rosmaraki et al., 2001). IL-15Rβ dimerises with the common gamma chain (IL-2Rγ, 
CD132) allowing IL-15 binding and signalling via Jak1/Jak3 and STAT5, driving NK cell 
differentiation (Huntington, 2014). The third component of the IL-15 receptor, IL-15Rα, can 
either be expressed intrinsically by developing NK cells or more commonly by trans-
presentation from other hematopoietic or parenchymal cells (Schluns et al., 2004). The 
mechanism of trans-presentation allows IL-15 to be chaperoned to the surface of developing 
NK cells by IL-15 producing cells.  
 
Several key TFs have now been identified as essential for the development of NK cells and 
other ILC subsets (Figure 1.4). They control the transition from each developmental stage 
and promote the expression of specific NK cell markers (Figure 1.4). How these factors 
work together to implement an NK cell-specific transcriptional programme is still to be fully 



















Figure 1.4 – Transcription factors that regulate conventional NK cell development 
Numerous transcription factors are essential for NK cell development, but few have been discovered to regulate 
the earliest steps that commit common lymphoid precursors (CLPs) to the NK lineage. Each transcription factor is 
shown at the earliest transition they are known to mediate. Those shown in brackets display a partial phenotype 




Of all the TFs identified to date, the only one that is clearly essential for the commitment of 
NK cells to the NK lineage is the basic leucine zipper (bZIP) transcription factor E4-binding 
protein 4 (E4bp4) (Male et al., 2014). After the development of the E4bp4-/- mice it was 
reported that E4bp4 was required for the development of iNK cells from NKPs (Gascoyne et 
al., 2009) (Kamizono et al., 2009). However, this work was performed using the definition of 
NKPs described by Rosmaraki et al. where only 1 in 12 of these NKP cells had NK cell 
potential (Rosmaraki et al., 2001). Using the refined NKP (rNKP) phenotype, where 1 in 2 
cells has NK cell potential, E4bp4 was observed to be indispensable for the production of the 
earliest NK cell progenitors as E4bp4-/- BM contained almost no rNKP or pre-NKP cells 
(Male et al., 2014). E4bp4 was also shown to be expressed in CLP cells and was absolutely 
required for these cells to develop into NK cells in vitro (Male et al., 2014). When expressed 
in NK cells E4bp4 regulates the expression of other important NK-specific TFs, in particular 
Id2 and Eomes, which were shown to be direct transcriptional targets of E4bp4 and are 
expressed at later stages of NK cell development (Male et al., 2014) (Nandakumar et al., 
2013). 
 
E4bp4 is particularly required for the development of cNK cells in the BM, as certain 
populations of trNK cells are not dependent on E4bp4 and are found in the liver, thymus and 
spleen of E4bp4-/- mice (Crotta et al., 2014) (Seillet et al., 2014a). These trNK cells in the 
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thymus have an immature phenotype (CD3- NK1.1+ NKp46+ CD122+), express low levels of 
Eomes and have lower levels of fitness compared to cNKs (Crotta et al., 2014). In an 
independent study, Seillet et al. identified CD49b- TRAIL+ trNK cells in the liver of E4bp4-/- 
mice, and these cells also do not express Eomes (Seillet et al., 2014a). Development of 
these E4bp4 and Eomes-independent NK cells represents a distinct pathway of NK cell 
development that is specific to the liver and thymus. 
 
E4bp4 is specifically required for the commitment to the NK cell lineage and the initial 
development of NK cells, but it is not needed for the maintenance of peripheral NK cells or 
the maturation of mNK cells in the bone marrow (Firth et al., 2013). Firth et al. used a 
tamoxifen inducible Cre/loxP-mediated deletion of E4bp4 to also show that E4bp4 is also not 
involved in NK cell memory responses, following MCMV infection (Firth et al., 2013). 
 
Additional analysis of the E4bp4-/- mouse has recently revealed that E4bp4 is essential for 
the development of all ILC subsets, as well as cNK cells (Fuchs et al., 2013) (Geiger et al., 
2014) (Seillet et al., 2014b). E4bp4 is highly expressed in all ILC subsets and is required for 
correct formation of Peyer’s patches (Seillet et al., 2014b). In the absence of E4bp4, the 
numbers of ILCs are greatly reduced in the small intestine (all subsets), colon (all subsets), 
lung (ILC1 and ILC2) and fat tissue (ILC2) (Fuchs et al., 2013) (Geiger et al., 2014) (Seillet 
et al., 2014b). This phenotype made E4bp4-/- mice highly susceptible to intestinal bacterial 
infection with Citrobacter rodentium and Clostridium difficile (Geiger et al., 2014) (Seillet et 
al., 2014b). Finally, E4bp4 was found to be required for the development of the earliest ILC 
progenitor (CHILP), defined as Lin- CD45+ CD27+ CD127+ c-Kit+ CD135- α4β7+ confirming its 
central role in controlling the development of all innate lymphocytes (Geiger et al., 2014). 
However, it should be noted that mice lacking E4bp4 still have lymph nodes, which indicates 
that some form ILC3 development is not completely blocked in its absence (Gascoyne et al., 
2009) (Kamizono et al., 2009). Further studies are required to define exactly how E4bp4 




The transcriptional repressor Inhibitor of DNA binding 2 (Id2) is important for the 
development of NK cells and other ILC subsets (Verykokakis et al., 2014). In the absence of 
Id2, very few NK cells develop and the residual cells that do remain display numerous 
maturation defects (Boos et al., 2007) (Ikawa et al., 2001). In the BM and periphery of Id2-/- 
mice, major decreases in the number of mNK cells are observed, yet numbers of NKPs and 
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iNK cells in the BM are not affected (Boos et al., 2007). Id2 therefore appears to be required 
for the later stages of NK cell development. However, some evidence suggests that Id2 may 
be important earlier in the developmental process. Using an Id2gfp reporter line Carrota et al. 
showed the earliest NK cell precursors, pre-pro NK cells, express high levels of Id2 (Carotta 
et al., 2011), but whether these cells can develop in the absence of Id2 has not been 
confirmed. It is possible that Id2 is important for the earlier stages of NK cell development 
but its role may not be essential until later in the developmental pathway. 
 
Id2 functions by counteracting the activity of E-box binding proteins (e.g. E2A, E2-2 and 
HEB) that are required for T and B cell development (Di Santo, 2014). As Id2 does not have 
a DNA binding domain, it binds directly heterodimerically to E-box proteins, preventing them 
from activating target genes and promoting T or B cell transcriptional programs (Ramirez 
and Kee, 2010). The expression of Ets1, another TF involved in NK cell development, is 
reduced in the absence of Id2; suggesting Id2 may function in multiple ways to promote the 
development of NK cells (Boos et al., 2007). Expression of Id2 in human thymic progenitor 
cells in vitro has also been found to promote NK cell production, providing further evidence 
of a central role for Id2 in NK cell development (Schotte et al., 2010). 
 
Id2 is also highly expressed in all other ILC populations (Seillet et al., 2014b) and is required 
for the production of certain ILC subsets, including LTi cells (Boos et al., 2007) and IL-22-
producing NKp46+ cells, present in the gut (Satoh-Takayama et al., 2010). This observation 
has led some to suggest that Id2 may be essential for the development of all ILC subsets 
and expressed by a potential ILC progenitor (Spits et al., 2013). Constantinides et al. and 
Klose et al. recently identified novel ILC precursor populations, both of which expressed Id2 
and could give rise to multiple ILC populations (Constantinides et al., 2014) (Klose et al., 
2014). However, neither of these precursor populations was able to develop into cNK cells 
and it is not clear if Id2 is an essential requirement for ILC lineage commitment or if 




Ets1 is expressed in many hematopoietic lineages and Ets1-deficent mice have defects in T, 
B and NK cells. Ets1-/- mice have reduced pre-NKP, rNKP and mature NK cells 
demonstrating that Ets1 is a regulator of NK cell development (Ramirez et al., 2012). The 
loss of NK cells in Ets1-/- mice is, however, less severe than that observed in E4bp4-/- or Id2-/- 
mice. Despite this, Ets1 is expressed early in NK cell development and chromatin 
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immunoprecipitation (ChIP) experiments suggest that Ets1 helps to promote NK cell 
development by regulating the expression of Id2, Tbet and IL2rβ (CD122) (Ramirez et al., 
2012). As mNKs are still produced in Ets1-/- mice, the activity of Ets1 is not essential and 
there may be some overlap of function with other TFs of the Ets family that are involved in 
NK cell development and maturation, such as PU.1 and MEF.  
 
The NK cells that develop independently of Ets1 are able to produce IFNγ, but are unable to 
degranulate correctly in response to activation of NK1.1 (Ramirez et al., 2012). They also 
have higher expression of the activation marker CD69, higher expression of granzyme B and 
are hyper-proliferative in response to IL-15 stimulation (Ramirez et al., 2012). E4bp4 and 
Helios expression were upregulated in the absence Ets1, providing evidence that Ets1 may be 
required to limit NK cell responses following cytokine stimulation (Ramirez et al., 2012). 





Tox is a high mobility group box TF which is involved in regulating chromatin accessibility for 
other TFs (Aliahmad et al., 2012). It is an important modulator of CD4 T cell development 
and also NKT cell development (Aliahmad et al., 2012). In the absence of Tox, mNKs are not 
present in the spleen or BM, numbers of iNK cells are reduced by 50%, but NKP cell 
numbers are unchanged (Aliahmad et al., 2010). Allied to this, Tox expression increases in 
iNK and mNKs, compared to that seen in NKPs (Aliahmad et al., 2010). However, the 
analysis of pre-pro NKPs and rNKPs has not been reported in Tox-/- mice and so the 
mechanism by which Tox promotes NK cell development remains unclear. As well as 
regulating NK cell development, Tox is also required for the development of LTi cells and the 
formation of lymph nodes and Peyer’s patches (Aliahmad et al., 2010). 
 
 
1.3.5 Tbet and Eomes 
The T-box family TFs Tbet and Eomesodermin (Eomes) work together to regulate sequential 
checkpoints of NK cell maturation (Gordon et al., 2012). Eomes deficient mice lack all DX5+ 
mNK cells, whilst Tbet deficient mice lack TRAIL+ DX5- iNK cells, present mainly in the liver, 
as well as all mNKs (Gordon et al., 2012). The combined deletion of Tbet and Eomes lead to 
the loss of all NK cells beyond the NKP stage (Gordon et al., 2012). Tbet was therefore 
thought to be required for the generation of iNK cells and Eomes required for mNK 
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development. However, further analysis using an Eomes-GFP reporter line has now 
ascertained that in the BM Eomes is expressed in TRAIL- DX5+ NK cells and Tbet 
expression is repressed in these cells (Daussy et al., 2014). When these Eomes+ cells leave 
the BM for the periphery they can then express Tbet, which promotes the final stages of 
development and maturation (Daussy et al., 2014). TRAIL+ DX5- Eomes- iNK cells in the liver 
express high levels of Tbet and develop into a distinct Eomes- NK cell lineage that resemble 
NKT cells in terms of cytokine production (Daussy et al., 2014). The development of this 
alternative lineage is blocked in the BM due to the repression of Tbet expression, allowing 
the development of Eomes+ cNK cells. Whilst the liver permits Tbet expression, which 
subsequently represses Eomes expression and promotes development of TRAIL+ DX5- 




Runx family proteins have numerous roles in hematopoietic lineages, with Runx3 being 
dominantly expressed in NK cells and CD8+ T cells (Ohno et al., 2008). Runx3 expression 
begins at the NKP stage and is maintained throughout NK cell development (Ohno et al., 
2008). During NK cell development Runx3 is important for regulating the expression of 
CD122 (Ohno et al., 2008) and NKp46 (Lai and Mager, 2012). Knockout mice of all Runx 
family genes are embryonic lethal, but the function of Runx family members can be 
determined by expressing a dominant negative (DN) form of Runx1 in haematopoietic 
progenitor cells, which interferes with the function of all Runx proteins (Ohno et al., 2008). 
The expression of DN Runx1 causes lower numbers of mNKs to be produced and fewer of 
these cells express Ly49 receptors (Ohno et al., 2008). Expression of DN Runx1 was 
actually observed to promote IFN-γ production in response to cytokine stimulation, but these 
cells were not found to be more cytotoxic than WT cells (Ohno et al., 2008). Using this 
approach it is difficult to be certain that other Runx family members are not responsible for 
these phenotypes, but Runx3 is highly expressed in NK cells, suggesting it is the most likely 
candidate. Recent evidence acquired using genome-wide ChIP-seq experiments suggests 
that Runx3 may act alongside Ets family TFs to regulate gene expression in NK cells, 











PU.1 is expressed in HSCs and is important for the development and function of numerous 
hematopoietic lineages (Carotta et al., 2010a). Previously, it was thought that PU.1 was 
required for NK cell development as it is strongly expressed in IL-2 expanded NK cells 
(Colucci, 2001). However, studies involving the conditional deletion of PU.1 in adult HSCs 
have confirmed that PU.1 is a key regulator of CLP development as in its absence all 
lymphoid cells and macrophages fail to develop (Carotta et al., 2010a). Analysis of PU.1GFP 
reporter mice has shown that PU.1 is expressed in hematopoietic progenitor cells but not in 
pre-pro or mNK cells (Nutt et al., 2005) (Carotta et al., 2010b). PU.1 is proposed to regulate 
the expression of cytokine receptors Flt3 and IL7Rα, both essential for T, B and NK cell 




Gata3 is a zinc finger transcription factor with a well-defined role in T cell development 
(Hosoya et al., 2010). Gata3 is expressed in developing NK cells, but loss of Gata3 
specifically affects the production of CD127+ thymic NK cells; it does not affect cNK cell 
development in the BM and spleen (Samson et al., 2003) (Vosshenrich et al., 2006). Gata3-/- 
NK cells have an immature phenotype, express lower levels of CD11b and CD43, and have 
a decreased ability to produce IFN-γ (Samson et al 2003). In the absence of Gata3, NK cell 
homing to the liver was also affected and all hepatic NK cell subsets were reduced (Samson 
et al., 2003). How Gata3 functions in trNK cells is still not entirely clear but it is suggested 
that it may control the expression of both Tbet and Eomes (Vosshenrich and Di Santo, 
2013). As well as trNK cells, Gata3 is required for the differentiation and function of all other 
IL-7Rα-expressing ILC subsets (Samson et al., 2003) (Serafini et al., 2014) (Vosshenrich et 
al., 2006) (Yagi et al., 2014). Gata3 has a number of specific roles in different ILC subsets, 
for example in ILC2s it was observed to control the expression of the retinoic acid receptor 
RORα (Hoyler et al., 2012) (Mjosberg et al., 2012). As Gata3 is essential for all ILC subsets 
except for cNK cells, this provides further evidence that these “killer” ILCs are in fact an 




Ikaros is part of the small family of Krüppel-type zinc finger TFs and is expressed in many 
hematopoietic progenitor cells, including HSCs (Huntington et al., 2013). Studies on Ikaros-/- 
mice have demonstrated that Ikaros has an essential role in lymphoid development as these 
1. Introduction 




mice that lack all T, B and NK cells (Georgopoulos et al., 1997) (Yoshida et al., 2006). Ikaros 
is expressed in developing NK cells and Ikaros-deficient progenitors cannot develop into NK 
cells in vitro, suggesting Ikaros is a critical regulator of NK cell development (Georgopoulos 
et al., 1997) (Wang et al., 1996). However, as Ikaros-/- mice also lack T and B cells, it is 
possible that Ikaros is needed for the development of CLPs and is not specifically required 




Myeloid ELF1-like factor (MEF) is a member of the Ets TF family and loss of MEF affects the 
development of NK and NKT cells (Lacorazza et al., 2002). Mef -/- mice have 60% less mNK 
cells in their spleen compare to WT littermates and the NK cells they do have are 
significantly less cytotoxic (Lacorazza et al., 2002). Lack of cytotoxicity in Mef -/- NK cells is 
due to an inability to produce perforin and IFN-γ, as MEF directly regulates the expression of 




Mice lacking the TF interferon regulatory factor (IRF)-2 have a deficiency in the development 
of both T helper type 1 cells and NK cells (Lohoff et al., 2000). Irf2-/- mice have a selective 
loss of mNK cells because they have relatively normal levels of iNK cells in their spleen and 
liver (Lohoff et al., 2000) (Taki et al., 2005). In the BM of Irf2-/- mice, NK cells were able to 
develop to a relatively mature CD11b- DX5+ phenotype, but these cells do not contribute to 
the peripheral NK cell pool as they appear to go through premature apoptosis (Taki et al., 




Blimp1 is a transcriptional repressor required for the differentiation of plasma cells and CD8+ 
effector T cells. Blimp1 is expressed by NK cells throughout their development and IL-15 
induces its expression in CD122+ NKPs (Kallies et al., 2011). Blimp1 is needed for the 
maturation and homeostasis of NK cells in the periphery, as in its absence mNK are still 
produced, but at a lower frequency to WT (Kallies et al., 2011). The maturation defect 
observed in Blimp1-deficent NK cells is similar to the phenotype seen in mice lacking T-bet 
and Kallies et al. demonstrated that the expression of Blimp1 is at least partly regulated by 
T-bet (Kallies et al., 2011). 
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The zinc finger TF Helios is not required for the development of NK cells, but has an 
important role in NK cell activation. Noé mice have a mutation in Ncr1 (NKp46), preventing 
its surface expression. NK cells in these mice produce high levels of IFNγ, degranulate more 
effectively than WT NK cells and are hyper-responsive during MCMV infection (Narni-
Mancinelli et al., 2012). Helios is expressed at higher levels in Noé mNK cells than in WT 
cells and short-hairpin RNA knockdown of Helios in Noé mNK cells reversed their hyper 
responsive phenotype (Narni-Mancinelli et al., 2012). This suggested that Helios down-
regulation is involved in the control of NK cell reactivity via NKp46 (Narni-Mancinelli et al., 
2012). Helios is also overexpressed in Ets1 deficient mNK cells, suggesting Ets1 may 
regulate NK cell activation, in part by acting through Helios (Ramirez et al., 2012). 
 
 
1.3.14 The transcriptional network controlling NK cell development 
The precise points at which each TF influences NK cell development has become clearer, 
yet how they interact with each other and work together to regulate the production of NK 
cells remains to be fully established. Combining the data from the studies discussed above, 
a picture can be built up of the network of TFs controlling NK cell development (Figure 1.5). 
Most of the interactions in this network have been observed through changes in expression 
of a downstream target, in the absence of the TF of interest or by the use of ChIP to confirm 
direct binding to promoter regions (Figure 1.5). There is cross-regulation between the 
central TFs in this network, namely E4bp4, Ets1 and Id2, which provides precise control of 
the initiation and progression of NK cell development (Figure 1.5). Understanding how other 













Figure 1.5 – Transcriptional network regulating NK cell development 
Summary of the known interactions between transcription factors during NK cell development. 1) Id2 and Eomes 
are direct transcriptional targets of E4bp4, are under expressed in its absence and can rescue NK cell 
development in its absence (Male et al., 2014). 2) Ets1 can rescue NK cell development in the absence of E4bp4 
(Male et al., 2014). 3) T-bet and Id2 are direct transcriptional targets of Ets1 and are under expressed in its 
absence (Ramirez et al., 2012). 4) Helios and E4bp4 are over expressed in the absence of Ets1 (Ramirez et al., 
2012). 5) Id2 binds to E-proteins to prevent commitment to the T or B cell lineages and Ets1 is also under 
expressed in its absence (Boos et al., 2007). 6) Blimp1 expression is reduced in the absence of T-bet. Adapted 




Whilst many TFs have been identified as important for the development of NK cells, a 
complete picture of the transcriptional regulation of this process remains unresolved. How 
the activities of individual TFs are controlled is not well understood, in particular, little is 
known about the molecular mechanisms that control E4bp4 activity during NK cell 
development. 
 
E4bp4, also referred to as nuclear factor regulated by IL-3 (NFIL3), was first identified as a 
transcription repressor which bound to an activating transcription factor DNA consensus 
sequence site in the adenovirus E4 promoter (Cowell et al., 1992). It was independently 
discovered to be a transcriptional activator of the IL-3 promoter in human T cells (Zhang et 
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required for IgE class switching (Kashiwada et al., 2010). Most significantly in NK cells, 
E4bp4 binds to the Eomes and Id2 loci and promotes their expression (Male et al., 2014).  
 
It remains unclear how in different contexts E4bp4 can have opposing effects on target gene 
expression. Other TFs involved with regulating immune cell development are known to be 
multi-functional with the ability to both activate and repress target genes. Ikaros is a 
transcriptional activator that promotes T cell development and recruits chromatin remodelling 
complexes to lineage-specific genes, such as CD8 (Koipally and Georgopoulos, 2002). 
Ikaros is also able to promote transcriptional repression by associating with histone 
deacetylase-containing complexes (Koipally et al., 1999) or by interacting with the 
transcriptional co-repressor CtBP (Koipally and Georgopoulos, 2000). Gata3 is essential for 
a number of stages in T cell development and is required to activate a number of T-cell 
specific genes, including T cell receptor genes in the intermediate stages of T cell 
developmental (Hosoya et al., 2010). However, it is also important for repression 
transcription of certain target genes, such as Foxp3, in naïve T cells, preventing them from 
becoming regulatory T cells (Hosoya et al., 2010). 
 
Recently, a number of reports have demonstrated that E4bp4 can influence the epigenetic 
modifications of chromatin at promoter regions of target genes. Many of these studies 
involve E4bp4 promoting a transcriptionally repressive state by inducing deacetylation of 
histone H3 and/or methylation of histone H3K9. In TH2 cells, E4bp4 directly binds the IL-13 
locus and in its absence increased histone H3 acetylation and increase methylation of 
histone H3K4 was observed (Kashiwada et al., 2011a). In a separate study, E4bp4 was 
shown to bind to the CD40L locus in CD4+ T cells where it promoted an increase in H3K9 
methylation, a reduction in H3 acetylation and a reduction in H3K4 methylation, all hallmarks 
of transcriptional repression (Zhao et al., 2013). MacGillavry et al. also found that many 
E4bp4 bound promoters in neuronal cells were hypoacetylated, suggesting E4bp4 serves to 
keep these genes in a suppressed, transcriptionally silent state (MacGillavry et al., 2011). 
 
In a report looking at cell survival in breast cancer cells, E4bp4 was found to prevent 
transcription of TRAIL and some FOXO genes, preventing apoptosis of these cells (Keniry et 
al., 2013). This study was the first to suggest a mechanism by which E4bp4 can regulate 
epigenetic modifications, as it was shown to promote deacetylation by recruiting histone 
deacetylase-2 and reducing levels of H3 acetylation (Keniry et al., 2013). Another possible 
mechanism of action for E4bp4 was proposed by Tong et al. who showed E4bp4 was able to 
interact with histone methyltransferase G9a and this interaction caused increased H3K9 
methylation at the loci of the E4bp4 target gene Fgf21 in liver cells (Tong et al., 2013). 
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However, the interactions observed in both of these studies were not performed on 
endogenous protein in the cell types of interest and so further investigations should confirm 
that these interactions occur in vivo and effect the transcription of E4bp4 target genes. 
 
As well as repressing transcription of target genes by modulating chromatin structure E4bp4 
has also been implicated with promoting transcription by epigenetic modulation. In 
chronically stimulated TH1 cells E4bp4 can bind to the IL-13 locus and promote its 
expression and this phenotype was observed alongside an increase in H3K4 methylation in 
these cells, a common mark of gene activation (Motomura et al., 2011). Additionally, the 
same study found that in TH2 cells, in the absence of E4bp4, the IL-10 locus had less H3 
acetylation at K9 and K14, suggesting E4bp4 is able to promote an active state of this locus 
in this cell type (Motomura et al., 2011). Nandakumar et al. recently showed that E4bp4 can 
interact with a histone H2A deubiquitinase, MYSM1, and this can promote a more active 
transcription state in the promoter of Id2 in NK cells (Nandakumar et al., 2013). They 
proposed that this interaction helps to keep the Id2 locus active during NK cell development, 
especially as in the absence of MYSM1 NK cell development and maturation was severely 
affected (Nandakumar et al., 2013). E4bp4’s interactions with chromatin remodelling 
enzymes may therefore be important for its activities in numerous different contexts. 
 
 
1.5 Other functions of E4bp4 
E4bp4 is essential for the development of cNK cells, commitment of developing lymphocytes 
to the NK lineage and the development of other ILC subsets including LTi cells. However, 
E4bp4 has been implicated in a variety of other roles in numerous cells types (Figure 1.7). 
Particularly, the characterisation of E4bp4-/- mice has revealed roles for E4bp4 in many 
immune lineages (Figure 1.7). 
 
 
1.5.1 CD8α+ conventional dendritic cell development 
E4bp4-/- mice are deficient in CD8α+ conventional dendritic cells (cDCs), but other DC 
subsets and progenitors are not affected by the absence of E4bp4, suggesting it has a role 
late in the developmental pathway specific for CD8α+ DCs (Kashiwada et al., 2011b).  A vital 
role for CD8α+ DCs is their ability to cross present antigen from endocytosed particles on 
MHC-I molecules and therefore E4bp4-/- mice are unable to mediate cross presentation and 
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activation (Schroder et al., 2002) and, by directly binding to the Ig GLε promoter, E4bp4 
activates its transcription (Kashiwada et al., 2010). Despite this clear phenotype it remains 
unclear whether E4bp4 is a regulator of the biological processes involving IgE, e.g. immune 
responses to pathogens at mucosal surfaces and allergic responses. 
 
 
1.5.3 T cell cytokine production and activity 
T helper cells are categorised into different subsets based on their ability to produce effector 
cytokines and regulate immune responses. Two conflicting reports have described a role for 
E4bp4 in CD4+ T helper cells, where it directly affects cytokine production. Motomura et al. 
reported that TH2 cells require E4bp4 to produce IL-10, but not for the production of IL-4, IL-
5 and IL-13 (Motomura et al., 2011).  In contrast, Kashiwada et al. found that E4bp4 
promoted the expression of IL-4 in TH2 cells developing in vitro and actively repressed the 
production of IL-5 and IL-13 (Kashiwada et al., 2011a). A similar phenotype was observed in 
vivo when looking at TH2 responses in mice immunised with ovalbumin and alum 
(Kashiwada et al., 2011a). Kashiwada et al. did observed that in the earliest stages of TH2 
differentiation E4bp4 actually suppressed IL-4 production and this may explain why 
Motomura et al. observed no effect on IL-4 production (Kashiwada et al., 2011a). However, it 
is not clear why the two studies disagree about the effect of E4bp4 on IL-5 and IL-13 
expression, although E4bp4 does appear to directly bind to the IL-13 promoter in TH2 cells 
and actively repress transcription (Kashiwada et al., 2011a). 
 
TH1 cells are also able to produce the TH2 cytokines IL-10 and IL-13 during chronic infection 
and the production of both of these cytokines also appears to be driven by E4bp4 (Motomura 
et al., 2011). In TH1 cells E4bp4 was shown to again bind directly to the IL-13 promoter, but 
rather than repress transcription, as seen in TH2 cells, it appears to promote transcription 
(Motomura et al., 2011). E4bp4-/- TH1 cells produce less IL-13 and also less IL-10, when 
chronically stimulated, and TH1 cells from mice transgenically overexpressing E4bp4 are 
able to produce more IL-10 and IL-13 than WT cells (Motomura et al., 2011). E4bp4 was not 
observed to bind directly to the IL-10 promoter but appeared to affect transcription by 
modulating chromatin structure (Motomura et al., 2011). These effects on cytokine 
production may have important clinical implications because E4bp4-/- mice spontaneously 
develop intestinal inflammation and colitis, which at least in part is due to the deregulation of 
T cell cytokine production (Motomura et al., 2011). 
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It has also been discovered that E4bp4 inhibits the activity of self-reactive T cells during 
systemic lupus erythematosus (SLE) (Zhao et al., 2013). E4bp4 was shown to down regulate 
the expression of CD40L in SLE CD4+ T cells which is required to promote autoantibody 
production from B cells (Zhao et al., 2013). E4bp4 was therefore suggested to be important 
for inhibiting CD4+ T cell activation and subsequent autoimmune responses. However, it is 
not clear if E4bp4’s activity is crucial in vivo as SLE CD4+ T cells isolated from patients had 
increased E4bp4 expression and are known to also have hyperexpression of CD40L (Desai-
Mehta et al., 1996). 
 
 
1.5.4 Macrophage activation and cytokine production 
Macrophages are central to inflammatory innate immune defences at mucosal surfaces, but 
they are also involved in the regulation of responses to enteric microbiota. E4bp4 has a role 
in controlling macrophage activity, since stimulation with lipopolysaccharide (LPS) or 
commensal bacteria causes bone marrow derived macrophages (BMDMs) to upregulate 
E4bp4 expression (Kobayashi et al., 2011) (Smith et al., 2011). The anti-inflammatory 
cytokine IL-10 also promotes the transcription of E4bp4 in BMDMs, suggesting E4bp4 is a 
component of the IL-10 anti-inflammatory signalling pathway (Lang et al., 2002) (Smith et al., 
2011).   E4bp4 produced in BMDMs controls the expression of the pro-inflammatory cytokine IL-
12 by binding directly to a DNA enhancer upstream of the IL-12b transcriptional start site and 
repressing its activity (Smith et al., 2011). In the absence of E4bp4, mice challenged with 
Toxoplasma gondii fared far worse than WT littermates and produced greater levels of 
systemic IL-12 (Smith et al., 2011). E4bp4 is therefore important for maintaining intestinal 
homeostasis by acting as a microbiota-induced IL-12b transcriptional inhibitor. 
 
A recent study by Kobayashi et al. has confirmed the spontaneous colitis that develops in 
E4bp4-/- mice is specifically due to the dysregulation of IL-12b in intestinal macrophages and 
is not dependent on the presence of other cytokines produced by lymphocytes (Kobayashi et 
al., 2014). Allied to this, CD14+ macrophages from patients with Crohn’s disease or 
ulcerative colitis, which produce large amounts of IL-12, express lower levels of E4bp4 
compared with those from non-inflammatory controls (Kobayashi et al., 2011). 
 
 
1.5.5 Circadian rhythm and TH17 development 
Internal circadian clocks are found in a diverse range of organisms, controlling physiological 
and behavioural responses and are driven by autoregulatory transcriptional and translational 
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feedback loops that generally oscillate over a 24 hour period (Ohno et al., 2007b). E4bp4 
mRNA and protein expression fluctuate in a regular pattern over a 24 hour period and in an 
opposing manner to essential circadian rhythm genes such as DBP (Mitsui et al., 2001) and 
period2 (Per2) (Doi et al., 2001). In the chick pineal gland E4bp4 expression is induced by 
light and its expression was to shown to suppress the expression of Per2 in a recombinant 
system (Doi et al., 2001). This repression was later confirmed in vivo and it was confirmed 
that E4bp4 regulation of Per2 is required for correct expression of Per2 in the cell-
autonomous clock (Ohno et al., 2007b). E4bp4 was also found to interact with Per2 protein 
and another mammalian circadian clock protein Cryptochrome2 (Cry2), suggesting E4bp4 is 
part of a negative regulator complex of mammalian circadian clock proteins (Ohno et al., 
2007a). 
 
E4bp4’s role in regulating the circadian clock has been linked to a number of biological 
processes, most prominently the development of interleukin-17-producing CD4+ T helper 
(TH17) cells. TH17 cells are pro-inflammatory modulators that protect mucosal surfaces from 
bacterial and fungal infections (Yu et al., 2013b). E4bp4-/- mice have significantly higher 
numbers of TH17 cells than WT mice in both the small intestine and colon (Yu et al., 2013b). 
TH17 development requires the orphan nuclear receptor, RORγt, and E4bp4 represses 
transcription of RORγt by binding directly to its promoter (Yu et al., 2013b). Yu et al. were 
also able to show that E4bp4 expression in TH17 cells is regulated by the circadian clock (Yu 
et al., 2013b). Primary circadian clock activators BMAL1 and CLOCK promote the activity of 
the TF REV-ERBα, which represses E4bp4 expression. Therefore TH17 development is 
directly linked to the circadian clock and occurs in a diurnal fashion (Yu et al., 2013b). 
 
 
1.5.6 Cell survival 
E4bp4 was first shown to inhibit apoptosis in IL-3-dependent pro-B cell lines, as enforced 
expression of E4bp4 provided protection from cell death upon cytokine withdrawal (Ikushima 
et al., 1997). Oncogenic proteins Ras and Gata-1 were both suggested to promote E4bp4 
expression in these pro-B cell lines, in response to IL-3 (Kuribara et al., 1999). However, the 
anti-apoptotic effects of E4bp4 in these cells were not consistently observed and the 
oncoprotein E2A-HLF, which causes childhood acute lymphoblastic leukaemia, was found to 
be a more potent pro-survival factor for pro-B cells (Yeung et al., 2004).  
 
Recently, Keniry et al. demonstrated that E4bp4 expression promotes cell survival in breast 
cancer cells and promotes resistance to oxidative stress (Keniry et al., 2013). E4bp4 
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prevented FOXO TFs from accessing the promoter of TRAIL (the death receptor ligand 
capable of inducing extrinsic apoptosis) by binding to nearby chromatin, recruiting histone 
deactelyase-2, reducing histone acetylation and ultimately preventing transcriptional 
activation (Keniry et al., 2013). E4bp4 was also found to be overexpressed in a number of 
different breast cancer cell types and its expression was associated with lower patient 
survival (Keniry et al., 2013). 
 
 
1.5.7 Motor neuron development and survival 
E4bp4 is expressed by embryonic chicken and rat motor neurons and high levels of 
expression have been associated with long term survival of neurons (Junghans et al., 2004). 
Overexpression of E4bp4 was found to promote neuronal growth in vitro and in vivo, 
reducing the number of dying neurons in chicken embryos by 45% (Junghans et al., 2004). 
Recently, it has been shown that this effect on neuronal survival may have clinical 
implications because expression of E4bp4 in neurons appears to protect against the 
neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) (Tamai et al., 2014). E4bp4 
expression is increased following neurotoxic damage and over expression of E4bp4 in ALS 
mice was found to reduce motor axon degeneration and delay the onset of disease (Tamai 
et al., 2014). 
 
In contrast, two studies have shown that E4bp4 has a different role in neurons more closely 
associated with the central nervous system. MacGillavry et al. found that E4bp4 represses 
regeneration and cellular outgrowth of dorsal root ganglion cells following neuronal injury 
(MacGillavry et al., 2009). In dorsal root ganglion cells, E4bp4 acts antagonistically, 
alongside the TFs CREB and C/EBP, to regulate expression of regeneration-associated 
genes (MacGillavry et al., 2009) (MacGillavry et al., 2011). These studies clearly 
demonstrate how E4bp4 has cell type specific roles and can perform different roles in cells 
at different developmental stages. 
 
 
1.5.8 Osteoblast function 
Myeloma bone disease is a common symptom in multiple myeloma patients, caused by 
defects in osteoblasts, which prevents new bone formation and repair (Silvestris et al., 
2008). E4bp4 is involved with this impairment of osteoblast function as it transcriptionally 
represses the activity of important osteoblast TFs Runx2 and Osterix (Ozkurt and Tetradis, 
2003) (Silvestris et al., 2008). E4bp4 expression is induced in osteoblasts by parathyroid 
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hormone-related protein, which is commonly released by myeloma cells (Ozkurt and 
Tetradis, 2003) (Silvestris et al., 2008). This observation was validated by looking at E4bp4 
expression in osteoblast isolated directly from myeloma patients, where high levels of E4bp4 
were correlated with low levels of Osterix expression and high levels of serum parathyroid 
hormone-related protein (Silvestris et al., 2008). 
 
 
1.6 Regulation of E4bp4 
E4bp4 is involved in a broad range of biological processes and is able to produce differing 
effects on target gene expression, in different cell types, and in different contexts. In many 
instances it is clearly essential to repress gene transcription, but in others it is required to 
promote transcription. Arguably the most striking phenotype of the E4bp4-/- mouse is its 
absolute lack of NK cells, NK cells precursors and its dramatic loss of all ILC subsets 
(Gascoyne et al., 2009) (Geiger et al., 2014) (Male et al., 2014) (Seillet et al., 2014b). Over 
the past five years since the E4bp4-/- mouse was first reported, the importance of E4bp4 as a 
central regulator of numerous aspects of the immune system has continued to grow. Despite 




1.6.1 Transcriptional regulation of E4bp4 
Due to its importance the activity of E4bp4 in a particular cell type is likely to be tightly 
regulated, but the precise molecular mechanisms by which this occurs remain unclear. In 
particular during NK cell development it is not known how E4bp4 activity is regulated and 
how it is able to promote an NK cell specific programme of gene expression. Various 
cytokines have been found to regulate the expression of E4bp4, including IL-3 in pro-B cells 
(Ikushima et al., 1997) (Yeung et al., 2004); IL-4, via STAT6 signalling, in T and B cells 
(Chen et al., 2003) (Schroder et al., 2002); IL-10, via STAT3 signalling in activated 
macrophages (Lang et al., 2002), and IL-15 in T cells (Ramsborg and Papoutsakis, 2007) 
and NK cells (Gascoyne et al., 2009). E4bp4 is expressed in CLPs and is required for the 
development of committed pre-NKPs, but NK cells don’t express the IL-15 receptor CD122 
until the rNKP development stage (Fathman et al., 2011). Therefore IL-15 is important for 
driving the expression of E4bp4 at a later stage of NK cell development, but it is likely to not 
be the only regulator. Other mechanisms must be utilised to control its activity early in NK 
cell development and in CLPs. 
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Glucocorticoids (GCs) have also been found to regulate the expression of E4bp4 (Priceman 
et al., 2006) (Wallace et al., 1997). In human and murine T cells, GCs can upregulate E4bp4 
expression leading to up regulation of Bim (member of Bcl-2 family, required for apoptosis) 
and eventually leading to GC-induced apoptosis (Beach et al., 2011) (Carey et al., 2013) 
(Priceman et al., 2006) (Zhao et al., 2013). A similar phenotype has also now been observed 
in osteoblasts, where E4bp4 induction, results in apoptosis (Chen et al., 2014). Whether 
GCs can regulate E4bp4 expression in NK cells and ILCs is unknown, but as these cells are 
involved in numerous inflammatory diseases, often treated by GCs, it would be interesting to 
determine if GCs influence E4bp4 activity in this cell type. 
 
 
1.6.2 Post transcriptional regulation of E4bp4  
Regulating TFs often occurs on the protein level, rather than at the level of transcription, so 
that rapid changes can occur to gene expression, allowing cells to adapt quickly to 
environmental signals. The activity of TFs is therefore essential for controlling cellular 
development and activation (Brivanlou and Darnell, 2002) (Deribe et al., 2010). The activities 
of TFs are controlled by four major mechanisms:  
 
A.   Regulation by protein-ligand binding; e.g. the transcriptional repressor DREAM is directly 
modulated by Ca2+ levels. Ca2+ binds directly to the DREAM protein, reducing its ability to 
repress transcription of target genes (Rivas et al., 2004). The DREAM protein has four Ca2+ 
binding motifs that, in the absence of Ca2+, interact as a tetramer with regulatory elements to 
inhibit transcription of target genes (Rivas et al., 2004). DREAM has a number of roles, but it 
is prominently involved with sensing pain in specific areas of the spinal cord (Cheng et al., 
2002). 
 
B.   Regulation by protein-protein interactions; e.g. the TF NFκB associates with IκB in the 
cytoplasm of unstimulated cells and cannot promote the activation of target genes (Viatour et 
al., 2005). Following cellular stimuli (e.g. by cytokines or bacterial lipopolysaccharides), 
NFκB can be rapidly activated by cellular signalling that induces phosphorylation and 
ultimately degradation of IκB, allowing NFκB to freely localise to the nucleus and promote 
gene expression (Viatour et al., 2005). Activation of NFκB is important for inflammatory 
responses as it induces cell proliferation and anti-apoptotic gene expression, but aberrant 
NF-kB activity is common during inflammatory disease (Viatour et al., 2005). 
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C.   Regulation by proteasomal degradation; e.g. The gene silencing TF REST is expressed 
in pluripotent stem cells and actively represses the transcription of neuronal-specific genes 
(Ballas et al., 2005). As stem cells develop into neuronal precursors REST is degraded more 
rapidly, reducing the amount of protein in the cell, allowing neuronal genes to be initially 
expressed (Ballas et al., 2005). Once neurons fully develop synthesis of REST is switched 
off completely and neuronal genes are fully active (Ballas et al., 2005). 
 
D.   Regulation by post translational modifications (PTMs); hundreds of TFs have been 
identified to be modified by numerous different PTMs that regulate their activity in a positive 
or negative fashion. For example, acetylation of the TF p53, by the acetyl-transferase p300, 
disrupts interactions with its inhibitor Mdm2, increases its DNA binding capacity, leading to 
the activation of stress-related genes (Tang et al., 2008). 
 
Many of these mechanisms for regulating TF activity overlap; PTMs can promote or prevent 
interactions between proteins, whilst other PTMs can lead to the degradation of a modified 
protein (Filtz et al., 2014). PTMs serve to exponentially increase the functionality of the 
proteome in vertebrates; by creating modified forms of pre-existing proteins, multiple 
functions can therefore be provided by a single gene product (Figure 1.8). PTMs help to 
make up for the relatively small number of genes encoded for by the genomes of complex 
mammals and permit the tissue and cell specific activities of individual TFs (Figure 1.8). 
Large numbers of different PTMs have now been identified, but some of the most common 
include: phosphorylation, ubiquitination, acetylation, glycosylation, methylation and 
SUMOylation. Some modifications are simple small chemical modifications whilst others are 
much larger more complex molecules, but all can have significant effects on the activity of a 
target protein. PTMs can alter every aspect of a TFs activity, including its localisation, 
stability, interactions with other proteins, DNA binding capacity, secondary and/or tertiary 
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interactions caused E4bp4 to repress target gene expression, by inducing a repressive 
chromatin structure. Whether these interactions are important in other cell types, and in 
other contexts, remains to be explored. 
 
The only mechanism of E4bp4 regulation that is associated with NK cells is its interaction 
with the histone H2A deubiqutinase MYSM1 (Nandakumar et al., 2013). Nandakumar et al. 
were able to show that MYSM1 associates with E4bp4 at the Id2 locus in NK cells and both 
are required for Id2 transcription (Nandakumar et al., 2013). E4bp4 co-immunoprecipitated 
with MYSM1, but only when the proteins were over expressed together in 293T cells, rather 
than directly from NK cells (Nandakumar et al., 2013). It would be interesting to ascertain if 
this interaction is required for the transcriptional regulation of other NK cell specific genes 
and if this is a mechanism employed by E4bp4 to regulate target gene expression in other 
cell types. 
 
As E4bp4 is central to numerous biological processes it is likely to be regulated by complex 
mechanisms and if these can be understood in more detail it may allow for the activity of 
E4bp4 to be modulated. For example, increased expression of E4bp4 in NK cell 
development has been shown to promote the development of greater numbers of NK cells 
(Gascoyne et al., 2009). This could potentially be important when it comes to developing a 
system for producing large quantities of cytotoxic NK cells for immunotherapeutic purposes. 
Numerous strategies have been developed for creating clinical-grade NK cells for adoptive 
transfer into patients, but modulating the activity of E4bp4 in these systems could help to 
further increase quantity and potentially cytotoxicity of the NK cells produced. 
 
To begin to ascertain in more detail how the activities of E4bp4 may be regulated, the Brady 
laboratory performed a yeast-two-hybrid screen to identify proteins that interact with E4bp4 
(Brady laboratory, unpublished). Full length E4bp4 protein was used as the bait and 
screened for interactions with the human leucocyte/activated mononuclear cell library 
(Hybrigenics). Twenty one proteins were identified in the screen, but only 11 of these 
received multiple positive identifications (Table 1.1). Many of the identified proteins have no 
known function or were common contaminants in yeast-two-hybrid analysis such as 
cytoskeletal proteins. No interactions were observed between E4bp4 and previously 
suggested binding partners including Dr1 (Cowell and Hurst, 1996), CREB (Acharya et al., 
2006) or any histone modification enzymes.  
 
Strikingly the protein with the highest number of positive identifications was PIAS1 (Table 
1.1). PIAS1 is a SUMO E3 ligase, which is involved in the addition of post translational 
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SUMO modifications onto target proteins. Additionally, positive hits were also achieved for 
PIAS3 and RanBP2, both of which are also SUMO E3 ligases (Table 1.1). This data 
provided the first evidence that E4bp4 may be post translationally SUMOylated. As very few 
others proteins were identified to interact with E4bp4 in the yeast-two-hybrid screen, other 
than SUMO E3 ligases, it was postulated that these interaction could be important for its 




Table 1.1 – E4bp4 interacting partners from yeast-two-hybrid screen.  
Gene Name Positive Identifications Protein function 
C18orf25 1 Unknown 
CHD1 1 DNA helicase binding protein  
DSP 2 Cytoskeletal protein 
FLJ13057 5 Unknown 
FLJ544447 1 Unknown 
FLNA 1 Cytoskeletal protein 
HIPK1 1 Serine/threonine protein kinase 
HIPK3 5 Serine/threonine protein kinase 
PIAS1 20 SUMO E3 ligase 
PIAS3 2 SUMO E3 ligase 
RANBP2 1 SUMO E3 ligase 
RNF111 1 SUMO-targeted ubiquitin ligase 
SETX 2 DNA helicase 
SNRP70 2 Splicesomal ribonucleoprotein 
SORL1 1 Neuronal apolipoprotein E receptor 
TLK2 2 Tousled-like serine/threonine kinase 
U5-200KD 1 RNA helicase 
ZBTB16 1 Zinc finger transcription factor 
ZMYM5 5 Zinc Finger MYM-Type Protein 
ZNF198 5 Zinc Finger Transcriptional cofactor 









The only previous evidence of a PTM regulating E4bp4 activity is for phosphorylation and 
the data about this PTM is limited and contradictory. Chen et al. first identified E4bp4 as a 
phosphoprotein almost 20 years ago and suggested phosphorylation was important for 
E4bp4’s ability to bind DNA (Chen et al., 1995). In contrast, a study by Doi et al. studying 
E4bp4 in the chick pineal gland, suggested E4bp4 is phosphorylated by Casein Kinase 1ε 
(CK1ε) and modification by this kinase reduces the activity of E4bp4 (Doi et al., 2004). 
However, both of these studies used recombinant and in vitro systems to study E4bp4 and 
their observations may not be indicative of what occurs to E4bp4 in vivo. Additionally, no 
specific phosphorylation sites for E4bp4 have been conclusively identified. As PTMs can 
have profound effects on the activity of TFs, understanding the modifications of E4bp4 could 
be vital for fully establishing how it regulates various processes in the immune system. 
Whether phosphorylation or potentially SUMOylation are required for the functions of E4bp4, 









1.7 Project aim and research questions 
E4bp4 is a regulator of various immunological processes including class switching in B cells 
to produce IgE, cytokine production by CD4+ T helper cells and in the development of CD8α+ 
cDCs (Male et al., 2012). Its most prominent role appears to be in the development of NK 
cells and other ILC subsets, where it is essential for developing lymphocytes to commit to 
become innate lymphocytes rather than T or B cells (Geiger et al., 2014) (Male et al., 2014) 
(Seillet et al., 2014b). However, very little is known about the molecular mechanisms that 
control the activities of E4bp4, particularly in NK cells. 
 
The main aim of this thesis was to ascertain a greater understanding of the regulation of the 
bZIP transcription factor E4bp4, particularly by PTMs and determine if this affected NK cell 
development and function. The specific research questions of this thesis were: 
 
1) Determine if E4bp4 is SUMOylated in vivo using HeLa cell lines stably expressing 
6His-SUMO1, 6His-SUMO2 and 6His-SUMO3. 
2) Ascertain the exact sites of E4bp4 SUMOylation using high accuracy mass 
spectrometry and mutate these sites to create versions of E4bp4 that lack all SUMO 
modifications. 
3) Using an in vitro NK cell development assay to establish whether SUMOylation of 
E4bp4 is required for regulating its activity. 
4) Confirm that E4bp4 is phosphorylated and use mass spectrometry to accurately 
determine which amino acids are phosphorylated. 
5) Mutate E4bp4 phosphorylation sites and establish whether the phosphorylation of 
E4bp4 is important for its function in NK cell development. 
6) Determine how the post translational modifications of E4bp4 influence its function as 




















40 mM Tris  
20 mM Acetic Acid 
1 mM EDTA pH 8.0  
 
LB medium 10 g/L Peptone  
10 g/L Yeast extract  
5 g/L Sodium chloride 
 
SOC medium 2% (w/v) Peptone 
0.5% (w/v) Yeast Extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM Glucose 
 
NZY+ medium 10% (w/v) NZ amine 
5% (w/v) Yeast extract 
5% (w/v) NaCl 
12.5 mM MgCl2 
12.5 mM MgSO4 
20 mM Glucose 
pH 7.5 – adjusted with NaOH 
 
LB agar medium 10 g/L Peptone  
5 g/L Yeast extract  
10 g/L Sodium chloride 
15 g/L Agar 
 
SDS-PAGE running buffer 25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS 
 
Transfer buffer 48 mM Tris 
39 mM Glycine 
0.04% (w/v) SDS 










Laemmli sample buffer 
 
125 mM Tris-HCl pH 6.8 
2% (w/v) SDS 
25% (v/v) Glycerol 
0.005% (w/v) Bromophenol Blue 
5% (v/v) β-mercaptoethanol 
 
PBST PBS 
0.1% (v/v) Tween20 
 
Blocking buffer PBS 
0.1% (v/v) Tween20 
3% (w/v) Skim Milk Powder 
 
CE buffer 10 mM Hepes pH 8.0 
1.5 mM MgCl2 
10 mM KCl 
1% (v/v) Trition X-100 
0.05% (v/v) β-mercaptoethanol 
Complete protease inhibitors 
 
NE buffer 10 mM Hepes pH 8.0 
1.5 mM MgCl2 
0.2 mM EDTA 
25% (v/v) glycerol 
450 mM NaCl 
0.05% (v/v) β-mercaptoethanol 
Complete protease inhibitors 
 
Low salt TBS 50 mM Tris-HCl pH 7.4 
100 mM NaCl 
0.01% (v/v) Trition X-100 
 
High salt TBS 50 mM Tris-HCl pH 7.4 
300 mM NaCl 
0.01% (v/v) Trition X-100 
 
FLAG elution buffer 150 ng/ul FLAG peptide 
50 mM Tris-HCl pH 7.4 
300 mM NaCl 
0.01% (v/v) Trition X-100 
 
 






0.1 M Sodium phosphate  
buffer pH 6.3 
45 mM Na2HPO4 
155 mM NaH2PO4 
50% (v/v) H2O 
 
0.1 M Sodium phosphate  
buffer pH 8.0 
190 mM Na2HPO4 
10 mM NaH2PO4 
50% (v/v) H2O 
 
SUMO cell lysis buffer 
 
6 M Guanidinium-HCl 
10 mM Tris 
0.1 M Sodium phosphate buffer pH8 
 
pH 8.0 wash buffer 8 M Urea 
10 mM Tris 
0.1 M Sodium phosphate buffer pH 8.0 
0.1% (v/v) Trition X-100 
5 mM β-mercaptoethanol 
 
pH 6.3 wash buffer 8 M Urea 
10 mM Tris 
0.1 M Sodium phosphate buffer pH 6.3 
0.1% (v/v) Trition X-100 
5 mM β-mercaptoethanol 
 
SUMO elution buffer 200 mM Imidazole 
5% (w/v) SDS 
150 mM Tris-HCl pH 6.7 
30% (v/v) glycerol 
720 mM β-mercaptoethanol 
0.005% (w/v) bromophenol blue 
 
Two-step lysis buffer 20 mM Tris-HCl pH 7.4 
10 mM MgCl2 
10 mM KCl 
2 mM EDTA 
10% (v/v) glycerol 
1% (v/v) Trition X-100 
Protease and phosphatase inhibitors 










MACS buffer PBS 
2 mM EDTA pH 8.0 
0.5% (w/v) BSA 
  
FACS buffer PBS 
1% (v/v) FBS 
 
Complete cytokine medium       DMEM 
10% (v/v) FBS 
100 U/ml Penicillin 
100 μg/ml Streptomycin 
10 ng/ml Flt3 ligand 
10 ng/ml IL-7 
100 ng/ml Stem cell factor 
50 μM β-mercaptoethanol 
  
IL-15 medium Minimal essential medium 
20% (v/v) FBS 
100 U/ml Penicillin 
100 μg/ml Streptomycin  
50 μM β-mercaptoethanol 
30 ng/ml IL-15 
 
NK cell differentiation medium DMEM 
20% (v/v) Human serum 
100 U/ml Penicillin 
100 μg/ml Streptomycin  
50 μM β-mercaptoethanol 
10 ng/ml IL-15 
5 ng/ml IL- 3 (first week of culture only) 
20 ng/ml IL-7  
20 ng/ml Stem cell factor 









2.2 Cells and cell culture 
2.2.1 Cell lines 
Immortalised cell lines and primary cells used in this study were maintained at 37˚C and 5% 
CO2. HEK-293T, HeLa, NIH-3T3, Cos-7, MNK-1 and LinXE cell lines were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) (Sigma Aldrich). OP9-GFP stromal cells were 
cultured in Iscove's Modified Dulbecco's Media (IMDM) (Sigma Aldrich) and BaF3 cells were 
cultured in RPMI-1640 (Sigma Aldrich). The media for all cell lines was supplemented with 
10% fetal bovine serum (FBS) (Gibco), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin (Sigma Aldrich). 
 
MNK-1 cells (gift from David S.J. Allan and James R. Carlyle, University of Toronto, Canada) 
are a murine NK cell line and were cultured in the presence of 25 mM HEPES, 50 µM β-
mercaptoethanol, 1 mM sodium pyruvate and 10 ng/mL IL-2 (Peprotech). HeLa cells stably 
expressing 6His-SUMO-1, 6His-SUMO-2 and 6His-SUMO-3 (gift from Ronald T Hay, 
University of Dundee, UK) were cultured in the presence of 5 μM puromycin, to maintain 
selection of 6His-SUMO proteins. LinXE cells were cultured under 15 μM hygromycin 
selection to maintain the expression of retroviral packaging genes. 
 
E108.1D2 stromal cells were cultured in Alpha-MEM with Glutamax (Gibco) supplemented 
with 50% Myelocult M5300 (Stem Cell Technologies), 7.5% FBS, 50µM β-mercaptoethanol, 
1 µM hydrocortisone, 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma Aldrich). For 
CD34+ stem cell differentiation experiments E108.1D2 cells were plated into 96-well 
EmbryoMax Gelatin (Millipore) coated plates, irradiated at 3000 rads/30 Gy and maintained 




Cell lines were transfected with a number of plasmid constructs and in each case a 100 mm 
dish of cells was grown to 60 - 85% confluencey on the day of transfection. HeLa and HEK-
293T cells were transfected with 8 μg of plasmid DNA and 40µl of the transfection reagent 
Lipofectamine (Invitrogen). LinXE cells were transfected with 2 µg of plasmid DNA using 
20µl of the transfection reagent Effectene (Qiagen). 3T3 cells were cultured in 24 well plates 
prior to transfection (for Luciferase reporter assay) and each well of cells was transfected 
with 200 - 500 ng of plasmid DNA and 5 µl Effectene. All transfectants were incubated for 48 
hours before transgene expression was analysed and/or cell lysates were prepared. 






All animals used were on a C57BL/6 background, between six and twelve weeks old and 
were matched for age and gender. Where possible, littermates were used. E4bp4-/- mice 
were generated as previously described (Gascoyne et al., 2009). Mice were genotyped with 
the forward primer 5'~CTCTGAGCTTGGCTGATGTG~3' (primer A) and reverse primer 
5'~GCTTCAAGTCTCCACCAAGC~3' (primer B) for detection of the wild type allele or 
5'~CCATGCTCCTGTCTTGATGA~3' (primer C) for detection of the knockout allele (Figure 
2.1). The phenotype of all mice used was confirmed by flow cytometry, with knockouts 
defined by the absence of NK1.1+ CD3- splenocytes (Figure 2.2). Whole mouse spleens 
were crushed through a 40 µM strainer into 1 ml PBS. 10% of the cell suspension was ACK 
lysed for 3 minutes, washed in PBS and resuspended in 200 µl FACS buffer for staining with 
antibodies against NK1.1 and CD3. All animal husbandry and experimental procedures were 







Figure 2.1 – Genotyping E4bp4-/- mice. 
Genomic DNA was isolated E4bp4-/- mice tail or ear clips. Two PCR reactions were performed on each sample to 
determine the presence of the WT and KO allele.  
 








Figure 2.2 – Phenotype of E4bp4-/- mice. 
Splenocytes from WT and E4bp4-/- mice were ACK lysed, before staining with antibodies against NK1.1 and CD3 
to identify the presence of NK cells.  
 
 
2.3 Molecular biology and cloning 
2.3.1 DNA electrophoresis 
DNA electrophoresis was performed using 1% agarose (Sigma), dissolved in TAE buffer and 
stained with 500 ng/ml Ethidium Bromide (Sigma). DNA samples were mixed with 5X DNA 
loading buffer (Bioline) and loaded into gel wells before electrophoresis was performed at 
100 volts for approximately 60 minutes. Gels were imaged using an EC3 Imaging System 
(Ultra Violet Products Ltd).  
 
 
2.3.2 Polymerase chain reaction 
E4bp4 complementary DNA (cDNA) was amplified by Polymerase chain reaction (PCR) 
using specific sets of primers and Q5 High-Fidelity DNA Polymerase (New England Biolabs). 
Individual PCR reactions contained: 200 µM dNTPs, 0.5 µM forward primer, 0.5 µM reverse 
primer, approximately 100 ng template DNA and 1 U DNA polymerase. PCR reactions were 
subjects to thermal cycling: 98°C for 30 seconds (1 cycle); 98°C for 15 seconds, 55°C for 15 
seconds, 72°C for 30 seconds (30 cycles); 72°C for 2 minutes (1 cycle); hold at 4°C. 
Following thermal cycling PCR products were purified using QIAprep PCR Purification Kit 
(Qiagen) and eluted in 30 µl H2O. 





2.3.3 Restriction enzyme digests 
Restriction enzymes (Promega) were used to cleave double stranded DNA (dsDNA) and 
reactions were set up using manufacturer’s instructions. Digests were incubated for 3 hours 
at 37°C before products were analysed on a 1% agarose gel. Bands of interest were excised 
from the gel using a scalpel and DNA was purified using the QIAquick Gel Extraction kit 
(Qiagen) and eluted in 30 µl H2O. 
 
 
2.3.4 Ligation and transformation of competent bacteria 
Digested PCR products were ligated into the desired vector using T4 DNA ligase (Promega) 
using the manufacturer’s instructions and an insert:vector ratio of 3:1. Ligations were 
performed at room temperature (RT) for 3 hours or at 16°C overnight (O/N). Ligations 
products were transformed into One Shot® TOP10 Chemically Competent E. coli cells (Life 
Technologies) to maintain the ligation product. 1 µl of ligation reaction was added to 25 µl of 
E. coli cells and incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 40 
seconds, incubated on ice for 2 minutes and then 250 µl SOC media was added to each 
reaction. Cells were allowed to recover at 37°C, shaking at 250 rpm, for 1 hour, before being 
plated on to LB agar plates containing the correct antibiotic to select for successful 
transformants. Bacterial cultures were selected with either 100 µg/ml Ampicillin (Sigma) or 
50 µg/ml Kanamycin (Sigma). 
 
 
2.3.5 Colony PCR 
To determine successful cloning of PCR products, transformed colonies were screened by 
colony PCR. Individual transformed colonies were used to inoculate 10 µl of LB medium and 
1 µl of this bacterial suspension was analysed in each PCR reaction. PCR reactions were 
performed using DreamTaq Green DNA polymerase (Thermo Scientific) and reactions were 
set up using manufacturer’s instructions. PCR conditions were: 98°C - 5 mins; 1 cycle of 
98°C – 1 min, 55°C – 1 min, 72°C – 2 mins; followed by 30 cycles of 98°C – 30 sec, 55°C – 
35 sec, 72°C – 90 sec; and finally 72°C – 7 mins. Following thermal cycling, reactions were 
directly loaded onto 1% agarose gels for analysis.  
 
 
2.3.6 Plasmid preparations and sequencing 
For small scale plasmid preparations, 3 ml LB media (plus antibiotic) was inoculated with a 
single colony of transformed E. coli and incubated at 37°C, shaking, for approximately 16 





hours. Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen) and DNA 
was eluted in 30 µl H2O. Larger scale plasmid preparations used 100 ml LB media (plus 
antibiotic) and the plasmid DNA was purified using the QIAfilter Plasmid Midi Kit (Qiagen). 
Using this kit, DNA was eluted in 200 µl H2O. The concentrations of DNA samples were 
determined using a Nanodrop ND-1000 and DNA samples were sent to Eurofins Genomics 
(Ebersberg, Germany) to be sequenced using a number of specific primers (Table 2.1). 
Each sequencing reaction contained 1.5 µg template DNA and 2 pmol/µl primer. 
 
Table 2.1 – Primers used for sequencing. 











2.3.7 Site directed mutagenesis 
Single base pair mutations were made in the E4bp4 cDNA (K10R, K116R, K219R, K337R, 
K394R, S182A, S285A S286A, S301A, S352A and S353A), in pCMV-script expression 
vector, using the QuikChange® XL site-directed mutagenesis kit (Agilent). Specifically 
designed primers (Table 2.2) were used to incorporate specific single base mutations during 
temperature cycling. The Dpn I restriction enzyme was used to remove methylated 
(unmutated) DNA, before double stranded DNA (dsDNA) was transformed into XL10-Gold 
ultracompetent cells (Agilent). 2 µl of mutated DNA was added to 45 µl of competent cells 
and incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 30 seconds, 
incubated on ice for 2 minutes and then 500 µl NZY+ media was added to each reaction. 
Cells were allowed to recover at 37°C, shaking at 250 rpm, for 1 hour, before being plated 
on to LB agar plates. Each mutated construct was sequenced to ensure that the mutation 
had been correctly incorporated. Mutations for double, triple, quadruple and quintuple 
mutants were made using the same method.  
 





Table 2.2 – Primers used for site-directed mutagenesis. 
Mutation Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
K10R AAAATGCAGACCATCAGAAAGGAGCCCGCACCC GGGTGCGGGCTCCTTTCTGATGGTCTGCATTTT 
K116R GGGAGAAGAAAATGCCACTTTAAGAGCTGAGCTGCT AGCAGCTCAGCTCTTAAAGTGGCATTTTCTTCTCCC 
K219R AACAAGTTCCCTGTGATCAGGCAGGAGCCCG CGGGCTCCTGCCTGATCACAGGGAACTTGTT 
K337R GCCAAGGCCATGCAGGTCAGAGTGGAGGCT AGCCTCCACTCTGACCTGCATGGCCTTGGC 
K394R TCAAGATTGGTCCCTCAGATCGGAACACTGGCATC GATGCCAGTGTTCCGATCTGAGGGACCAATCTTGA 
S182A CAGTCATCAAGCACGCTCCCCAGAGCTCG CGAGCTCTGGGGAGCGTGCTTGATGACTG 
S210A GGGAGGCTGCCGGGCCCCTGAGAACAAG CTTGTTCTCAGGGGCCCGGCAGCCTCCC 
S285A GGTGTAGTGGGCAAGGCTTCTGATGGGGAAG CTTCCCCATCAGAAGCCTTGCCCACTACACC 
S286A GTAGTGGGCAAGTCTGCTGATGGGGAAGACG CGTCTTCCCCATCAGCAGACTTGCCCACTAC 
S301A TAAGGGCCCCATCCATGCTCCAGTGGAGC GCTCCACTGGAGCATGGATGGGGCCCTTA 
S353A ATGCAGAAACTCTCTGCACCCGCCGATGCG 





2.3.8 Cloning of mutant E4bp4 cDNA into pMSCV-IRES-hCD2 
WT E4bp4 cDNA and each mutant E4bp4 cDNA were cloned into the pMSCV-IRES-hCD2 
retroviral expression vector (Gascoyne et al., 2009) (Male et al., 2014). Each cDNA was 
excised from the pCMV-script vector using NotI and XhoI restriction enzymes (Promega) and 
the pMSCV-IRES-hCD2 vector was digested in the same way. Each of the E4bp4 fragments 
was separately ligated into pMSCV-IRES-hCD2 and ligation products were transformed into 
competent E. coli cells. 
 
 
2.3.9 Cloning of mutant E4bp4 cDNA into pCSGW 
The WT E4bp4 cDNA and a number of mutant E4bp4 cDNAs were cloned into the pCSGW 
lentiviral expression vector. The E4bp4 cDNAs were amplified using specific forward and 
reverse primers, designed to incorporate BamHI and NotI digest sites at the 5’ and 3’ ends of 
the PCR product respectively:  
 
pCSGW-E4bp4 forward primer: 5’-CTAGGATCCACCATGCAGCTGAGAAAAATG-3’ 
pCSGW-E4bp4 reverse primer: 5’-GTAGCGGCCGCGAGTCACAAGTCCTCTTC-3’ 
 





The PCR products and pCSGW vector were digested with BamHI and NotI restriction 
enzymes, purified, ligated together and transformed into competent E. coli. Successfully 
transformed colonies were tested for the presence of E4bp4 using colony PCR. Positive 
colonies were expanded and plasmid DNA was purified and sequenced. 
 
 
2.3.10 Cloning of FLAG-E4bp4 
E4bp4 cDNA (in the pCMV-script vector) was amplified by PCR using primers designed to 
incorporate:  5’ NotI restriction digest site, 5’ ATG start codon, 5’ FLAG tag, 3’ stop codon, 
and  3’ XhoI restriction digest site (Table 2.3). The PCR amplification was performed in two 
stages: 1) E4bp4 cDNA was amplified from pCMV vector template using primers FLAG-
E4bp4-FW #1 and FLAG-E4bp4-RV; 2) The product from stage 1 was amplified further using 
primers FLAG-E4bp4-FW #2 and Flag-E4bp4-RV. The resulting product was purified, 
digested with NotI and XhoI restriction enzymes, ligated into the pCMV-script vector and the 
resulting ligation product was transformed into competent E. coli. Successfully transformed 
colonies were tested for the presence of FLAG-E4bp4 using colony PCR. Positive colonies 
were expanded and plasmid DNA was purified and sequenced. 
 
 
Table 2.3 – Primers used for cloning FLAG-E4bp4. 
Name Primer sequence (5’ – 3’) 
FLAG-E4bp4-FW #1 CAAGGATGACGACGATAAGCAGCTGAGAAAAATGCAGACCAT 
FLAG-E4bp4-FW #2 ATTGCGGCCGCCACCATGGATTACAAGGATGACGACGATAAG 
FLAG-E4bp4-RV ATACTCGAGTCACCTGGAGTCCGAAGCCGAGATCGGT 
Features: 












2.4 SDS-PAGE and Western blotting 
Cell lysates and protein samples were mixed 1:1 with Laemmli sample buffer and reduced 
by boiling in 5% β-mercaptoethanol for 5 minutes. Samples were separated on 8% 
polyacrylamide gels, submersed in SDS-PAGE running buffer, subjected to a constant 100 
volts for approximately 90 minutes. To visualise the whole protein content of samples gels 
were stained with Imperial Protein Stain (Thermo Scientific) using manufacturer’s 
instructions. 
 
For Western blotting (WB), gels were not stained and samples were transferred from SDS-
PAGE gels onto PVDF membranes using a wet transfer, run at constant 100 volts for 1 hour 
at 4˚C. Transferred membranes were blocked with blocking buffer for 1 hour at RT or at 4˚C 
O/N. Primary antibodies (Table 2.4) were used to probe blots for 1 hour at RT or O/N at 4˚C. 
All primary antibodies were used at the appropriate concentration and diluted in blocking 
buffer (Table 2.4). All blots were washed 3 x 10 minutes in PBST buffer prior to incubation 
with the appropriate HRP-conjugated secondary antibody (Table 2.4). Membranes were 
washed again for 3 x 10 minutes before chemiluminescence was detected using Western 
Lightning® Plus-ECL detection reagents (Perkin Elmer). Images of exposed blots were 
digitally acquired using the ChemiDoc™ XRS+ system (Bio-Rad).  
 
 
2.5 Flow cytometry and cell sorting 
Cells to be analysed by flow cytometry were washed in PBS buffer, centrifuged at 500 g for 5 
minutes at 4°C and suspended in 200 µl FACS buffer. Cells were stained with the 
appropriate fluorochrome conjugated antibodies, all of which were used at a concentration of 
1/100 (Table 2.5). Cells were stained for 15 - 30 minutes, at 4°C, in the dark. Cells were 
washed with 2 ml FACS buffer, centrifuged again and suspended in 300 µl FACS buffer for 
analysis. Flow cytometry was performed using an LSRFortessa™ cell analyser (Becton 
Dickinson Bioscience) and off-line data analysis was performed using FlowJo software. 
 
Cells for sorting were prepared in the same way and resuspended in FACS buffer at a 
concentration < 5 x 106 cells ml-1. Cells were sorted using a FACSAria II (Becton Dickinson 
Bioscience) and positive cells were sorted in bulk into 15 ml falcon tubes containing 
appropriate growth media, supplemented with 20% FBS. 
 





Table 2.4 – Antibodies used for Western blotting. 
PRIMARY ANTIBODIES    
Target Origin Clone Source Concentration 
E4bp4 Goat C18 Santa Cruz Biotech 1/1000 
SUMO2/3 Rabbit 3742 AbCam 1/1000 
FLAG Mouse M2 Sigma Aldrich 1/500 
c-Myc Mouse 9E10 Roche 1/1000 
6X His Mouse 4D11 AbCam 1/5000 
Alpha-Tubulin Mouse DM1A eBioscience 1/2000 
RanGAP1 Rabbit ab4784 AbCam 1/1000 
Phospho-serine Mouse PSR-45 Sigma 1/500 
Histone H3 Rabbit ab1791 AbCam 1/10000 
HA Rabbit ab9110 AbCam 1/1000 
SUMO1 Rabbit PW9460 Enzo Life Sciences 1/1000 
 
 
HRP-CONJUGATED SECONDARY ANTIBODIES 
Antibody Origin Clone Source Concentration 
Anti-mouse Rabbit ab98790 AbCam 1/10000 
Anti-rabbit Goat ab97080 AbCam 1/10000 


















Table 2.5 – Fluorochrome conjugated antibodies. 
Antigen Clone Conjugate Origin Isotype Source 
CD3 17A2 e450 Rat IgG2b eBioscience 
CD19 eBio1D3 e450 Rat IgG2a eBioscience 
hCD2 RPA-2.10 APC Mouse IgG1 eBioscience 
NK1.1 PK136 PE Mouse IgG2a eBioscience 
CD11b M1/70 PE Rat IgG2b eBioscience 
GR-1 RB6-8c5 PE Rat IgG2b eBioscience 
CD8 29A1.4 PerCP e710 Rat IgG2a eBioscience 
B220 RA3-6B2 PE Rat IgG2a eBioscience 
Ter119 Ter119 PE Rat IgG2b eBioscience 
CD2 RM2-5 PE Rat IgG2b eBioscience 
CD11b M1/70 PE-Cy7 Rat IgG2b eBioscience 
CD4 GK1.5 FITC Rat IgG2b eBioscience 
CD127 A7R34 FITC Rat IgG2a eBioscience 
hCD56 CMSSB APC Mouse IgG1 eBioscience 




2.6 Analysis of SUMOylation in vivo 
Protocol adapted from (Tatham et al., 2009). HeLa cell lines 6His-SUMO-1, 6His-SUMO-2, 
6His-SUMO-3 and the parental HeLa cells were transfected with pCMV-E4BP4 or pCMV 
(empty vector). After transfection each plate of cells was resuspended, washed with PBS 
and 20% of the cell suspension was removed as an input sample. The remaining cells were 
lysed in 5 ml SUMO cell lysis buffer containing 6 M Guanidinium-HCl, whilst the input sample 
cells were lysed in 100 µl 2x Laemmli sample buffer and analysed by WB for the expression 
of E4bp4 and 6His-SUMO.  
 
Ni2+ affinity purification was performed on the larger cell lysates to enrich for all of the SUMO 
modified proteins. 50 µl of Ni2+ NTA agarose beads (Qiagen) were incubated with each cell 
lysate O/N at 4˚C. The following day, the unbound material was discarded before the 
agarose beads were washed extensively with SUMO cell lysis buffer, pH 8.0 wash buffer 





and three times with pH 6.3 wash buffer. His-tagged proteins were eluted from agarose 
beads with 50 µl elution buffer, containing 200 mM imidazole. The samples were boiled for 5 
minutes to ensure all material had been eluted and samples were analysed by WB for the 
presence of E4bp4, 6His-SUMO and RanGAP1 (positive control for the purification of 
SUMO-modified proteins). 
 
To analyse the effect of Listerolysin O (LLO) on the SUMOylation of E4bp4, transfected 
6His-SUMO2/3 cells were transferred into serum-free media 2 hours before being treated 
with 3 nM purified LLO (gift from David Ribet, Institute Pasteur, France) for 20 minutes at RT 
(Ribet et al., 2010). The purified LLO was added directly to the culture medium. Following 
LLO treatment cells were resuspended in PBS and lysed as described above. 
 
 
2.7 Immunoprecipitation of FLAG-E4bp4 
HeLa cell lines 6His-SUMO1, 6His-SUMO2 and 6His-SUMO3 were transfected with pCMV-
FLAG-E4bp4 or pCMV (empty vector). After transfection, cells were lysed using a two-step 
lysis protocol (Klenova et al., 2002). Cells were lysed in two-step lysis buffer (containing 
protease inhibitors, phosphatase inhibitors and 25 mM N-Ethylmaleimide to inhibit SUMO 
proteases), incubated on ice for 15 minutes, sonicated for 30 seconds, NaCl was added to 
each sample, at a final concentration of 420 mM and then each lysate was incubated for 60 
minutes rotating at 4°C. Following this incubation the lysates were sonicated again, 
centrifuged for 30 minutes at 10,000 g and the supernatant collected. 
 
To efficiently immunoprecipitate (IP) FLAG-E4bp4, cleared lysates were diluted 1:1 with low 
salt TBS and incubated with Anti-FLAG® M2 Affinity Gel (Sigma Aldrich) O/N at 4˚C. 
Samples were centrifuged at 5000 g for 30 seconds and the supernatant was removed (flow 
through sample). Each sample was washed three times with low salt TBS and three times 
with high salt TBS to remove any non-specially bound proteins. Laemmli sample buffer was 









2.8 Optimisation of FLAG-E4bp4 expression and purification  
To produce large quantities of E4bp4 for biochemical analysis, different cell lines were 
transfected to determine their ability to produce recombinant E4bp4. One 100 mm dish of 
3T3, Cos-7, LinXE and 293T cells was transfected with FLAG-E4bp4 using the 
Lipofectamine transfection reagent. 48 hours after transfection, 2 x 106 cells from each plate 
were lysed in 100 µl Laemmli sample buffer and 25 µl of each was analysed by WB for the 
expression of E4bp4. 
 
To increase expression of E4bp4 in 293T cells, each plate of cells was also transfected with 
a plasmid expressing VP35. Each 100 mm dish of cells was transfected with a total of 8 µg 
DNA, but with varying amounts of VP35. One plate of cells was transfected with: 0, 1, 2, 3 
and 4 µg of VP35 plasmid DNA and 8, 7, 6, 5 and 4 µg of pCMV-FLAG-E4bp4 DNA. Forty-
eight hours after transfection, 2 x 106 cells from each plate were lysed in 100 µl Laemmli 
sample buffer and 25 µl of each was analysed by WB for the expression of E4bp4. WBs 
were analysed using ImageLab software (Biorad) to quantify intensity of bands on blots. 
 
FLAG-E4bp4 was transfected into 293T cells, with 5 µg pCMV-FLAG-E4bp4 and 3 µg VP35 
per 100 mm tissue culture dish, and after 48 hours cells were lysed using the two-step lysis 
protocol (section 2.7). Cleared lysates were diluted 1:1 with low salt TBS and incubated with 
Anti-FLAG® M2 Affinity Gel O/N at 4˚C. Samples were centrifuged at 5000 g for 30 seconds 
and the supernatant was removed (flow through sample). Each sample was washed three 
times with low salt TBS and three times with high salt TBS to remove any non-specially 
bound proteins. Initially, a number of elution techniques were tested including: Laemmli 
sample buffer; 0.1 M glycine pH 2.5; 0.1 M glycine pH 10; 1 M Arg-HCl pH 2.5; 0.5 M Arg-
HCl pH 2.5; 150 ng/µl FLAG peptide and 300 ng/µl FLAG peptide. 
 
After initial optimisation all elutions were carried out using 150 ng/µl FLAG peptide in high 
salt TBS. Four elution fractions were taken from each resin and when elution buffer was 
removed, fresh buffer wash added to replace it. Each elution fraction was incubated with the 
resin for 4 - 16 hours, at 4°C, on a rotating wheel. For each sample all elution fractions were 
combined and concentrated using Amicon Ultra 0.5 ml centrifuge filters with a 30 kDa 
molecular weight cut off (Millipore). Purified samples were stored at -80°C, but 10% of each 
was always removed and mixed 1:1 with Laemmli sample buffer for analysis by WB and 
coomassie stained SDS-PAGE gel. 
 
 





2.9 Mass spectrometry analysis 
FLAG-E4bp4 was transfected into 10 x 100 mm tissue culture dishes of HEK-293T cells and 
48 hours after transfection cells were lysed (using the two-step lysis protocol - section 2.7) 
and FLAG-E4BP4 was purified separately from each lysate. The eluted samples were 
combined was concentrated using Amicon Ultra 0.5 ml centrifuge filters (Millipore). 10% of 
the final purified product was removed for analysis by WB and coomassie stained SDS-
PAGE gel, whilst the remaining was analysed by mass spectrometry (MS). 
 
Purified FLAG-E4bp4 was concentrated using vacuum centrifugation and resuspended in 
100 mM ammonium bicarbonate (Sigma Aldrich) pH 8. Reduction of disulfide bonds was 
carried out using a final concentration of 5 mM dithiothreitol (Fisher Scientific) for 1 hour at 
51°C and iodoacetamide (Sigma-Aldrich) was then added at a final concentration of 14 mM 
and allowed to react in the dark for 45 mins to label the reduced cysteines (Villen and Gygi, 
2008). Proteomics-grade trypsin (Promega) was added at a 1:20 w/w ratio to digest the 
E4bp4 protein for 6 hours at 37 °C. For SUMOylated peptide analysis the sample was 
sequentially digested with endoproteinase GluC (Roche), which was added at a 1:10 w/w 
ratio and incubated for 6 hours at RT. After quenching the digestions by freezing to -80°C 
the peptides were dried by vacuum centrifugation. The SUMOylated peptides were desalted 
with ZipTips (EMD Millipore) (Rappsilber et al., 2003) and reconstituted into the correct 
loading solvent for nano LC–MS whilst phosphopeptides were processed further.  
 
For phosphopeptide analysis, phosphorylated peptides were enriched using titanium dioxide 
(GL sciences) as previously described (Li et al., 2009). Titanium dioxide beads were first 
dissolved at a ratio of 1:50 (w/v) into a loading buffer comprised of saturated glutamic acid in 
H2O, 65% acetonitrile (MeCN), 2% trifluoroactic acid (TFA) (v/v/v) and incubated at RT on a 
shaker for 10 mins. Tryptic peptides were resuspended in loading buffer and then added to 
the titanium dioxide slurry at a ratio of 1:4 (w/w) using the original protein weight, and 
incubated at RT on a shaker for 30 mins. The slurry was spun down to pellet the titanium 
dioxide bound phosphopeptides and the supernate discarded. To wash the 
phosphopeptides, the pellet was resuspended in loading buffer and incubated at RT on a 
shaker for 15 mins, spun down and the supernate discarded. This step was repeated using 
34.5% H2O, 65% MeCN and 0.5 TFA (v/v/v), and followed by a repetition with 34.9% H2O, 
65% MeCN and 0.1 TFA (v/v/v). To elute the phosphopeptides, the pellet was resuspended 
in 50% 300 mM ammonium hydroxide (NH4OH) in H2O and 50% MeCN (v/v) and incubated 
at RT on a shaker for 15 mins, spun down and the supernate collected. This step was 
repeated using 50% 500 mM NH4OH and 50% MeCN (v/v) pooling the supernate each time 





for a further 2 times. The eluted phosphopeptides were then desalted with ZipTips 
(Rappsilber et al., 2003) and reconstituted into the correct loading solvent for nano LC–MS. 
 
Peptides were chromatographically resolved on an Ultimate 3000 RS-LC-nano System 
(Dionex), with an Acclaim PepMap100, C18 stationary phase, 2 μm particle size, 100 Å pore 
size, 75 μm internal diameter x 15 cm length column (Thermo Fisher). The LC gradient 
conditions comprised of a flow rate of 0.3 μL/min and a gradient starting at 1% B (5% H2O, 
95% MeCN, and 0.1% formic acid) and 99% A (0.1% formic acid and 100% H2O) and 
increased to 50% B over 80 min followed by an increase to 95% B over 25 mins. Real-time 
tandem mass spectra were acquired on an LTQ Velos Pro linear ion trap (Thermo Scientific) 
with a 120 min acquisition time. Phosphopeptides were analysed using a 375–2000 m/z 
scan range and CID fragmentation collision energy of 35%. Tandem mass spectra were 
collected using top 6 data-dependent acquisition, with a dynamic exclusion list (repeat count 
of 2, repeat duration of 30 seconds, exclusion list size 100, and exclusion duration of 60 
seconds). Initial phosphopeptide identification from the nanoLC–MS/MS data was performed 
using a Sequest search in Proteome discoverer 1.3 (Thermo Fisher) against the Mouse 
Uniprot database. Reverse decoy false-discovery-rate values of 0.01/0.05 were used 
(strict/relaxed), allowing for 4 missed cleavages and a 2 Da precursor mass tolerance. 
Dynamic side-chain modifications included in the search were carbamidomethyl (+57.021; 
from iodoacetamide treatment), phosphorylation (+79.966) on serine, threonine, and tyrosine 
residues, and oxidation (+15.995) on methionine residues. Putative phosphopeptides were 
then validated using an algorithm for phosphorylation site identification (Wu et al., 2013) and 
manually assessed for accuracy.   
 
The SUMOylated peptides were analysed using a mixture of data-dependent acquisitions 
and targeted MS/MS scans to search for peptides containing putative sites of SUMOylation 
based on a SUMO tag of GGTQQFV.  Specifically, targeted MS/MS scans were always 
collected for the following m/z values, which correspond to E4bp4 peptides predicted to have 
SUMOylated lysines: K10 m/z2+ = 531.99; K116 m/z2+ = 796.49; K219 m/z2+ = 853.54; K337 
m/z2+ = 825.52).  De novo analysis of a tandem MS corresponding to K219 SUMO (m/z2+ = 
853.54) revealed fragment ion peaks to support this modification.  To validate the observed 
fragmentation, a synthetic version of this peptide containing the SUMOylated tag on K219 
was purchased:  FPVIK(GGTQQQFV)QE (Anaspec, Eurogenetec).   The retention time and 
MS/MS fragment ions observed for the peptide standard were found to match the 
experimental tandem MS, thus confirming the identification of K219 SUMOylation on E4bp4. 
 





2.10 In vitro development of NK cells from transduced lineage 
negative bone marrow cells 
To isolate lineage negative (Lin-) bone marrow (BM) cells, mouse leg bones were crushed in 
PBS + 2% FBS to release bone marrow cells. These cells were resuspended in MACS 
buffer and stained with a phycoerythrin (PE)-conjugated lineage cocktail of antibodies (α-
B220, α-CD2, α-Ter119, α-NK1.1, α-Mac-1 and α-GR1 (Table 2.5)) for 5 minutes at 4°C. 
Stained cells were incubated with anti-PE Microbeads (Miltenyi) for 15 minutes at 4°C to 
allow negative selection of lineage negative cells. The cells and cell-bead conjugates were 
washed with MACS buffer before being applied to an LS column (Miltenyi) attached to a 
MidiMACS™ magnet (Militenyi). The unstained Lin- BM cells flowed directly through the 
column and were retained for culture in complete cytokine medium at a concentration of 5 x 
105 cells ml-1. Lin- BM cells were cultured for 48 hours before retroviral transduction. 
 
LinXE cells were transfected with pMSCV-E4BP4-hCD2 (or E4bp4 mutant versions, or 
empty vector) and after 48 hours the supernatant was collected from each plate of cells. 
Virus particles were concentrated by centrifugation at 18,000 g for 45 minutes at 4°C; 
resuspended in complete cytokine media and mixed with cultured Lin- BM cells, in the 
presence of 8 μg/ml polybrene, at a concentration of 105 cells ml-1. The cell-virus suspension 
was aliquoted into 96-well plates (100 µl per well) and centrifuged for 45 minutes at 700 g 
and RT. Following centrifugation, 100 µl of complete cytokine media was added to each well 
and the cells were cultured for 72 hours. 
 
Transduced Lin- BM cells were resuspended in IL-15 medium at a concentration of 3 x 104 
cells ml-1 and distributed into wells of a 24-well plate containing cultured OP9-GFP stromal 
cells. The transduced Lin- BM cells were cultured on the OP9-GFP stroma for 7 days, with a 
medium change on day 4. After 7 days of culture, the cells were washed with PBS and 
stained with antibodies against NK1.1, CD19, CD11b and hCD2 (Table 2.5) for analysis by 
flow cytometry. 
 
Percentages of NK cells in the transduced populations were compared. For E4bp4-/- 
experiments, each sample was normalised to WT E4bp4 and combined to give an overall 
mean ± S.E.M. (n = 3). For experiments using WT Lin- BM, each sample was normalised to 
the empty vector, before a mean was calculated. Results were verified to be significant using 
the Student’s paired T-test (Graphpad Prism), where values of p < 0.05 were considered as 
statistically significant. 





To analyse the effects of kinase inhibitors on NK cell development WT Lin- BM cells were 
isolated (by negative selection with anti-PE microbeads) and cultured in complete cytokine 
medium for 5 days before being transferred into 24-well plate containing cultured OP9-GFP 
stromal cells. Cells were cultured for 7 days in IL-15 medium, in the presence or absence of 
30 ng/ml IL-15, 10 µM 4-(4-(2,3-Dihydrobenzodioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-
yl)benzamide (D4476) (Sigma Aldrich) and 20 µM 4,5,6,7-Tetrabromobenzotriazole (TBB) 
(Sigma Aldrich). The media was refreshed on day 4 and after 7 days of culture, the cells 
were washed with PBS and stained with antibodies against NK1.1 and CD19 and analysed 
by flow cytometry. 
 
 
2.11 Cycloheximide time course analysis of protein stability 
2.11.1 Creation of stably transduced cell lines 
LinXE cells were transfected with pMSCV-E4bp4-hCD2 (or E4bp4 mutant versions) and 
after 48 hours the supernatant was collected from each plate of cells. Virus particles were 
concentrated by centrifugation at 18,000 g for 45 minutes at 4°C; resuspended in 4 ml 3T3 
culture medium and then added to 3T3 cells growing in 100 mm dishes. Each plate of 3T3 
cells was incubated with concentrated virus for 4 hours in the presence of 8 μg/ml polybrene. 
Fresh 3T3 culture media was added to each plate of cells before they were cultured for 48 
hours. Transduced cells were analysed for surface hCD2 expression using flow cytometry to 
determine the transduction efficiency. Transduced 3T3 cells were cultured for a further 14 
days (with a passage every 2-3 days), before the cells were resuspended in FACS buffer, 
stained (α-hCD2-APC) and the hCD2 positive population was bulk sorted for each cell line. 
Sorted cells were cultured for a maximum of 10 passages and hCD2 expression was 
regularly checked by flow cytometry. 
 
2.11.2 Cycloheximide time course 
Stably transduced 3T3 cell lines were incubated with 50 µg/ml cycloheximide (Sigma 
Aldrich) for 0, 2, 4, 6, 8, 12 and 16 hours. At the end of the time course each sample (~5 x 
106 cells) was suspended in 400 µl CE buffer and lysed by passing repeatedly through a fine 
gauge needle and incubated for 30 minutes on ice. Samples were centrifuged for 15 minutes 
at 3500 g (4°C) and the supernatant removed (cytoplasmic extract). The remaining nuclei 
were suspended in 200 µl NE buffer, sonicated for 15 seconds and incubated at 4°C, 
rotating, for 1 hours. Samples were centrifuged for 20 minutes at 20000 g (4°C) to remove 
any insoluble material and supernatant maintained (nuclear extract). Nuclear extracts were 





analysed by WB for the presence of E4bp4 and Histone H3 was used a loading control to 
compare samples. WBs were analysed using ImageLab software (Biorad) to quantify 
intensity of bands on blots. 
 
 
2.12 Luciferase assay 
E4bp4 transcriptional activity was analysing using numerous pGL3 vectors (containing the 
Firefly luciferase reporter gene) and the Dual-Luciferase® reporter assay system. The 
vectors used were: pGL3-E4bp4-CS (previously created by Yeung et al., 2004), which 
contained the E4bp4 consensus sequence identified by Cowell et al. (1992); pGL3-E4bp4-
CS-ZH, which contained the E4bp4 consensus sequence identified by Zhang et al. (1995); 
pGL3-5’-Eomes and pGL3-5’-Id2, which both contained the 2 kb regions upstream of these 
genes from the mouse genome (created by Dr Victoria Male, Brady Laboratory). 
 
3T3 cells were cultured in 24-well plates and each well was transfected with 200 ng pMSCV-
E4BP4-hCD2 (or mutant versions, or empty vector), 200 ng pGL3-E4BP4 (or empty vector) 
and 50 ng pRL-CMV. After 48 hours, cells were lysed with passive lysis buffer and the Dual-
Luciferase® reporter assay system (Promega) was used to determine the activities of Firefly 
and Renilla Luciferases. Cell lysates were combined with LAR II solution and Stop & Glo® 
reagent in 96-well plates and the luminescence produced by each sample was recorded by a 
FLUOstar Omega plate reader (BMG Labtech). The plate reader was set to analyse each 
well for 8 seconds, with a 2 second pre-measurement delay between samples. Using Renilla 
luciferase as an internal control Relative Luciferase activities (RLAs) were calculated for 
each sample. RLAs from independent experiments were combined by expressing individual 
samples relative to empty vector to give an overall mean ± S.E.M. Results were verified to 
be significant using the Student’s unpaired T-test (Graphpad Prism), where values of p < 









2.13 Regulation of E4bp4 target genes in NK cells 
2.13.1 Phenotyping of MNK-1 cells 
MNK-1 cells were cultured in the presence or absence of 10 µg/ml IL-2 for 36 hours and at 4 
hour time points the cell viability was analysed. Cells were stained with trypan blue and the 
percentage of live/dead cells was determined using a haemocytometer. MNK-1 cells were 
also analysed for their expression of numerous cell surface markers. Cells were washed with 
PBS, suspended in 200 µl FACS buffer and stained separately with antibodies against 
NK1.1, CD8, CD3, CD127, CD19, CD11b, CD122 and CD4 (Table 2.5). 
 
2.13.2 Lentiviral transduction of MNK-1 cells 
HEK-293T cells were transfected with pCSGW-E4bp4 (or E4bp4 mutants), pSPAX2 and 
pMD2.G (each 100 mm dish: 6 µg pCSGW, 6 µg pSPAX2, 2.5 µg pMD2.G) and after 48 
hours the supernatant was collected from each plate of cells. Virus particles were 
concentrated by centrifugation at 18,000 g for 45 minutes at 4°C, suspended in MNK-1 
growth media and mixed with MNK-1 cells. For each condition two plates of 293T cells were 
transfected and virus particles were used to transduce 1.5 x 106 cells in 2 ml culture media, 
in the presence of 8 μg/ml polybrene. The virus/cell mix was aliquoted into 96-well plates 
and centrifuged at 700 g for 45 minutes, at RT. After centrifugation the virus/cells were 
transferred to 100 mm tissue culture dishes to be cultured for 48 hours. 
 
2.13.3 Quantitative PCR 
After transduction, MNK-1 cells were lysed and RNA was isolated for transcriptional analysis 
using the RNeasy mini kit (Qiagen). RNA from each sample was eluted in 50 µl RNase-free 
H2O and was converted to cDNA using 1st Strand transcriptor cDNA synthesis kit (Roche). 
Each cDNA synthesis reaction contained 2 µg total RNA and 2.5 µM anchored-oligo(dT)18 
primer, which were initially denatured at 65ºC for 10 minutes. Subsequently, 5X reaction 
buffer, 20 U RNase inhibitor, 1 mM deoxynueclotide mix and 10 U Transcriptor Reverse 
Transcriptase were added to each reaction. Reactions were then incubated at 55ºC for 30 
minutes, 85ºC for 5 minutes, before being quenched on ice for 15 minutes. 
 
Quantitative PCR (QPCR) reactions were performed using TaqMan primer/probes (Table 
2.5) to determine gene expression levels of potential E4bp4 target genes. Each cDNA 
sample was analysed in technical duplicate, with each individual reaction prepared 
containing 5 µl 2X TaqMan Fast Advanced Master Mix (Life Technologies), 0.5 µl TaqMan 
Gene Expression Assay (Table 2.5), 2.5 µl RNase-free H2O and 2 µl cDNA sample. 





Samples were analysing using an Applied Biosystems 7500 Fast Real-Time PCR system 
with the following thermal cycling profile: 50ºC for two minutes, 95ºC for 20 seconds and 
then 45 cycles of 95ºC for 3 seconds and 60ºC for 30 seconds. Ct values from samples were 
compared with a standard curve made from a known concentration of plasmid DNA (Eomes, 
Id2, T-bet, Gata3, Gfi1) or murine splenocyte genomic DNA (Notch, E2A, EBF, HPRT1). 
 
Three independent experiments were performed analysing the expression of all genes and 
each sample was normalised to HPRT1, before a mean ± S.E.M. was calculated for each 
gene. Results were verified to be significant using the Student’s paired T-test (Graphpad 
Prism), where values of p < 0.05 were considered as statistically significant. 
 
Table 2.6 – TaqMan gene expression probes used for QPCR. 
Gene target Entrez Gene ID Probe number Amplicon length (bp) 
Eomes 13813 Mm01351985_m1 58 
Id2 15902 Mm00711781_m1 152 
T-bet 57765 Mm00450960_m1 69 
Gata3 14462 Mm00484683_m1 57 
Gfi1 14581 Mm00515855_m1 70 
Notch1 18128 Mm00435249_m1 76 
TCF3 (E2A) 69714 Mm00469848_m1 81 
EBF2 13592 Mm00438625_m1 66 




2.14 In vitro development of NK cells from transduced human 
umbilical cord blood stem cells 
CD34+ umbilical cord blood (UCB) stem cells were kindly provided by Aurore Saudemont 
(Anthony Nolan Research Institute, and University College London). These cells had been 
previously isolated from whole cord blood by ficoll gradient centrifugation, to isolate all 
mononuclear cord blood cells and by MACS column magnetic separation to enrich for CD34+ 
cells. Isolated cells were cryopreserved in liquid nitrogen for long term storage and transport. 
CD34+ cells were cultured using protocol previously described by Luevano et al. (Luevano et 





al., 2014). Cells were thawed and resuspended in NK cell differentiation media at a 
concentration of 2.5 x 103 cell ml-1. CD34+ cells were cultured on irradiated E108.1D2 feeder 
cells for 48 hours before lentiviral transduction.  
 
HEK-293T cells were transfected with pCSGW-IRES-td-tomato (created by Dr Ilaria Nisoli, 
Brady laboratory), pSPAX2 and pMD2.G (each 100 mm dish: 6 µg pCSGW, 6 µg pSPAX2, 
2.5 µg pMD2.G) and after 48 hours the supernatant was collected from each plate of cells. 
Virus particles were concentrated by centrifugation at 18,000 g for 45 minutes at 4°C, 
suspended in NK cell differentiation media and mixed with CD34+ cells. Each plate of virus is 
used to transduce 1.25 x 105 cells in 5 ml of culture media in the presence of 8 μg/ml 
polybrene. The virus/cell mix was aliquoted into 96-well plates and centrifuged at 700 g for 
45 minutes, at RT. After centrifugation the virus/cells were transferred back onto E108.1D2 
feeder cells and cultured for 3 days before all transduced td-tomato positive cells were FACS 
sorted in bulk. Cells were cultured for a further 9 days (total 14 days in culture) with a half 
media change every 3 days. Following the culture period, cells were washed with PBS and 
stained with antibodies against CD56 and CD45 (Table 2.5) for analysis by flow cytometry to 
















3.1.1 Regulation of E4bp4 
The transcription factor (TF) E4bp4 is an essential regulator of many biological processes, 
including the circadian rhythm, the development of CD8α cDC’s and cytokine production by 
TH2 cells (Male et al., 2012). Most prominently, it is absolutely required for the production of 
NK cells and commitment to the NK lineage during lymphocyte development (Male et al., 
2014). Despite its importance, very little is known about how the actions of E4bp4 are 
regulated, particular inside NK cells. PTMs are a key mechanism for regulating TF activity, 
as they can rapidly and reversible alter how a TF recognises DNA or interacts with a partner 
protein and they allow external signals to directly influence gene expression (Benayoun and 
Veitia, 2009). However, little is known about the PTMs of E4bp4 and whether these regulate 
its function. Using a yeast-two-hybrid screen, it was discovered that E4bp4 can interact with 
numerous SUMO E3 ligases, in particular PIAS1 (Table 1.1). From this data it was 
postulated that E4bp4 may be post translationally SUMOylated, but it was not known 




Proteins of the small ubiquitin-like modifier (SUMO) family are reversible post-translational 
protein modifiers that regulate diverse cellular processes including DNA repair, chromosome 
segregation and transcription (Gareau and Lima, 2010). SUMO proteins are ~11 kDa in size 
and have a very similar three-dimensional structure to ubiquitin (Figure 3.1). In mammals 
there are four SUMO isoforms, designated SUMO1 to SUMO4. The mature forms of SUMO2 
and SUMO3 only differ from each other by three N-terminal amino acids and are therefore 
commonly referred to as SUMO2/3 (Wilkinson and Henley, 2010). SUMO1 shares 
approximately 50% sequence identify with SUMO2/3 (Figure 3.1) and serves distinct 
functions as it often conjugates to different target proteins in vivo (Vertegaal et al., 2006) The 
SUMO4 isoform has 87% similarity to SUMO2, but its conjugation to target proteins has only 
been reported in conditions of extreme stress (Wei et al., 2008). SUMO4 has a critical 
proline residue that prevents efficient maturation and conjugation to target proteins and is 
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Some substrates are modified by a singular SUMO isoform (e.g. the nuclear dot protein 
Sp100 is modified by SUMO2/3 only), whilst many are modified by both SUMO1 and 
SUMO2/3 (Vertegaal et al., 2006). However, it is unclear how the SUMOylation machinery 
can distinguish between SUMO1 and SUMO2/3 for conjugation onto target proteins and how 
modifications with the different isoforms will impact on the function of a particular substrate 
protein (Wilkinson and Henley, 2010). SUMO2 and SUMO3 are also able to form chains on 
target proteins, due to an internal Ψ-K-x-E acceptor site (Knipscheer et al., 2007). This 
characteristic is very similar to that observed for ubiquitin, but the extent of polySUMO 
modification in the proteome has yet to be established (Golebiowski et al., 2009). The 
significance of these SUMO chains and whether they have specific biological functions also 
is not understood (Bekes et al., 2011). 
 
 
3.1.4 Effect of SUMOylation 
The first reported targets of SUMO modification were the GTPase-activating protein 1 
(RanGAP1) (Mahajan et al., 1997) and the promyelocytic leukaemia protein (PML) (Muller et 
al., 1998), but since then SUMOylation has been found to influence proteins involved in 
almost every aspect of cellular activity. SUMOylation has been found to be important for 
regulating TF activity, nuclear transport, chromosome segregation, DNA repair and 
mitochondrial dynamics (Geiss-Friedlander and Melchior, 2007). 
 
There is no way to predict how SUMOylation will affect the function of a particular protein, as 
any aspects of a target protein could be affected. However, on a molecular level, generally 
there are three consequences of SUMOylation (Figure 3.3). SUMOylation can block the 
binding site of protein, preventing interactions with a partner protein, for example, E2-25k 
cannot interact with its partner ubiquitin E1 enzyme when it is modified (Pichler et al., 2005). 
Conversely, SUMO modifications may help to promote new interactions with other proteins, 
either by direct non-covalent interaction or via a novel interaction domain created at the 
interface between the SUMO and substrate (Figure 3.3). SUMOylation of RanGAP1 
promotes its interaction with RanBP2 and its relocation to the nuclear pore (Mahajan et al., 
1997). Thirdly, SUMOylation can induce a conformational change in the SUMOylated target 
protein, directly affecting its function (Figure 3.3). A good example of this is the DNA 
modifying enzyme TDG (thymine-DNA glycosylase), which recognises and removes 
mismatched base pairs (Baba et al., 2005) (Hardeland et al., 2002). Modification by SUMO1 
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3.1.5 SUMOylation and transcription  
TFs and transcriptional co-regulators are one of the most abundant classes of SUMOylated 
proteins (Cubenas-Potts and Matunis, 2013). SUMOylation of TFs appears to often be 
associated with enhanced transcriptional repression and it has also been suggested that 
there is a general causal relationship between transcription and SUMOylation (Cubenas-
Potts and Matunis, 2013). Inducing hypersumoylation in cells has been observed to increase 
gene repression (Chupreta et al., 2005) and conversely inducing hyposumoylation, by 
depleting Ubc9 or SUMO, enhances ectopic gene expression (Ouyang et al., 2009) (Spektor 
et al., 2011). One mechanism by which these transcriptional changes may occur was 
identified by Ouyang et al. who showed that recruitment of the LSD1-CoREST1-HDAC 
complex to chromatin required SUMO2/3 (Ouyang et al., 2009). SUMO2/3 interacts directly 
with a SIM in CoREST1, which promotes the formation of the transcriptionally repressive 
complex (Ouyang et al., 2009). Secondly, SUMOylation has been shown to enhance DNA 
methyltransferase activity, which causes transcriptional repression in target genes by 
blocking DNA accessibility (Lee and Muller, 2009). Finally, SUMO has been found to localise 
to polycomb group (PcG) bodies which are small subnuclear hubs of transcriptional 
repression (Cubenas-Potts and Matunis, 2013). The assembly of PcG bodies is dependent 
on SUMO and without it they cannot correctly repress inappropriate gene expression, for 
example during embryonic development (Kang et al., 2010). 
 
SUMOylation appears to regulate the activity of a wide range of TFs, of which many are 
integral to development, e.g. IRF-2 (Han et al., 2008), Ets1 (Ji et al., 2007) and Bcl11b 
(Zhang et al., 2012); apoptosis, e.g. FLASH (Alm-Kristiansen et al., 2009) and ATF3 (Wang 
et al., 2013), and cancer, e.g. MITF (Bertolotto et al., 2011) and Myc (Kessler et al., 2012). 
For many of these TFs, the underlying mechanism by which they are regulated is unclear. 
However, in the case of Bcl11b, SUMOylation causes the recruitment of the transcriptional 
co-activator p300 and the subsequent induction of target genes (Zhang et al., 2012). This 
turns Bcl11b from a repressor to an activator and is critical in developing thymocytes for 
promoting a T-cell specific gene program (Zhang et al., 2012). An alternative example of the 
importance of SUMOylation is provided by the melanoma oncogene, MITF, which becomes 
more active when it cannot be SUMOylated (Bertolotto et al., 2011). A germline missense 
mutation in the MITF SUMOylation site produces a more transcriptionally active protein that 
is more oncogenic and promotes cell growth, migration and invasion (Bertolotto et al., 2011). 
This mutation occurs significantly higher in patients with melanoma and renal cell carcinoma, 
meaning an individual carrying this mutation has a fivefold increased risk of developing 
either cancer (Bertolotto et al., 2011). 





3.1.6 Studying SUMOylation 
One key observation regarding SUMOylation is that only a small proportion of an available 
substrate needs to be SUMOylated to produce a large effect. Indeed, only small percentages 
(< 5%) of most SUMOylation targets appear to be modified at steady state, mainly due to the 
rapid action of SENPs and SUMO conjugating enzymes (Wilkinson and Henley, 2010). The 
highly dynamic nature of the SUMOylation cycle is at least in part responsible for this, as 
rapid cycles of modification and demodification allow the whole pool of a target protein to be 
affected by SUMOylation in a short time frame (Geiss-Friedlander and Melchior, 2007). The 
underlying mechanisms for this effect has not been determined for many SUMOylated 
proteins, but two mechanisms have been proposed for how low level SUMOylation can have 
a dramatic effect on TF activity.  
 
Firstly, SUMOylation of a TF could induce chromatin-remodelling activity to induce a 
repressive or active chromatin state that will remain, even after SUMOylation of the TF is 
removed. Secondly, the presence of the SUMO modification will promote interactions with 
other transcriptional co-factors which can come together to form a repressive or active 
transcriptional complex that, once assembled, will remain stable even if the SUMO 
modifications are lost (Hay, 2005). One well studied example of this is DAXX, which interacts 
with histone deacetylase (HDAC) enzymes that remove acetyl groups from histone proteins, 
allowing them to bind more tightly to DNA, making it more inaccessible (Kuo et al., 2005). 
SUMO-mediated recruitment of HDACs therefore induces transcriptional repression of DAXX 
target genes (Kuo et al., 2005).  
 
Understanding how SUMOylation can control the activity of a particular protein presents a 
number of challenges. As mentioned above, the activity of SENPs, which rapidly remove 
SUMO from target proteins, is one of the main challenges when studying SUMOylation, 
especially as these enzymes work inside the cell and also after cell lysis (Da Silva-Ferrada 
et al., 2012). It is therefore important to either lyse cells under denaturing conditions or use 
broad cysteine protease inhibitors, e.g. N-ethylmaleimide (Horowitz et al., 2013), in cell lysis 
buffers. As only a small percentage of a particular protein will be modified at steady state 
and many proteins, particularly TFs, constitute a tiny proportion of all the protein within a cell, 
detecting endogenously modified protein is often not possible, even with highly sensitive 
mass spectrometry (MS).  
 
Many studies involve the over expression of SUMO isoforms or protein of interest and many 
have used in vitro assays to identify the modification of protein. SUMOylation levels inside 





the cell can also be manipulated to help aid detection of a modified target protein, as global 
SUMOylation levels increase with cell stress responses. SUMOylation levels have been 
shown to increase following heat shock, osmotic and oxidative stress and inhibition of the 
proteasome (Golebiowski et al., 2009) (Saitoh and Hinchey, 2000) (Schimmel et al., 2008). 
These experimental approaches are beneficial, but must be used in combination to ensure 
that false positive modifications are not identified. MS of endogenously modified protein and 
unambiguous mass accuracy is the only definitive way to confirm the modification of a 




3.1.7 SUMOylation of E4bp4 
Following the identification of a possible interaction between E4bp4 and PIAS1 (Table 1.1), 
other evidence was saught from the literature to suggest if E4bp4 was SUMOylated. 
Numerous proteomic screens have been performed looking to identify novel SUMOylation 
targets and analyse global changes in the SUMOylation status of mammalian cells. 
Interestingly, four of these studies have positively identified E4bp4 as a potential target of 
SUMO2/3 modification. Golebiowski et al. and Schimmel et al. both analysed all the 
SUMOylated proteins in HeLa cells expressing 6His-SUMO2 or TAP-SUMO2 respectively 
and looked for changes induced by cell stress, either heat shock or proteasomal inhibition 
(Golebiowski et al., 2009) (Schimmel et al., 2008). Using MS, both studies identified multiple 
E4bp4 peptides alongside thousands of other peptides that were enriched following SUMO2 
purification. Both studies also suggested that E4bp4 SUMOylation was not affected by cell 
stress; neither heat shock or proteasomal inhibition. 
 
Schou et al. also performed a similar set of experiments, but looked at dynamic 
SUMOylation changes during mitosis (Schou et al., 2014). They found that E4bp4 was 
enriched following purification of 6His-SUMO2 and an increase in E4bp4 SUMOylation was 
observed at the end of mitosis, consistent with many others TFs (Schou et al., 2014). 
However, none of these studies were able to identify the presence of specific SUMOylated 
E4bp4 peptides in their MS analysis and therefore do not provide definitive evidence of 
SUMOylation at specific lysine residues. Additionally, in these studies, SUMO is over 
expressed in cells before the analysis and this has the potential for false positive 
identification of SUMOylation sites. Further targeted approaches are required to confirm the 
SUMOylation of E4bp4 and, more importantly, determine if it is essential for the function of 
E4bp4. 





3.1.8 Aims and objectives 
There is now evidence to suggest that E4bp4 may be SUMOylated, but this has not been 
determined in vivo. It is not known whether the SUMOylation of E4bp4 is required for its 
activity as a TF and, in particular, in the regulation of NK cell development. Therefore this 
work aimed to confirm if E4bp4 is SUMOylated and determine if this modification is essential 
for its function. In order to achieve this, the following objectives were set: 
 
1. Analyse the amino acid sequence of E4bp4 and look for potential SUMOylation sites. 
2. Confirm that E4bp4 is SUMOylated in vivo using a number of approaches. 
3. Determine the sites of E4bp4 modification using high accuracy MS and create mutant 
versions of E4bp4 that lacks the ability to be SUMO modified. 
4. Determine if SUMOylation is required for the activity of E4bp4 during the 





3.2 E4bp4 has five potential SUMOylation sites 
Initial bioinformatic analysis was performed to determine if the primary amino acid sequence 
of E4bp4 contained any predicted sites for SUMOylation. As SUMOylation occurs principally 
at the consensus sequence Ψ-K-x-E, it is possible to search for potential SUMOylation sites 
using a number of web based bioinformatic tools.  SUMOplot (Xu et al., 2008), SUMOsp 2.0 
(Xue et al., 2006) and seeSUMO (Teng et al., 2012) identified five potential SUMOylation 
sites in the E4bp4 primary amino acid sequence at lysine residues 10, 116, 219, 337 and 
394 (Table 3.1). All three searches provided a confidence score for the likelihood of a 
positive identification, based on the sequence arrangement around the centrally modified 
lysine. All three tools identified K10, K219 and K337 as the most likely sites for SUMOylation 
(Table 3.1). 
 
Recently, another online tool for predicting mammalian SUMOylation sites, SUMOhydro, 
was developed. This tool included amino acid hydrophobicity as a parameter in the 
prediction process and had improved prediction performance (Chen et al., 2012). In some 
instances, hydrophobicity has been found to be critical for SUMOylation site recognition 
(Matic et al., 2010). Using SUMOhydro, five potential SUMOylation sites were identified, but 
K180 was predicted to be SUMOylated rather than K116 which had previously been 
predicted by the alternative prediction tools (Table 3.1). However, the prediction score for 





K180 was significantly lower than the other four sites, suggesting it is unlikely to be modified 
(Table 3.1). In line with the predictions made by the alternative prediction tools, SUMOhydro 




Table 3.1 – Identification of putative E4bp4 SUMOylation sites using bioinformatic prediction tools. 
Position Peptide SUMOplot 
score (0 – 1) 
SUMO sp2.0 
score (0 – 6) 
seeSUMO 
score (0 – 1) 
SUMOhydro 
score (0 – 2) 
K10 MQTIKKEPAPL 0.94 5.422 0.902 1.205 
K116 NATLKAELLSL 0.91 1.578 0.851 x 
K180 CISVIKHSPQSS x x x 0.053 
K219 FPVIKQEPVEL 0.94 5.611 0.938 1.681 
K337 AMQVKVEALDS 0.93 3.393 0.936 0.882 
K394 DWSLKSEHWHH 0.91 1.009 0.876 0.751 
SUMOylation consensus sequence highlighted 
 
 
Most of the potential SUMOylation sites of E4bp4 were also found to be highly conserved 
across a range of vertebrate species, from humans to Zebrafish and Xenopus (Figure 3.4). 
K394 was not as well conserved as the other sites and was only present in three out of the 
six species analysed (Figure 3.4). This initial bioinformatic data suggested that K10, K219 
and K337 were likely to be the sites of E4bp4 SUMOylation, with K116 and K394 also 
possible, but less likely sites of modification. 
 
 
3.3 E4bp4 is multiply SUMOylated 
To ascertain which isoform(s) of SUMO can interact with E4bp4, HeLa cell lines which 
express 6xHis tagged forms of each SUMO isoform were used. Using a protocol adapted 
from Tatham et al. (Tatham et al., 2009), E4bp4 was transiently expressed in HeLa cell lines 
that stably produce 6His-SUMO1, 6His-SUMO2 and 6His-SUMO3 (Figure 3.5). Cells were 
lysed under denaturing conditions, 20% of the sample was removed as an input sample and 
all the remaining SUMO-modified proteins were purified using Ni2+ affinity chromatography 
(Figure 3.5). Subsequently, input and Ni2+ affinity purified samples were analysed by 
Western blot (WB) for the presence of E4bp4. 
 





E4bp4 (~60 kDa) was detected in all the 6His-SUMO samples following purification, as well 
as additional higher molecular weight forms of the protein at ~80 kDa, ~100 kDa and ~120 
kDa (Figure 3.6). These higher molecular weight forms were not observed in the input 
samples and were more prominent in the 6His-SUMO2 and 6His-SUMO3 samples than in 
the 6His-SUMO1 sample (Figure 3.6). As each SUMO conjugate adds 10-15 kDa onto the 
apparent molecular weight of a protein, it is likely that these higher molecular weight forms of 
E4bp4 correspond with various SUMOylated and multiply SUMOylated forms of the protein. 
SUMO2 and SUMO3 share 95% sequence homology, and are generally functionally 
homologous therefore, as expected, the banding pattern observed for these two samples 
was almost identical (Figure 3.6). As E4bp4 has five potential SUMOylation sites (Figure 
3.4), it is plausible that it is modified by SUMO at multiple sites. SUMO2 and SUMO3 are 
also known to form chains as they have an internal SUMO acceptor site, therefore E4bp4 
could have multiple SUMO modifications attached to a single lysine residue (Tatham et al., 
2001). RanGAP1 was used as the control in these experiments as it is known to be highly 
SUMOylated by both SUMO1 and SUMO2/3 and the presence of its SUMOylated form (~80 
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To confirm these findings, it was important to perform the inverse experiment by which 
E4bp4 is specifically immunoprecipitated (IP) from cell lysates containing 6His-SUMO and 
the presence of SUMO modified E4bp4 is then detected by WB. To allow E4bp4 protein to 
be efficiently purified from cell lysates, an expression construct was created that expressed 
E4bp4 with a FLAG® tag at its amino terminus. The FLAG peptide is a recombinant, 
hydrophilic 8-amino acid peptide that is specially recognised by several anti-FLAG 
monoclonal antibodies, allowing for simple, high specificity purification of the tagged protein 
(Einhauer and Jungbauer, 2001). Additionally, the small size of the FLAG tag means it is 
unlikely to obscure any epitopes or alter protein function, transport or secretion (Einhauer 
and Jungbauer, 2001). To create this expression construct a two-stage PCR amplification 
procedure was used to produce an E4bp4 cDNA with the attached FLAG tag (Figure 3.7). 
Specific primers first amplified the E4bp4 cDNA whilst incorporating a 5’ FLAG tag, a 3’ stop 
codon and a 3’ XhoI restriction digest site (Stage 1). The second pair of primers incorporated 
an ATG start codon and NotI restriction digest site at the 5’ end of the cDNA (Stage 2). 
Using the incorporated restriction digest sites, the cDNA was ligated into the pCMV-script 
expression vector for expression in the HeLa cells (Figure 3.7). The construct was initially 
transfected into parental HeLa cells and FLAG-E4bp4 was detected in whole cell lysate 
when analysed by WB (Figure 3.7).  
 
In order to allow E4bp4 to be purified from cell lysates using the FLAG tag, lysates have to 
be prepared in non-denaturing conditions to allow the use of anti-FLAG monoclonal 
antibodies for the purification. Therefore, it was essential to use a SUMO protease inhibitor 
in all cell lysis buffers, as it is known that SENPs act efficiently to remove SUMO 
modifications from substrates (Gareau and Lima, 2010). The broad cysteine protease 
inhibitor, NEM, has been used effectively to inhibit SENP activity (Sarge and Park-Sarge, 
2009). NEM was used in cell lysis buffers and to observe its importance HEK-293T cells 
were transfected with FLAG-E4bp4 and lysed in the presence or absence of NEM (Figure 
3.8A). High molecular weight (SUMOylated) forms of E4bp4 could only be observed in cell 
lysates when 25 mM NEM was present in the cell lysis buffer (Figure 3.8A). 
 
FLAG-E4bp4 was expressed in HeLa 6His-SUMO1, 6His-SUMO2 and 6His-SUMO3 cell 
lines and cell lysates were prepared under non-denaturing conditions (with NEM) to allow 
purification of FLAG-E4bp4 using anti-FLAG® M2 affinity resin (anti-FLAG M2 monoclonal 
antibody permanently conjugated to agarose). FLAG purified samples were analysed by WB 
and, when probed with an anti-E4bp4 antibody, additional higher molecular weight forms of 
E4bp4 were again observed in the 6His-SUMO2 and 6His-SUMO3 samples (Figure 3.8B). 
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3.4 Mutating putative SUMOylation sites of E4bp4 abolishes 
modification of the protein 
 
To determine if a particular lysine side chain is a site of SUMO modification, the amino acid 
of interest can be mutated to an arginine residue (Figure 3.9). This mutation will abolish any 
SUMO modification at that site, whilst maintaining the structural integrity of the protein 
(Tatham et al., 2009) (Figure 3.9). E4bp4 had five putative SUMOylation sites and the 
central lysine at each site was individually mutated in the E4bp4 cDNA to an arginine using 
site directed mutagenesis (Table 3.2). To ensure the mutations had been created correctly, 
all mutant cDNAs were sequenced. Numerous double, triple and multi-site E4bp4 SUMO 
mutants were created using this approach (Table 3.2). To ensure the mutations had been 
made correctly in each cDNA and no unwanted extra mutations had occurred, each cDNA 
was sequenced. Analysing the SUMO modifications of these mutants was used to establish 




Table 3.2 – Mutant forms of E4bp4 created lacking putative SUMOylation sites 
Name Lysine – Arginine 
mutations 
Name Lysine – Arginine 
mutations 
E4bp4-K10R K10 E4bp4-K219-337R K219, K337 
E4bp4-K116R K116 E4bp4-K337-394R K337, K394 
E4bp4-K219R K219 E4bp4-3X-1-SUMO K10, K116, K219 
E4bp4-K337R K337 E4bp4-3X-2-SUMO K10, K219, K337 
E4bp4-K394R K394 E4bp4-3X-3-SUMO K116, K219, K337 
E4bp4-K10-219R K10, K219 E4bp4-4X-SUMO K10, K116, K219, K337 
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suggesting K219 is an important site of SUMOylation. However, the K219R mutation did not 
abolish all of the higher molecular weight bands, suggesting multiple sites of E4bp4 are 
modified and a potential hierarchy exists between the sites (Figure 3.10) (Figure 3.11). As 
K219R was observed to be a significant SUMOylation site, nearly all of the multi-site mutants 
that were created contained K219R (Table 3.2). 
 
All of the multi-site mutations affected the SUMOylation of E4bp4 (Figure 3.10) (Figure 
3.11). The 5X SUMO mutant lacked all of the putative E4bp4 SUMOylation sites and this 
resulted in ablation of all the higher molecular weight forms of E4bp4 (Figure 3.10) (Figure 
3.11). This same effect was seen with the 4X SUMO mutant, as well as the K10-219-337R 
SUMO mutant (Figure 3.10) (Figure 3.11). This confirmed the bioinformatic prediction data 
which suggested that these three sites are the SUMOylation sites of E4bp4. 
 
Each E4bp4 mutant was also expressed in the 6His-SUMO1 cell line (Figure 3.12). 
Expression of WT E4bp4 in these cells resulted in the production of two higher molecular 
weight forms of E4bp4. However, these were very low in abundance and not as prominent 
as those produced in the 6His-SUMO2 and 6His-SUMO3 cell lines (Figure 3.12), suggesting 
that E4bp4 is more commonly modified by SUMO2/3 than SUMO1. As previously observed 
for SUMO2/3, the E4bp4-K219R mutation resulted in a loss of the higher molecular weight 
forms of E4bp4, but additionally, the K337R mutation also affected E4bp4 SUMOylation 
(Figure 3.12). All of the multi-site E4bp4 mutants also lacked any higher molecular weight 
SUMOylated forms (Figure 3.12). This confirmed that K219 and K337 are sites of E4bp4 
SUMO1 modification but, as this modification did not appear abundant, E4bp4 is more 
commonly modified by SUMO2/3. These mutant forms of E4bp4 that lacked any detectable 
SUMOylation could now be tested to determine if SUMOylation directly affects the function 
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3.5 Analysis of E4bp4 SUMOylation by mass spectrometry 
To support the data acquired using the 6His-SUMO HeLa cells, it was important to 
accurately determine which residues of E4bp4 are sites of SUMO modification. MS has 
emerged as a powerful technology for accurately determining the sites of various post 
translational modifications, including phosphorylation, acetylation and ubiquitination on a 
target proteins (Witze et al., 2007). Global proteomic MS studies have now revealed how 
PTMs change during the cell cycle, development and disease states (Jeram et al., 2009).  
 
Standard MS analysis for PTMs involves trypsin digestion of the protein(s) of interest and the 
resulting peptides are separated by chromatography before analysis on the MS. After an 
initial MS scan, peptides of high abundance, or those of a molecular weight of interest are 
fragmented by collision-induced dissociation (CID) to produce a collection of resulting ions 
that are detected by MS/MS, allowing the peptide to be sequenced (Figure 3.13). During 
CID many peptide fragments are generated, but the major product ions are derived from 
fragmentation events occurring at consecutive peptide bonds, referred to as the b- and y-ion 
series (Jeram et al., 2009). b-ions derive from fragmentation at the N-terminus of the peptide 
and y-ions from fragmentation at the C-terminus (Figure 3.13). Simple chemical PTMs do 
not undergo significant fragmentation during CID, they simply alter the mass of one or more 
fragment ions by a predictable mass e.g. acetylation causes a mass increase of 42.01 Da 
(Figure 3.13B). Identification of PTM modification sites where the PTM is a peptide is more 
complex, as the PTM itself will fragment during CID, resulting in a greater number of product 
ions in the MS/MS spectra. Trypsin digest of a ubiquitin modified peptide results in a –GG 
remnant side chain on the modified lysine residue and the trypsin does not cleave at the 
modified lysine as the ubiquitin modification blocks the cleavage site (Jeram et al., 2009) 
(Figure 3.13C). This –GG modified peptide with a missed cleavage site can therefore be 
detected in MS/MS spectra and the resulting b and y ions, with the –GG isopeptide adding 
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When studying SUMO modifications by MS, three main problems arise. Firstly, SUMO 
modified forms of target proteins are generally very low abundance within a cell (Becker et al 
2013). Secondly, SUMO modifications are rapidly turned over and are highly susceptible to 
degradation. It is therefore essential to use general protease inhibitors in cell lysis buffers 
(e.g. NEM) or some groups have used proteasome inhibitors (e.g. MG132) to promote levels 
of modified protein (Schimmel et al., 2008). However, even if enough material is attainable, 
trypsin cleavage of SUMO results in long peptide ‘tails’ remaining conjugated to the target 
protein peptides (Figure 3.14A). For example, human SUMO2/3 isopeptides are 32 amino 
acids in length after trypsin digest, which adds 3567.53 Da to the molecular weight of a 
modified peptide (Figure 3.14A). This large size and inevitable high charge state makes any 
modified peptide very difficult to detect in standard MS (Da Silva-Ferrada et al., 2012). If the 
peptide is detectable the ‘tail’ peptide can produce multiple fragment ions during CID making 
the resulting MS/MS spectra almost impossible to interpret (Da Silva-Ferrada et al., 2012). 
Due to these reasons limited numbers of proteins have been analysed in detail for their 
SUMOylation sites; however some strategies have been developed to try to conquer this 
problem. 
 
Mutated forms of SUMO that contain an Arg residue next to the –GG at the C’ terminus of 
the SUMO2 protein have been created, meaning that trypsin digest of SUMO2 produces 
modified peptides with a simple –GG modification (Galisson et al., 2011) (Tammsalu et al., 
2014). This strategy allows for simple identification of SUMO modified peptides via MS/MS 
spectra and Tammsalu et al. have combined this approach with multi protease digests to 
identify over 1000 SUMOylated peptides in more than 500 human proteins (Tammsalu et al., 
2014). Other strategies have involved the development of specialised database searching 
programs, including ChopNSpice (Hsiao et al., 2009) and SUMmOn (Jeram et al., 2010), 
which use automated pattern recognition and database searching to identify potential SUMO 
acceptor sites from complex MS/MS spectra. Some studies have also employed novel digest 
strategies to reduce the size of the SUMO isopeptide, including the use of elastase 
(Chicooree et al., 2013) or aspartic acid cleavage (Osula et al., 2012) alongside trypsin, 
whilst others have used stressed conditions to increase SUMOylation levels in cells 
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residues at pH 8 (Figure 3.14B). Additionally, digesting with Glu-C and trypsin reduced the 
size of the E4bp4 backbone peptides and in particular, digested after the glutamic acid 
residue which is part of the SUMO consensus modification site (Figure 3.14B). This strategy 
produced ‘T’ shaped, branched, SUMOylated peptides which were amenable for MS/MS 
identification. 
 
For the Glu-C/trypsin double digest strategy to be successful, large quantities of modified 
E4bp4 protein were required for MS analysis. As E4bp4 is a TF, it is not abundant 
endogenously in any cell type, even in NK cells where it has such critical functions. 
Therefore, to produce material for MS analysis, E4bp4 needed to be over expressed and 
then purified from a mammalian cell line to enable the protein to acquire all of its correct 
PTMs. Four different mammalian cell lines (Cos-7, 3T3, HEK-293T and LinXE) were 
transiently transfected with FLAG-E4bp4 and equivalent numbers of transfected cells were 
analysed by WB for their expression of E4bp4 (Figure 3.15A). HEK-293T cells were 
observed to produce the highest levels of recombinant protein and so these were chosen to 
produce material for MS experiments. 
 
Gantke et al. recently demonstrated that the expression of the Ebola virus protein, VP35, in 
293T cells, blocked plasmid activation of double-stranded-RNA-dependent protein kinase, 
therefore increasing translation and recombinant protein production (Gantke et al., 2013). To 
increase levels of FLAG-E4bp4 expression, VP35 protein was co-transfected into 293T cells 
at varying ratios (Figure 3.15B). At a ratio of 5:3 (FLAG-E4bp4:VP35 plasmid DNA), three 
times the amount of FLAG-E4bp4 was expressed by the 293T cells, compared to FLAG-
E4bp4 on its own (Figure 3.15B). Using these conditions, large quantities of FLAG-E4bp4 
























d cells were 
a loading con
bp4 was tra















 in total and 









lls were all tra
mli sample b
les were com


























































ers show on 
 MS anal
n rather th
us as the 
hat any un
-gel digest























result in substantial sample loss and as E4bp4 has multiple modified forms, of different 
molecular weights it was important to ensure that they were all in the sample that was to be 
analysed by MS. Therefore, to produce a highly purified sample of FLAG-E4bp4 for MS 
analysis the FLAG purification process was optimised and in particular the method for eluting 
the purified protein. 
 
Cell lysates containing FLAG-E4bp4 were prepared under non-denaturing conditions using a 
protocol adapted from Klenova et al. (Klenova et al., 2002) to allow IP of FLAG-E4bp4 using 
anti-FLAG® M2 affinity resin. A variety of methods were initially tested to elute the FLAG-
E4bp4 from the anti-FLAG gel, with 0.1 M glycine pH 2.5 and SDS sample buffer proving 
most effective (Figure 3.16A). However, SDS sample buffer could not be used for preparing 
a MS sample as it would not be appropriate for an in-solution protease digest prior to MS 
analysis as it reduces all proteins. 
 
As an alternative strategy, the 3X FLAG peptide, a synthetic peptide of 23 amino acids, 
containing three repeats of the Tyr-Lys-Xaa-Xaa-Asp motif recognised by the anti-FLAG 
monoclonal M2 antibody, was used to competitively elute E4bp4 under native conditions. 
This elution method was compared to 0.1 M glycine pH 2.5, using two concentrations of 
peptide and was performed at a number of salt concentrations as higher concentration of 
salt can influence the competition effects of the 3X FLAG peptide (Figure 3.16B). Equivalent 
samples were compared and FLAG-E4bp4 was purified under all conditions, but the most 
FLAG-E4bp4 protein was purified using 3X FLAG peptide in the presence of 300 mM NaCl 
(Figure 3.16B). Increasing the concentration of 3X FLAG peptide from 150 ng/µl to 300 
ng/µl did not seem to affect the elution (Figure 3.16B). 
 
Using these elution conditions, a larger sample of FLAG-E4bp4 was purified and analysed 
by both WB and also on a coomassie gel (Figure 3.17). The sample contained large 
amounts of E4bp4, including numerous higher molecular weight SUMO modified forms 
(Figure 3.17). When the WB was probed for SUMO2/3, the same E4bp4-SUMO bands were 
observed in the purified sample. However, when probing with an anti-SUMO1 antibody these 
same bands were not detected (Figure 3.17). This again confirmed that E4bp4 is 
preferentially modified by SUMO2/3. Analysing a fraction of the purified sample on the SDS-
PAGE gel, stained with Imperial protein stain, showed the E4bp4 protein had been highly 
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attached to the central modified lysine residue. The digested peptides were purified and 
analysed by LC-MS/MS using an LTQ Velos Pro linear ion trap (Thermo Scientific). 
 
The predicted masses for a range of E4bp4 SUMO-conjugated peptides were calculated 
based on predicted trypsin and Glu-C digest sites (Table 3.3). The MS data was scanned for 
the presence of any of the predicted E4bp4-SUMO peptides (Table 3.3) and a peptide with a 
mass of 853.51 Da was detected, corresponding to a modified form of FPVIKQE (Figure 
3.18). Tandem mass spectra for this peptide confirmed the presence of a SUMO2/3 
modification at K219 (Figure 3.18). The spectra did contain a number of unidentified peaks, 
some of which could be as a result of fragmentation of the GGTQQQFV isopeptide ‘tail’, but 
some may also have resulted from fragmentation of a contaminated peptide (Figure 3.18). 
To confirm the identification of the K219 SUMO modified peptide, a synthetic peptide was 
designed with the same predicted amino acid sequence as the modified K219 peptide 
following trypsin and Glu-C sequential digest (Figure 3.19A). The MS/MS spectra of the 
recombinant peptide was analysed and showed nearly all the same ion peaks as the K219 
modified peptide identified in the FLAG-E4bp4 sample (Figure 3.19B). This confirmed K219 
as an endogenous site of E4bp4 SUMOylation. Despite this, it was not possible to confirm 
SUMO modification at the other putative modification sites, K10 and K337. Further work is 
required to fully ascertain the modification status of these sites. 
 
 





Peptide (m/z)             
(2+ charge) 
Peptide plus 
GGTQQQFV (m/z)      
(2+ charge)  
Peptide plus 
GGTQQQFV (m/z)     
(3+ charge) 
K10 MQTIKK 374.77 797.52 531.99 
K116 NATLKAE 373.75 796.49 531.33 
K219 FPVIKQE 430.80 853.54 569.37 
K337 AMQVKVE 402.77 825.52 550.68 
K394 WSLKSE 375.19 797.89 532.26 
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3.6 Removing SUMOylation sites of E4bp4 causes increased NK 
cell production 
SUMOylation can affect the function of TFs in a number of different ways; such as their 
localisation within the cell, their interactions with other proteins and ultimately their 
transcriptional activity (Gill, 2005). SUMOylation of TFs is important for a number of cellular 
processes, for example, SUMOylation of Bcl11b is required for the later stages of T-cell 
development (Zhang et al., 2012), whilst SUMOylation of TFs Myc and MITF is linked to 
metastatic cancer development (Bertolotto et al., 2011) (Kessler et al., 2012). 
 
E4bp4 is an essential TF for numerous cellular processes, but arguably, the most striking 
phenotype of E4bp4-/- mice is their complete lack of cNK cells (Gascoyne et al., 2009). 
E4bp4 is specifically required at the commitment point for NK cell development to allow 
CLPs to develop into NK cell committed progenitors (Male et al., 2014). Interestingly, E4bp4 
is also a limiting factor in NK cell development because over expression of E4bp4 in 
developing WT progenitors increases the number of NK cells that develop in vitro (Gascoyne 
et al., 2009) (Male et al., 2014). 
 
As E4bp4 has multiple SUMO modifications, it was postulated whether these were required 
for its ability to promote NK cell development. In order to answer this question, an NK cell 
development assay, which had previously been developed in the Brady laboratory, was 
utilised (Gascoyne et al., 2009) (Male et al., 2014). Lineage negative (Lin-) BM cells were 
isolated from E4bp4-/- mice and cultured in lymphocyte inducing conditions before 
transduction with a retrovirus, expressing a gene of interest (Figure 3.20). The transduced 
cells were cultured on stromal OP9 cells, in the presence of IL-15, to promote NK cell 
development (Figure 3.20). E4bp4-/- Lin- BM cells cannot develop into NK cells due to their 
lack of E4bp4, but by transducing the cells with a retrovirus expressing E4bp4, NK cell 
development can be rescued (Gascoyne et al., 2009). Using this assay the activity of E4bp4 
with and without SUMO modifications was compared to determine if the PTMs are essential 
for its function. 
 
Initially, the E4bp4 mutant cDNAs which lacked SUMOylation sites were cloned into the 
pMSCV-IRES-hCD2 retroviral expression vector (Figure 3.21A). Five different mutant 
cDNAs were cloned into MSCV: K10-116-219R, K10-219-337R, K116-219-337R, 4X SUMO, 
5X SUMO. These mutants were cloned as they were found to have very little or no SUMO 
modifications. Each cDNA was cut out of the pCMV-script expression vector using NotI and 
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The K10-116-219R, 4X SUMO and 5X SUMO mutants were all expressed in E4bp4-/- Lin- 
BM cells and, following culture in IL-15, the cells were analysed by flow cytometry to 
determine the number of transduced cells that had developed into NK cells. Using the IRES 
hCD2 expressed by the retrovirus it was possible to analyse only the transduced cells 
(Figure 3.22). The OP9 stromal cells were excluded from the analysis as they are GFP 
positive (Figure 3.22). Strikingly, there were consistently more than double the number of 
NK cells produced in the samples transduced with the SUMO mutants, compared to that of 
WT E4bp4 (Figure 3.22). No NK cells developed from the E4bp4-/- Lin- BM cells that had 
been transduced with an empty retrovirus, as previously reported (Figure 3.22). The 
phenotype of the NK cells that developed in the SUMO mutant samples was similar to the 
WT E4bp4 sample, with a small percentage (4-7%) of the cells developing into mature NKs 
and expressing CD11b (Figure 3.22C). The lack of SUMO modifications clearly appeared to 
promote the activity of E4bp4 and induce greater numbers of NK cells to develop. 
 
A similar experiment was performed using WT Lin- BM cells that were transduced and 
cultured in the same conditions (Figure 3.20). Transduction of these cells with a retrovirus 
expressing E4bp4 had previously been shown to increase NK cell production in vitro 
(Gascoyne et al., 2009). Transduction of WT Lin- BM cells with the K10-116-219R SUMO 
and 5X SUMO mutants again resulted in a significant increase in the production of NK cells 
when compared to WT E4bp4 (Figure 3.23). This further confirms that removing SUMO 
modifications from E4bp4 promotes its activity, which is helping to drive the production of NK 
cells. Additionally, this assay demonstrates how E4bp4 is a limiting factor for NK cell 
development, which has potentially important implications for the development or expansion 
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3.7 Discussion  
SUMOylation is a highly dynamic PTM that is critical for many cellular functions including cell 
cycle progression, DNA repair and transcription (Hay, 2005). Many TFs have been 
discovered as targets for SUMO modification and this is often associated with enhanced 
transcriptional repressive activity (Filtz et al., 2014) (Gill, 2005). However, the underlying 
mechanism by which SUMOylation affects transcriptional activity of most TF’s is yet to be 
fully determined. E4bp4 is an essential TF, involved in numerous cellular processes, many 
involving the immune system, and this work has shown for the first time that it is a target of 
SUMOylation. 
 
Using HeLa cells expressing 6His-SUMO, E4bp4 was discovered to be SUMOylated in vivo 
by SUMO1 and to a much greater extent by SUMO2/3. Many proteins have been found to be 
SUMOylated more prominently by one SUMO isoform over the other, but the reasons for this 
are still unclear (Vertegaal et al., 2006). The same modified forms of E4bp4 were observed 
whether E4bp4 was the target of the pull down or if it was for 6His-SUMO. Up to four 
different modified forms of E4bp4 were present on the WBs, suggesting E4bp4 either has 
multiple SUMO modification sites and/or multiple modifications are occurring at the same 
lysine residue where they have formed poly-SUMO chains (Knipscheer et al., 2007). As 
E4bp4 has multiple functions in different cell types, it is possible that it has a variety of 
SUMOylation states, which vary depending upon the context in which it is functioning. 
 
Initial bioinformatic analysis revealed that E4bp4 had five highly conserved potential 
SUMOylation sites and also suggested that three of these sites (K10, K219 and K337) were 
the most likely to be modified. However, it should be noted that the prediction of 
SUMOylation sites does not take into account the three-dimensional structure of the protein. 
Predicted SUMOylation sites could be identified that are not exposed at the surface of the 
protein and therefore in vivo could not be modified (Da Silva-Ferrada et al., 2012). To 
identify which of the predicted sites was modified lysine-arginine mutations were made to 
abolish the potential for SUMOylation at those sites. Individual mutants were created as well 
as forms of E4bp4 that lacked three, four or all five putative SUMO modification sites. Using 
a similar approach, the SUMO modification sites of the TFs XBP1 (Chen and Qi, 2010), 
FOG-2 (Perdomo et al., 2012) and NRL (Roger et al., 2010) were identified. For example, 
Perdomo et al. created ten different mutants of FOG-2 to identify the four SUMO modified 
lysine residues in the protein (Perdomo et al., 2012). 
 





When these mutants were all expressed in the 6His-SUMO2 cell line, K219R was 
immediately identified as a key site for modification, as it was the only single site mutant that 
had any perturbation of the SUMOylated forms of E4bp4. However, this mutation alone was 
not sufficient to remove all the higher molecular weight forms of E4bp4. When combined with 
K10R and K337R, all SUMO modification was abolished, as was the case for the 5X SUMO 
mutant and 4X SUMO mutant. This clearly demonstrated that E4bp4 is SUMO modified at 
K10, K219 and K337, with K219 being the most prominent site of modification. Interestingly, 
these are the same three sites that were predicted as the most likely sites for E4bp4 
SUMOylation in the initial bioinformatic analysis. These observations suggest that there may 
be a hierarchy or some synergy between the modification sites as three must be mutated in 
order to remove all SUMO modifications. However, mutations of K10 and K337 individually 
do not seem to affect SUMOylation at all. In many instances SUMOylation results in the 
addition of single SUMO moieties onto an acceptor Lys residue, yet the formation of 
polySUMO chains of SUMO2/3 has been observed (Tatham et al., 2001). It may be that a 
polySUMO chain occurs at K219, however, it was not possible to determine if this was the 
case using this assay.  
 
Currently there is no structural information available about E4bp4, indeed no full three 
dimensional structure has been determined for any bZIP TF. The structure of the DNA-
binding, basic region and leucine zipper region, of the TF CREB was previously solved 
(Schumacher et al., 2000), and this is likely to be similar to the N-terminus of E4bp4. 
However, the structure of the majority of the E4bp4 protein is unknown and it is therefore 
difficult to know the distances between the E4bp4 SUMOylation sites in three dimensional 
space. The three SUMOylation sites (K10, K219 and K337) are not found in the DNA binding 
or dimerisation domains of E4bp4 and both K219 and K337 are found within the hypothetical 
transcription repression domain. This domain was identified through mutational studies as 
essential for the transcription activity of E4bp4 (Cowell and Hurst, 1994). This suggests 
SUMOylation at these sites may influence the transcriptional activity of E4bp4, potentially 
through its interactions with other transcriptional cofactors, rather than influencing its ability 
to bind DNA. 
 
Identical observations were made with all mutants when they were expressed in both the 
6His-SUMO2 and 6His-SUMO3 cell lines. This was expected as they share 95% sequence 
homology (Hay, 2005). However, when expressed in the 6His-SUMO1 cells, significantly 
less modified E4bp4 was detected, demonstrating that E4bp4 is predominantly modified by 
SUMO2/3. Two modified forms of E4bp4 were observed but these were abolished by the 
K219R mutation and also affected by the K337R mutation. Nearly all of the multi-site 





mutants lacked any detectable SUMO1 modification. This was vital for function analysis of 
these mutants, as it was clear that the K10-219-337R mutant, 4X SUMO mutant and 5X 
SUMO mutant were not modified by any SUMO isoform. These mutants could be compared 
to WT E4bp4 to determine if SUMO modifications are important for E4bp4’s function. 
 
To unambiguously establish which E4bp4 residues were modified by SUMO, high accuracy 
MS was used to specifically identify SUMOylated E4bp4 peptides. Although MS has been 
used extensively to identify specific modification sites of small PTMs, such as 
phosphorylation, identifying endogenous SUMOylation sites is challenging (Da Silva-Ferrada 
et al., 2012) (Jeram et al., 2009) (Witze et al., 2007). SUMOylation results in the addition of a 
large peptide to the ε-amino group of modified lysine residues, creating a branched 
polypeptide. Identification of large branched peptides by tandem MS is complex and in some 
instances unfeasible as peptides of interest are too large to detect. The low stoichiometry of 
the SUMO-modified forms of a specific protein, and the ease with which the modifications 
can be removed by proteases, adds to the difficulties of direct MS analysis (Jeram et al., 
2009) (Witze et al., 2007). Subsequently, few studies have been able to identify SUMO-
modified peptides of endogenously modified protein by MS. However, one technique has 
recently been described, involving the use of monoclonal antibodies against the different 
SUMO isoforms (Becker et al., 2013). Many MS studies analysing SUMOylation targets have 
involved the over expression of SUMO in order to aid the detection of modified peptides (Da 
Silva-Ferrada et al., 2012). Additionally, a number of studies have exploited the link between 
SUMOylation and the proteasome; increasing SUMOylation levels inside cells by blocking 
the proteasome with inhibitors, such as MG132 (Schimmel et al., 2008).  
 
In this study, both of those strategies were avoided so that only endogenous E4bp4 
SUMOylation sites were identified. The expression of E4bp4 in 293T cells was optimised, as 
well as the purification process to allow the elution of E4bp4 in non-denaturing conditions. 
This subsequently allowed for in-solution digestion of the protein so that no loss of 
SUMOylated material was incurred. Analysis of purified E4bp4 by WB confirmed the 
presence of SUMO2/3 conjugated forms of E4bp4, with limited amounts of SUMO1 
modification detected. To aid the identification of modified E4bp4 peptides, a novel 
trypsin/Glu-C double digest strategy was employed to reduce the size of both backbone 
E4bp4 peptides as well as the size of the SUMO isopeptide tag. The digested peptides were 
analysed by MS and the data was searched for the presence of SUMO2/3 modified E4bp4 
peptides. The analysis of tandem mass spectra revealed a SUMO2/3 modification at K219 of 
E4bp4. As the spectra for the peptide contained a number of unidentified ions, and the 
trypsin/Glu-C digest strategy was novel, a recombinant peptide was acquired with the same 





branched structure as the K219 SUMO modified peptide. The MS spectra of this peptide was 
analysed and matched that of the endogenous K219 peptide, confirming its identification. 
 
E4bp4 was observed to have more than one modified residue in 6His-HeLa cells and 
mutational studies demonstrated that both K10 and K337 are sites of modification. However 
it was not possible to identify these modified peptides by MS. The main difficulty with this 
analysis was the low abundance of the SUMO-modified E4bp4 peptides and the large 
amount of unmodified peptides in the sample. Further optimisation is required to prepare a 
purified E4bp4 sample with a higher proportion of SUMO-modified peptides. This could 
involve either enrichment of all SUMO-modified proteins prior to FLAG-E4bp4 purification or 
the use of size exclusion chromatography to separate the larger modified forms of E4bp4 
from the unmodified ones.  
 
Two recent SUMO proteomic studies used mutated versions of SUMO1 and SUMO2 that 
produce a simple -GG motif following trypsin digest, which significantly aided identification of 
SUMOylated peptides (Impens et al., 2014) (Tammsalu et al., 2014). Interestingly, both of 
these studies identified the same modified E4bp4 SUMO modified peptide as identified here, 
further confirming K219 as a site an endogenous site of SUMO modification (Impens et al 
2014) (Tammsalu et al., 2014). The study by Impens et al. also was able to show that K219 
is modified by SUMO1, but more preferentially by SUMO2/3, again confirming the results 
observed here (Impens et al., 2014). K219 is therefore a critical SUMOylation site for E4bp4 
and is possibly more abundant than any other E4bp4-SUMO modified peptide, as these 
were not identified in the proteomic studies. 
 
The E4bp4 mutants that lacked SUMO modifications, in particular the 5X SUMO mutant 
which lacked all potential SUMOylation sites, provided a tool to determine if SUMOylation 
was required for the function of E4bp4. Gascoyne et al. previously demonstrated that  
E4bp4-/- Lin- BM cells could not develop into NK cell in vitro, unless they were retrovirally 
transduced with a vector expressing E4bp4 (Gascoyne et al., 2009). Using this in vitro NK 
cell development assay, WT E4bp4 was compared to the K10-116-219R mutant, the 4X 
SUMO mutant and the 5X SUMO E4bp4 mutant for their ability to rescue NK cell 
development. All three E4bp4 SUMO mutants consistently increased the production of NK 
cells, compared with WT E4bp4. On average, the 4X SUMO and 5X SUMO mutants 
produced 2.5 times more NK cells. The NK cells produced by the SUMO mutants also had a 
similar phenotype to WT E4bp4 with regards to CD11b expression. This provided the first 
clear evidence that SUMOylation was able to regulate the activity of E4bp4 and that 
manipulation of PTMs could have such a dramatic effect on a complex biological process. 





This notion was further support by evidence using WT Lin- BM cells in the in vitro NK cell 
assay and transducing them with WT E4bp4 or 5X SUMO mutants. Expression of E4bp4 in 
these cells has previously been shown to increase the production of NK cells, compared to 
an empty vector/untransduced cells, suggesting that E4bp4 is a limiting factor during NK cell 
development (Gascoyne et al., 2009) (Male et al., 2014). Both the K10-116-219R mutant 
and 5X SUMO mutant were able to consistently promote greater levels of NK cell production 
from the WT Lin- BM cells than WT E4bp4. In fact both mutants caused more than 65% of 
the transduced cells to become NK cells. SUMOylation therefore negatively regulates the 
activity of E4bp4 and by removing these modifications its activity can be significantly 
increased. This is the first study to demonstrate that SUMOylation is important for the 
development of NK cells.  
 
In future studies it would be of significant interest to determine if the observations made in 
this study could be repeated in vivo. To test this hypothesis, E4bp4-/- Lin- BM cells could be 
transduced with E4bp4 or E4bp4 5X SUMO and then transferred into lethally irradiated mice. 
The ability of E4bp4 and the 5X SUMO mutant to promote NK cell development would then 
be compared by analysing NK cells numbers in their BM, spleen and blood of each mouse 3 
- 4 weeks post transfer. It would be expected that the cells transduced with the 5X SUMO 
mutant would produce greater numbers of NK cells in all host compartments, compared to 
WT E4bp4. 
 
TFs are generally expressed at relatively low levels within cells, making their direct 
quantitative analysis challenging (Vaquerizas et al., 2009). Even in NK cells where E4bp4 
has important regulatory functions, the protein is only expressed at a low level and is barely 
detectable by WB (Brady laboratory, unpublished). Therefore one limitation of this study was 
that all the experiments on the SUMOylation of E4bp4 involved recombinant over expression 
of the protein. Ideally these observations would be supported by work performed on the 
endogenous E4bp4 protein, particularly within NK cells, however this was not feasible. The 
problem of detecting endogenous SUMOylation of E4bp4 is also enhanced by the fact that 
only a small fraction of any SUMO substrate is generally modified at steady state. Future 
work involving high affinity monoclonal antibodies raised against E4bp4 may make isolation 
of the endogenous E4bp4 protein possible and its PTMs could then be analysed. 
 
Many TFs have now been identified to be SUMOylated and, whilst many of these require 
SUMO for their activity, a number have been identified that like E4bp4 are more active in the 
absence of SUMO modifications. These include MITF (Bertolotto et al., 2011), XBP1 (Chen 
and Qi, 2010), MAML1 (Lindberg et al., 2010), FOG-2 (Perdomo et al., 2012) and MafA 





(Shao and Cobb, 2009). The transcriptional activities of MAML1, MafA and XBP1 are all 
increased when their SUMOylation sites are mutated from Lys to Arg, demonstrating that 
SUMOylation can repress the activity of a wide variety of TFs. However, these studies are 
not able to demonstrate how the SUMOylation of these particular TFs can affect a whole 
biological process, as has been shown here for E4bp4. The only study to date that is able to 
show such a dramatic effect on the phenotype of developing cells was by Bertolotto et al. 
who examined SUMOylation of MITF (Bertolotto et al., 2011). Their study demonstrated that 
in the absence of SUMOylation, MITF is a more potent transcriptional activator in melanoma 
and renal carcinoma cells and unmodified MITF makes these cancer cells more 
tumourgenic, with increased migration, invasion and clonogenicity (Bertolotto et al., 2011). 
 
Before this study, SUMOylation had not been directly linked to the development of NK cells, 
but a number of TFs known to be involved in regulating NK cell development have been 
identified as targets of SUMO modification. Ikaros has two SUMOylation sites and mutation 
of these affected its repression of target gene transcription and influenced its interactions 
with transcriptional co-repressors (Gomez-del Arco et al., 2005). Ets1 is essential for the 
early stages of NK cell development and also has two SUMOylated lysine residues (Ji et al., 
2007). Mutation of these sites increased its transcriptional activity, suggesting that SUMO 
also negatively regulates its activity (Ji et al., 2007). IRF-2, which is required to produce 
mNK cells, has three SUMOylation sites and mutating these sites had varying effects on its 
transcriptional activity (Han et al., 2008). SUMOylation of IRF-2 increases it ability to inhibit 
IRF-1 transcriptional activity and decreases it ability to activate transcription of type I 
interferon genes (Han et al., 2008). However, none of these studies were able to show if the 
SUMO modifications of Ikaros, Ets1 and IRF-2 were critical for their activities in vivo and, in 
particular, if these modifications were required for NK cell development. 
 
SUMOylation is however important for the development of other immune cell lineages. One 
recent study by Van Nguyen et al. demonstrated that SENP1 (SUMO protease) is essential 
for the development of T and B cells, as SENP1-/- HSCs isolated from fetal livers were 
unable to differentiate into T or B cell in vitro, yet the myeloid lineage development was 
unaffected (Van Nguyen et al., 2012). Interestingly, Van Nguyen et al. did not mention NK 
cells or innate lymphoid cells in their report, so whether the development of these cells is 
affected by an absence of SENP1 is still to be determined. SUMOylation was also linked to 
the development of T cells through its interactions with the TFs Bcl11b and JunB (Garaude 
et al., 2008) (Zhang et al., 2012). Bcl11b is required at three checkpoints in the development 
of functional T cells in the thymus and SUMOylation functions to inhibit transcriptional 
repression by Bcl11b (Zhang et al., 2012). SUMOylation also results in the recruitment of the 





transcriptional co-activator p300 to the promoters of Bcl11b repressed genes (Zhang et al., 
2012). This activity is essential to allow T cell specific genes, supressed by Bcl11b, to be 
expressed in immature thymocytes to help drive T cell maturation (Zhang et al., 2012). 
SUMOylation of JunB is required for activation of mature T cells and the regulation of 
cytokine genes, particularly IL-2 (Garaude et al., 2008). In the absence of SUMO 
modifications, JunB is not able to associate with open chromatin structures and promote the 
expression of IL-2 and IL-4 genes (Garaude et al., 2008).  
 
SUMOylation of E4bp4 is an important regulatory process and provides evidence for the 
complex mechanisms that exist to control E4bp4 activity during cellular processes. E4bp4 
has very recently been discovered to be critical for the development of other ILC subsets 
and TH17 T cells, as well as NK cells, so it would now be interesting to determine if 
SUMOylation of E4bp4 has a role in any of these developmental processes. If SUMO 
modifications affect the transcriptional activity of E4bp4 is a vital question to answer and 
could provide an insight into the mechanism by which E4bp4 can produce such a strong 
phenotype. Additionally, it is not clear what other PTMs regulate E4bp4 and whether these 





















4.1.1 Regulation of transcription factors by phosphorylation 
Phosphorylation is the most abundant and therefore most well studied of all PTMs, with 
approximately one third of all the mammalian proteome thought to be a target for 
phosphorylation (Mumby and Brekken, 2005). Phosphorylation involves the formation of an 
ester bond between a phosphate group (PO43-) and the side chain of a polar amino acid 
(serine, threonine or tyrosine). Phosphorylation is rapidly reversible, with hundreds of known 
kinases able to modify target proteins and phosphatases able to subsequently remove the 
modifications (Holmberg et al., 2002). The actions of these enzymes allow biological 
processes to be tightly controlled and quickly manipulated in response to changes in the 
cellular environment (Whitmarsh and Davis, 2000). Phosphoproteomic studies have 
revealed how a wide variety of cellular proteins are phosphorylated, with TFs a commonly 
modified class of protein (Wu and Liao, 2007). 
 
TFs can have diverse effects on the expression of different target genes, depending on cell 
type, the presence/absence of certain stimuli, and interactions with tissue specific cofactors 
and accessory proteins (Filtz et al., 2014). Phosphorylation can increase the functionality of 
TFs and allow them to respond to external stimuli, via signalling pathways, to induce 
changes in gene expression (Holmberg et al., 2002). The phosphorylation of a TF can 
modulate its activity in a number of ways: 1) DNA binding activity; 2) localisation; 3) protein 
interactions; 4) stability; 5) transcriptional activity (Figure 4.1). 
 
The DNA binding activity of the bZIP TF c-Jun is directly and indirectly regulated by 
phosphorylation (Papavassiliou et al., 1995). c-Jun has five phosphorylation sites, three of 
which are close to its N-terminal DNA binding domain and phosphorylation at these sites 
directly interferes with DNA binding (Papavassiliou et al., 1995). However, phosphorylation 
of the other two sites at the C-terminus of the protein, by JNK MAP kinase, causes a 
conformational change that prevents phosphorylation at the N-terminus of the protein and 
therefore promotes DNA binding (Papavassiliou et al., 1995). 
 
Phosphorylation of the oncogene c-Myc regulates its stability as phosphorylation at both T58 
and S62 causes it to be rapidly degraded by the proteasome. However, phosphorylation of 
S62 alone causes c-Myc to promote cell cycle progression and ultimately tumorigenesis 
(Hann, 2006). Phosphorylation at this site is caused by extracellular proliferative signals that 
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Multi-site phosphorylation of Nuclear Factor of Activated T cells (NFAT) demonstrates how 
phosphorylation can influence the localisation of TF. The dephosphorylation of NFAT by 
calcernurin, a Ca2+ sensitive serine/threonine phosphatase, causes conformation changes in 
the protein, exposing a nuclear localisation sub-domain, allowing the TF to accumulate in the 
nucleus and activate gene expression (Okamura et al., 2000). When Ca2+ levels fall and 
cells are no longer stimulated, calcernurin will no longer be active, causing NFAT to be 
phosphorylated by multiple kinases and therefore once again sequester in the cytoplasm 
(Okamura et al., 2000). 
 
Phosphorylation can provide more than a static on/off regulation of TF activity; multiple 
phosphorylation events can dynamically and precisely tune the transcriptional activity of the 
protein (Pirkkala et al., 2001). The addition or removal of several phosphate groups can 
have a dramatic effect on the activity of a TF as each phosphate group adds a negative 
charge to the modified amino acid, potentially inducing conformation changes and attracting 
or preventing interactions with other molecules (Holmberg et al., 2002). Phosphorylation of 
Heat Shock Factor 1 (HSF1) regulates the scale of its transactivation in response to 
numerous protein-damaging stresses, including heat shock (Pirkkala et al., 2001). HSF1 has 
four phosphorylation sites, which are modified by different kinases in response to stress, 
causing it to localise to the nucleus. The more phosphorylated HSF1 becomes, the higher its 
transcriptional activity (Holmberg et al., 2001). The regulation of HSF1 is complex as three of 
its phosphorylation sites (S303, S307 and S363) are also modified under normal conditions, 
as well as in response to stress (Holmberg et al., 2001). However, phosphorylation of S230 
is specific to stress responses and is absolutely essential for the activation of HSF1 
(Holmberg et al., 2001). 
 
Multiple phosphorylation events of the same TF can also allow integration of two different 
signalling pathways to cause the same changes in gene expression (Filtz et al., 2014). The 
process by which substrate specificity is achieved by signal transduction pathways is very 
important, particularly when a single protein has multiple phosphorylation sites. This 
generally involves the recognition of particular consensus amino acid sequences or three-
dimensional protein structures by kinases (Whitmarsh and Davis, 2000). Additionally, protein 
complexes can help to promote precise modification, by bringing together a specific TF and 
kinase combination, allowing them to interact. 
 
Ets1 is an essential TF for the development of multiple immune lineages and its activity is 
regulated by numerous phosphorylation sites and kinases, allowing it to integrate signals 





from a number of signal transduction pathways. Mitogen activated protein kinase (MAPK) 
mediated phosphorylation of Ets1 positively regulates its transcriptional activity and 
promotes its interaction with the transcriptional co-activators p300 and CBP (Tootle and 
Rebay, 2005). This phosphorylation does not affect the stability of Ets1, its ability to bind 
DNA or its subcellular localisation (Tootle and Rebay, 2005). In contrast, phosphorylation of 
Ets1 by calmodulin-dependent protein kinase II at multiple sites near its DNA binding 
domain, interfere with its ability to bind DNA and cause a conformational change, reducing 
the protein’s stability (Pufall et al., 2005). The activity of Ets1 can therefore be fine-tuned by 
distinct phosphorylation events, allowing it to respond to different external stimuli. 
 
 
4.1.2 Phosphorylation of E4bp4 
E4bp4 was first proposed to be phosphorylated by Chen et al. who observed that 
phosphatases affected the apparent molecular weight of E4bp4 on SDS-PAGE (Chen et al., 
1995). They suggested that the phosphorylation of E4bp4 promoted its ability to recognise 
DNA, as phosphatase treatment interfered with the binding of E4bp4 to target DNA 
sequences in vitro (Chen et al., 1995). Doi et al. studied E4bp4 in the chick pineal gland and 
its role in regulating the circadian clock (Doi et al., 2004). They identified E4bp4 as a target 
of phosphorylation, suggesting it was modified by Casein Kinase 1ε (CK1ε) and that serine 
182 was a site of phosphorylation (Doi et al., 2004). Expression of CK1ε with E4bp4 
promoted proteasomal degradation of E4bp4 and also affected its transcriptional activity (Doi 
et al., 2004). This finding seems to contradict with the previous observation of Chen et al. 
(1995) who suggested phosphorylation was required for E4bp4 to be functional. 
 
However, neither of these studies provided direct biochemical evidence that E4bp4 is 
phosphorylated and the only evidence of modification was a small shift in molecular weight 
on SDS-PAGE. Since then, many phosphoproteomic studies have been performed and 
these have aimed to identify all of the phosphorylated proteins in certain cells and tissues. 
These studies often analyse global changes in phosphorylation during various cellular 
events, such as mitosis or cellular responses to stress. The large data sets that these 
studies produce are openly available and searching these provides further evidence that 
E4bp4 is phosphorylated. 
 
To date, E4bp4 has been identified as a target of phosphorylation by ten phosphoproteomic 
studies that analysed the phosphoproteome of various cell types and tissues (Table 4.1). 
These studies have identified nine serine residues and one threonine residue as possible 





sites of phosphorylation in the E4bp4 protein: S130, T132, S210, S258, S285, S286, S301, 
S352 and S353 (Table 4.1). Both S285 and S286 were present on the same 
phosphopeptide and most of the studies did not generate sufficient data to determine exactly 
which serine residue is modified. The same situation occurred with S352 and S353, but a 
number of studies were able to ascertain that S353 is a more likely site of phosphorylation. 
In all the studies that positively identified E4bp4 phosphopeptides, none identified 
phosphorylation at S182, the phosphorylation site previously identified by Doi et al. (Doi et 
al., 2004). Across all ten studies, S286, S301 and S353 were identified numerous times, 
providing the strongest evidence that these three residues are sites of E4bp4 
phosphorylation. However, these studies do not provide full conclusive evidence of 
phosphorylation at a particular residue. They often identify thousands of potential 
modification sites and are looking at global changes in cellular phosphorylation levels; 
therefore there is the potential for false positive identification. It should also be noted that, of 
the 462 amino acids in the murine E4bp4 protein, 64 residues are serines and 18 threonines, 
suggesting there is great potential for E4bp4 to have multiple phosphorylation sites. 
 
Despite its growing importance, particularly in the development of innate lymphocyte 
subsets, very little is known about the mechanisms that regulate E4bp4 function. In 
particular, little is known about how PTMs affect the function of E4bp4. Despite it being 
nearly 20 years since the first evidence of E4bp4 phosphorylation, nothing is known about 
how this PTM may affect its function. No studies have looked specifically at the 
phosphorylation of E4bp4 in vivo and how this affects its functions, for example during NK 
cell development.  
 
  





Table 4.1 – Phosphoproteomic screens that identify E4bp4 as a target of phosphorylation 




H. sapiens HeLa cell line GPIHS*PVELK S301 
(Villen et al., 
2007) 
M. musculus Primary liver cells TSEADEGVVGKSS*DGEDEQQVPK S285, S286 
 
(Dephoure 
et al., 2008) 




(Chen et al., 
2009) 
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2011) 







* highlights phosphorylated residues 





4.1.3 Aim and objectives 
This study aimed to provide unambiguous evidence for the phosphorylation of E4bp4, 
determine exactly which sites are modified and establish if these regulate the function of the 
protein. In order to achieve this, the following objectives were set: 
 
1. Determine if E4bp4 is phosphorylated and use mass spectrometry to identify exactly 
which amino acid residues are modified. 
2. Create mutated forms of E4bp4 lacking phosphorylation sites. 
3. Determine if phosphorylation is important for the function of E4bp4, particularly 
during NK cell development by analysing activity of E4bp4 mutants. 




4.2 Prediction of E4bp4 phosphorylation 
Bioinformatic analysis was performed to analyse the potential phosphorylation sites 
previously identified for E4bp4 in phosphoproteomic screens (Table 4.1). All of the putative 
phosphorylation sites were found to be highly conserved across a range of vertebrate 
species from humans through to zebrafish, including S182 the phosphorylation site 
suggested by Doi et al. (Doi et al 2004) (Figure 4.2). Three prediction servers were used to 
analyse the putative phosphorylation sites of E4bp4 to determine which are the most likely to 
be modified and which kinase may recognise each site (Table 4.2). The murine E4bp4 
primary amino acid sequence was analysed by GPS 2.1 (Xue et al., 2011), NetPhosK (Blom 
et al., 2004) and Scansite 3.0 (Obenauer, 2003), which all make predictions based on the 
amino acid sequence surrounding the phosphorylated serine, comparing the input sequence 
to known sites of phosphorylation (Table 4.2). The results from the three prediction tools 
varied but GPS 2.1 predicted S210 and S353 as the most likely sites of phosphorylation; 
NetPhosK predicted S286 and S353 and Scansite predicted S182 and S210 (Table 4.2). All 
three tools predicted S130, S285 and S352 as the least likely to be phosphorylated (Table 
4.2). They also predicted that E4bp4 would be modified by Mitogen-activated protein 
kinases, cyclin-dependent kinases and casein kinases at the various potential 
phosphorylation sites (Table 4.2). This analysis provided further evidence that 





















































Table 4.2 – Prediction of E4bp4 phosphorylation sites and modifying kinases 








S130 KFGLISSTAYAQ 4.62 0.023 0.243 GRK 
T132 GLISSTAYAQEI 11.0 0.011 0.285 MAPK 
S182 SVIKHSPQSSLS 6.47 0.967 0.552 CK 1/2 
S210 QGGCRSPENKFP 12.0 0.866 0.707 CDK 
S258 STYSHSPPLLQV 10.6 0.071 0.425 CDK 
S285 GVVGKSSDGEDE 4.02 0.937 0.442 CK 1/2 
S286 VVGKSSDGEDEQ 6.38 0.990 0.427 CK 1/2 
S301 KGPIHSPVELQR 9.33 0.958 0.459 CDK 
S352 GMQKLSSPADAI 5.45 0.098 0.275 Auora B 
S353 MQKLSSPADAIA 16.41 0.997 0.422 MAPK 
 
Phosphorylated residue highlighted 
GRK = G-protein coupled receptor kinase; MAPK = Mitogen-activated protein kinase; CDK = Cyclin-dependent kinase;          
CK = Casein kinase  
 
4.3 E4bp4 is multiply phosphorylated 
High accuracy MS was used to definitively determine the phosphorylation sites of E4bp4. 
Previously, a similar approach was used to identify SUMOylation sites of E4bp4 (section 
3.4). The MS analysis aimed to unambiguously determine exactly which of the putative 
E4bp4 phosphorylation sites existed and also search for any unknown modification sites. For 
this analysis a purified sample of E4bp4 was required, therefore FLAG-E4bp4 was 
expressed in 293T cells and purified by immunoprecipitation. FLAG-E4bp4 was 
competitively eluted from the anti-FLAG M2 affinity resin using the 3X FLAG peptide and 
elution fractions were combined and concentrated. Analysis of the purified sample by WB 
revealed that E4bp4 was clearly phosphorylated, because a strong signal was observed 
when probing for anti-phosphoserine (Figure 4.3A). The sample was also analysed on an 
SDS-PAGE gel stained with Imperial Protein Stain (Thermo Scientific) and this confirmed 
that the purification of FLAG-E4bp4 was successful because few contaminating proteins 
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The phosphopeptide enriched sample was analysed by a Thermo Scientific™ Velos Pro ion 
Trap mass spectrometer and the resulting data was searched against the mouse Uniprot 
database using Sequest, looking for phosphorylated peptides, indicated by a mass increase 
of 79.966 Da (Table 4.3). All reported identifications were validated by manual inspection of 




Table 4.3 – Predicted masses of potential E4bp4 phosphopeptides  
Modified 
residue 
Peptide Peptide mass 
(m/z, 1+ charge) 
Peptide + 
phosphate  
(m/z, 1+ charge) 
Peptide + 
phosphate  
(m/z, 2+ charge) 
S130 FGLISSTAYAQEIQK 1655.853 1735.853 908.430 
S182 HSPQSSLSDVSEVSSVEHTQES
PAQGGCR 
3025.344 3105.344 1593.176 
S210 SPENK 574.272 654.272 367.640 
S258 GTYSTSIYQSYMGSSFSTYSHS
PPLLQVHGSTSNSPR 
4011.834 4091.834 2086.421 
S286 SSDGEDEQQVPK 1318.575 1398.576 699.788 
S301 GPIHSPVELQR 1232.674 1312.675 656.837 




Analysis of the MS/MS data revealed clear evidence of three E4bp4 phosphorylation sites. 
Peptides were identified with phosphorylated serine residues at serine 301 (Figure 4.4), 
S353 (Figure 4.5) and at either serine 285 or serine 286 (Figure 4.6). The tandem mass 
spectra for the S301 and S353 peptides unambiguously identified phosphorylation at these 
sites, with most b and y ions observed for both peptides (Figure 4.4) (Figure 4.5). The final 
peptide identified confirmed E4bp4 phosphorylation at either S285 or S286 (Figure 4.6). 
Analysis of the CID tandem mass spectra for this peptide could not unambiguously 
determine whether the phosphorylated residue was S285 or S286, as these two residues are 
adjacent to each other at the N-terminus of the peptide and some of the ions were low in 
abundance (Figure 4.6). However, phosphorylation can alter the ability of trypsin to identify 
digestion sites, causing mis-cleavages when phosphorylated serine residues are location 
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4.4 Mutating E4bp4 phosphorylation sites 
To determine if a particular serine or threonine residue is a site of phosphorylation, it can be 
mutated to an alanine residue, which will abolish any phosphorylation at that site, whilst 
maintaining the three-dimensional structure of the protein (Holmberg et al., 2002) (Figure 
4.7). Analysing the functionality of serine-alanine mutants allows the importance of particular 
phosphorylation sites to be determined. This method has been successfully used to analyse 
the phosphorylation sites of numerous TFs including p53 (Maclaine and Hupp, 2011), HSF1 
(Holmberg et al., 2001) and NFκB (Viatour et al., 2005).  
 
All of the confirmed E4bp4 phosphorylation sites were individually mutated in the E4bp4 
cDNA using site direct mutagenesis (Table 4.4). Both S285 and S286 sites were separately 
mutated as it was not possible to unambiguously determine exactly which site was 
phosphorylated. Mutations were made at S182 and S210 as they were predicted to be 
phosphorylated, but modification of neither site was confirmed in this study. Doi et al. 
previously suggested that S182 was a site of phosphorylation that influenced the function of 
E4bp4, so it was mutated to determine if this was correct (Doi et al., 2004). Numerous 
double mutants lacking two phosphorylation sites were also generated, primarily involving 
S286, S301 and S353 as these sites were consistently identified in the phosphoproteomic 
screens and were all confirmed here to be modified in this study (Table 4.4). All of the 
mutations were made in the E4bp4 cDNA, which had been previously cloned into the MSCV-
IRES-hCD2 expression vector (Figure 3.21). This meant that all the mutants could be 
expressed in numerous cell types, but specially in developing Lin- BM cells, so that their 




Table 4.4 – E4bp4 phosphorylation-mutant cDNAs generated 
Name Serine – Alanine 
mutations 
Name Serine – Alanine 
mutations 
E4bp4-S182A S182 E4bp4-S353A S353 
E4bp4-S210A S210 E4bp4- S286-301A S286, S301 
E4bp4-S285A S285 E4bp4-S286-353A S286, S353 
E4bp4-S286A S286 E4bp4-S301-353A S301, S353 
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In the absence of E4bp4, the Lin- BM cells were unable to develop into NK cells, but 
transduction with WT E4bp4 rescued the development of NK cells (Figure 4.8). All of the 
single site serine-alanine mutants were analysed and most did not affect NK cell 
development, except for S286A, which, on average, produced almost double the number of 
NK cells compared to WT E4bp4 (Figure 4.8). The S353A mutant also had a smaller, but 
insignificant effect on NK cell production (Figure 4.8). The S286-301A and S286-353A 
mutants even greater increases in the production of NK cells, compared to WT E4bp4, in 
particular, the S286-353A mutant increased NK cell production three fold (Figure 4.8). This 
demonstrated that phosphorylation of S286 is potentially a key regulatory mechanism for 
controlling the activity of E4bp4 and that to a lesser extent phosphorylation of S353 is also 
required. Phosphorylation of S353 may also be dependent or influenced by the 
phosphorylation status of S286, as it had a larger affect on NK cell development in 
combination with the S286A mutation.  
 
Serine 301 was clearly demonstrated to be phosphorylated by MS analysis in this study, but 
mutating this site had no effect on NK cell development, even in combination with S286A the 
level of NK cell production was the same as the single S286A mutant (Figure 4.8). Mutating 
the S182 and S210 phosphorylation sites did not affect the function of E4bp4 in any way, 
this suggests that these sites are not likely to be modified and if they are, it is not important 
for NK cell development. The S285A mutation also did not affect NK cell development, 
further confirming that this site is not phosphorylated. 
 
To expand on these findings, a number of the phosphorylation mutants were also expressed 
in WT Lin- BM cells to determine if they could promote greater levels of NK cell production 
than WT E4bp4. Transduction of WT Lin- BM with WT E4bp4 has been previously shown to 
increase the production of NK cell in vitro, demonstrating that E4bp4 is a limiting factor in NK 
cell development (Gascoyne et al., 2009) (Male et al., 2014) and this observation was 
confirmed here. More significantly, the expression of E4bp4 phosphorylation mutants 
increased NK cell production to a greater extent than WT E4bp4 (Figure 4.9). The 
expression of S286A and S286-353A consistently produced greater numbers of NK cells 
than WT E4bp4 or the S353A mutant (Figure 4.9). However, in this assay (unlike with 
E4bp4-/- Lin- BM) the S286-301A mutant did not affect NK cell production (Figure 4.9). The 
differences observed between WT E4bp4 and phosphorylation mutants were greater with 
E4bp4-/- Lin- BM cells, than when using WT cells, most likely due to the presence of 
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Figure 4.9 – Removing phosphorylation sites from E4bp4 increases in vitro NK cell production from WT 
Lin- BM  
Lin- BM cells were isolated from WT BM and cultured for two days in the presence of IL-7, Flt3 ligand and SCF 
before retroviral transduction with a MSCV-IRES-hCD2 construct (WT E4bp4 or E4bp4 phosphorylation site 
mutants). Transduced cells were cultured for three days, before being transferred onto OP9 stromal cells and 
cultured in the presence of IL-15 for 7 days. A) Flow cytometry was used to analyse cultured cells to identify live 
lymphocytes that were positive for hCD2 (marker of transduced cells) and subsequently to examine their 
expression of NK1.1 and CD19. B) Relative level of NK cell production by the different E4bp4 phosphorylation 
mutants and WT E4bp4 normalised to the empty vector. Data are representative of three independent 
experiments for each mutant. Results were verified to be significant using paired Student’s t-tests, error bars 
show SEM. *, P < 0.05. 
 
 





4.6 Phosphorylation by Casein Kinase 1ε is important during NK 
cell development  
As the phosphorylation of E4bp4 has a regulatory role during NK cell development, it was 
postulated that inhibition of specific kinases may influence this process. Doi et al. previously 
suggested that E4bp4 was phosphorylated by casein kinase Iε (CKIε) (Doi et al., 2004), so 
inhibition of this enzyme may affect E4bp4 and subsequently NK cell development. To test 
this hypothesis, NK cells were developed in vitro in the presence or absence of an inhibitor 
of casein kinase I activity, D4476 (Rena et al., 2004). 
 
Lin- BM cells were isolated from WT BM, grown for 5 days in lymphocyte inducing conditions 
(Figure 3.20), before being transferred onto OP9 stromal cells and grown in the presence or 
absence of IL-15 and D4476. In the presence of the kinase inhibitor, the number of NK cells 
that developed dramatically increased, regardless of whether the cells were grown with IL-15 
(Figure 4.10). Incidentally, the kinase inhibitor seemed to have a greater effect on the cells 
when they were grown without IL-15 (Figure 4.10). When this assay was repeated with a 
casein kinase II inhibitor, 4,5,6,7-tetrabromobenzotriazole (TBB), there was no effect on NK 
cell development (Figure 4.10). In fact TBB actually caused a small reduction in the number 
of NK cells that developed, but this may simply be due to toxicity issues. Phosphorylation of 
E4bp4 and potentially other TFs is clearly a mechanism by which NK cell development can 
be regulated and chemical kinase inhibitors represent a simple method by which the 
development of NK cells can be influenced. 
 







Figure 4.10 – Inhibition of Casein Kinase I promotes NK cell development. 
WT Lin- BM cells were grown in lymphocyte producing conditions (IL-7, Flt3L, SCF) for five days, before being 
transferred onto OP9 stromal cells. Cells were grown in presence or absence of IL-15 and 10 µM D4476 (an 
inhibitor of casein kinase I) or 20 µM TBB (an inhibitor of casein kinase II). After seven days of culture cells were 
analysed by flow cytometry to identify live lymphocytes (scatter), which were GFP- (stromal OP9 cells are GFP+) 






Phosphorylation is a critical regulator of TF function that can rapidly and reversibly alter the 
function of a TF and lead to changes in gene expression (Filtz et al., 2014). TFs can have 
multiple phosphorylated residues allowing them to receive signals from different signalling 
pathways, enabling them to respond to different stimuli, or alternatively only respond if two 
separate signals are received (Holmberg et al., 2002). Multiple phosphorylation sites can 





also allow the activity of a TF to be tuned with incremental phosphorylation, leading to 
equivalent changes in gene expression (Filtz et al., 2014). The TF E4bp4, which is essential 
for the development of NK cells, has previously been suggested as a target for 
phosphorylation, but whether this is important for its function is not known. 
 
In this study, E4bp4 has been conclusively established to have multiple phosphorylation 
sites and more significantly removing the modified serine residues influenced the activity of 
E4bp4 during NK cell development. Initial searches of the data sets produced by numerous 
phosphoproteomic studies revealed a number of highly conserved potential E4bp4 
phosphorylation sites. When a purified sample of E4bp4 was analysed on a WB, a clear 
signal was observed when probing for phosphoserine, providing clear evidence that E4bp4 
is phosphorylated in vivo. However, to precisely determine the exact locations of E4bp4 
phosphorylation, the purified E4bp4 was analysed using high accuracy MS. This was not a 
straightforward process as phosphorylated forms of most proteins constitute < 5% of the 
total protein within a cell. Therefore, to aid the identification of E4bp4 phosphorylation sites, 
phosphopeptides were enriched using TiO2 beads. The MS analysis provided unambiguous 
evidence that E4bp4 has at least three phosphorylation sites at serine 301, 353 and either 
285 or 286. This confirmed the data of previous phosphoproteomic screens (Choudhary et 
al., 2009) (Dephoure et al., 2008) (Kettenbach et al., 2011) (Olsen et al., 2010) (Weintz et 
al., 2010) (Yu et al., 2011) which identified the same phosphorylated E4bp4 peptides. Doi et 
al. previously proposed that S182 was a site of E4bp4 phosphorylation (Doi et al., 2004), but 
in this study no clear evidence was obtained to support this claim and this site does not 
appear to be important for the function of E4bp4. 
 
As the S285-286 peptide was of low abundance and the S285 residue was at the N-terminus 
of the peptide, it was not possible to categorically determine which serine residue in the 
peptide was modified. Close proximity of a phosphorylated serine residues to a trypsin 
cleavage site can cause miscleavage by trypsin, due to the presence of the negative charge 
of the phosphate group changing the protein chemistry around the trypsin digest site (Steen 
et al., 2005) (Previs et al., 2008). This suggested that S285 is unlikely to be the site of 
modification as it is at the very N-terminus of the peptide and therefore next to a trypsin 
digest site. More significantly, the phosphoproteomic study by Choudhary et al. identified the 
same E4bp4 phosphopeptide and their observations suggested that S286 is indeed the site 
of phosphorylation on this peptide (Choudhary et al., 2009). 
 
The MS analysis revealed no other phosphorylated E4bp4 peptides in the sample. However 
one of the limitations of this approach means that it is not possible to rule out 





phosphorylation at other sites. It may be that other sites do exist but are extremely low in 
abundance and therefore could not be detected in this analysis. Alternatively, 
phosphorylation sites can be missed if they exist on tryptic peptides that are too small or too 
large to be accurately identified by the MS. To be certain that all E4bp4 phosphorylation 
sites have been identified, alternative protein digest strategies could be employed using 
enzymes such as Glu-C or Lys-C. A more complex but potentially useful strategy would be 
to use top-down MS, which involves the analysis of whole proteins, allowing all the PTMs on 
a single protein to be observed at one time (Lanucara and Eyers, 2013) (Zhang and Ge, 
2011). Using this approach the whole protein is fragmented inside the mass spectrometer, 
meaning complete sequence coverage can be achieved, as the protein is not subject to 
enzymatic digestion prior to MS analysis (Zhang and Ge, 2011). All individual modification 
sites can potentially be mapped on the protein, with some PTMs present on multiple 
peptides which can help to confirm their existence (Zhang and Ge, 2011). Additionally this 
approach allows the absence of a modification at a specific site to also be confirmed. 
However, top-down MS does require highly specialised hardware and software to analyse 
the complex detailed spectra that are produced and a number of technical challenges still 
remain with dealing the large data sets acquired (Lanucara and Eyers, 2013) (Zhang and 
Ge, 2011). 
 
All of the E4bp4 phosphorylation sites that were identified in this study are within or very 
close to the C-terminal transcriptional repression domain of E4bp4. This means they 
potentially influence the transcriptional activity of E4bp4, but are less likely to influence its 
DNA binding ability. However, minimal information about the possible three-dimensional 
structure of E4bp4 is available; only the structure of the DNA binding domain of CREB (bZIP 
TF) has been solved (Schumacher et al., 2000). E4bp4 is likely to have a similar structure at 
its N-terminus where it binds to DNA, but the structure of the majority of the protein is 
unknown. It is therefore difficult to know how the E4bp4 phosphorylation sites come together 
in three-dimensional space. It maybe that they all cluster together at a particular region of 
the protein’s surface, but currently there is no way to predict this. 
 
As E4bp4 was found to be multiply phosphorylated, it was essential to determine whether 
phosphorylation was important for its function. In order to do this, numerous serine-alanine 
mutants were created by site-directed mutagenesis and the functionality of these mutants 
was compared to WT E4bp4 to determine how the loss of a phosphorylation site affected its 
function. These mutants were compared to WT E4bp4 for their ability to rescue the 
development of NK cells from E4bp4-/- Lin- BM. The S286A, S286-301A and S286-353A 
mutants all consistently rescued NK cell development to a greater extent that WT E4bp4. In 





fact, the S286-353A mutant on average promoted three times the number of NK cells to 
develop compared to WT E4bp4. Strikingly, mutating a single serine residue, S286, almost 
doubled the number of NK cells that were produced, demonstrating that phosphorylation at 
this residue is critical for regulating E4bp4’s activity.  
 
Another intriguing observation was that mutation of S353 alone only made a small increase 
in NK cell production, but in combination with S286A increased NK cell production compared 
to WT E4bp4 and the S286A mutant alone. This suggested there may be a hierarchy of 
E4bp4 phosphorylation sites. The S301 phosphorylation sites did not seem to be essential 
for NK cell development and may be involved in regulating its function in different cell types 
or in different contexts. S182 and S210 which were proposed to be phosphorylation sites of 
E4bp4, but were not identified by MS in this study, also did not influence its function as 
mutation of these residues did not affect the production of NK cells from E4bp4-/- Lin- BM. 
 
These observations were supported by data from a similar experiment using WT Lin- BM. In 
these cells the E4bp4 phosphorylation mutants also promoted a greater level of NK cell 
production compared to WT E4bp4. However the differences observed between the mutants 
and WT E4bp4 were not as substantial in this experiment as the transduced cells already 
expressed endogenous E4bp4. Nevertheless more than 50% of all the cells transduced with 
the S286-353A mutant developed into NK cells.  
 
These two experiments clearly demonstrated that phosphorylation is a key regulatory 
mechanism for controlling the activity of E4bp4. This finding is supported by the data from 
the original study on E4bp4 phosphorylation by Doi et al. who also suggested that 
phosphorylation inhibited the activity of E4bp4 (Doi et al., 2004). Doi et al. observed that 
when E4bp4 was phosphorylated by CKIε it became less transcriptionally active and more 
prone to proteasomal degradation (Doi et al., 2004). However, the first study to identify 
E4bp4 as a phosphoprotein by Chen et al. suggested that phosphorylation was required for 
E4bp4’s ability to bind DNA (Chen et al., 1995). This suggestion contradicts what is 
observed here and what was observed by Doi et al. (Doi et al., 2004), as E4bp4 is more 
active without phosphorylation you would expect it to be able to still bind target DNA 
sequences more effectively. Significantly, Chen et al. made their observations from 
experiments performed in vitro with E4bp4 produced from non-mammalian cells (Chen et al., 
1995), which may why explain their findings do not agree with what was observed here. 
 
Like E4bp4, the activities of numerous TFs are negatively regulated by phosphorylation and 
multiple phosphorylation events of the same protein can often sequentially reduce activity. 





For example in T cells, NFAT has 13 phosphorylation sites that are dephosphorylated by 
calcineurin when cells are stimulated (Okamura et al., 2000). Progressive dephosphorylation 
allows NFAT to localise to the nucleus and increases its transcriptional activity (Okamura et 
al., 2000). Similarly, phosphorylation of the TF c-Jun, at three sites near its N’ terminal DNA-
binding domain, act to negatively control its ability to bind DNA and must be removed for the 
transcription of target genes to be activated (Papavassiliou et al., 1995). This type of 
regulatory mechanism is essential to control the activity of TFs and prevents aberrant 
transcription that can often lead to human disease (Cohen, 2014). 
 
Doi et al. suggested that CKIε was specifically involved with modifying E4bp4 and was a key 
regulator of its function (Doi et al., 2004). It was postulated whether disrupting the activity of 
this kinase would have an effect on NK cell production. Interestingly, the CKIε inhibitor, 
D4476, promoted the development of NK cells, in the presence and absence of IL-15. 
Further confirming that phosphorylation has an inhibitory role during NK cell development. 
However, it was not possible to determine if the inhibitor directly affected the phosphorylation 
of E4bp4 during NK cell development and it is possible that the inhibitor is having a number 
of off target effects. Development of a specific antibody against the phosphorylated form of 
E4bp4 would allow this to be ascertained. Despite the simplicity of this approach, it 
demonstrates that basic pharmacological intervention can have a significant impact on the 
NK cell development. This has a number of important applications, but most prominently in 
the development of NK cells for immunotherapy. It would also be interesting to determine 
whether this observation could be repeated in vivo. If the administration of this type of 
inhibitor was able to boost an individual’s NK cell development, even for a short period of 
time, it could have significant therapeutic potential. 
 
Many TFs are multiply phosphorylated like E4bp4 and this can sometimes allow signals to 
be integrated from a number of stimuli as each one can result in a different modification on 
the TF (Benayoun and Veitia, 2009) (Deribe et al., 2010). There is redundancy of signalling 
mechanisms involving phosphorylation within the cell, therefore it is likely that many kinases 
and phosphatases are involved in E4bp4 phosphorylation and de-phosphorylation 
respectively. Whether E4bp4 is phosphorylated by CKIε in vivo is still to be ascertained, but 
as inhibiting this enzyme can directly affect NK cell development, it is possible that it is 
important for E4bp4 function. Doi et al. suggested CKIε modified S182 (Doi et al., 2004), but 
the bioinformatic prediction tools used here predicted that S286 may also be phosphorylated 
by a casein kinase. As this study has shown that this is a critical phosphorylation site for 
E4bp4 activity, it will be vital to ascertain which kinase modifies this residue. The 
bioinformatic prediction tools also predicted that E4bp4 may be phosphorylated by a number 





of other kinases, for example S301 was predicted to be modified by a type of cyclin 
dependent kinase, based on the amino acid sequence around the phosphorylated serine, 
whilst S353 was predicted to be modified by a mitogen activated kinase. Potentially these 
two different types of kinase may phosphorylate E4bp4, at different residues, following the 
receipt of different external signals.  
 
Prior to the initiation of this study, a yeast-two-hybrid screen was performed to identify 
interacting partners of E4bp4. Surprisingly few proteins were identified in the experiment, but 
an interaction with the SUMO E3 ligase PIAS1 was observed, leading to the investigation 
into the SUMOylation of E4bp4. However, another protein identified in that screen was 
homeodomain-interacting kinase 3 (Hipk3). Whether this enzyme phosphorylates E4bp4 has 
yet to be explored, but it is known to regulate transcription and phosphorylation in vivo, and 
is implicated in drug resistance and inhibition of apoptosis in a number of tumours (Curtin 
and Cotter, 2004). 
 
Phosphorylation appears to strongly regulate the function of E4bp4, which is analogous to 
what is observed for other major transcription factors such as p53, NFκB and c-Myc 
(Holmberg et al., 2002). It is now essential to ascertain how phosphorylation affects the 
activity of E4bp4 on a molecular level; for example it may affect the stability of the protein, as 
suggested by Doi et al. (Doi et al., 2004) or alternatively it may influence its ability to bind 
DNA or other components of the general transcriptional complex. As phosphorylation has a 
similar effect to SUMOylation on the function of E4bp4, it will be interesting to determine if 


















Post translational modifications influence the 










The alteration of TF activity by PTMs is a key feature of signal transduction pathways that 
allow cells to rapidly respond to environmental cues by varying levels of gene expression 
(Brivanlou and Darnell, 2002) (Deribe et al., 2010). TF activities are tightly controlled by 
PTMs, as misregulation of transcriptional responses is a fundamental contributor to various 
human diseases, particularly cancer (Cohen, 2014). A vast array of different PTMs have now 
been identified which influence the activity of TFs and these commonly alter DNA binding 
capacity, localisation, stability, protein interactions or transcriptional activity (Benayoun and 
Veitia, 2009) (Filtz et al., 2014). An individual TF can be modified by multiple PTMs, which 
work together to achieve a common outcome; one PTM may even promote the modification 
of TF by another PTM (Benayoun and Veitia, 2009) (Deribe et al., 2010). Alternatively, 
different PTMs may negatively cooperate and actively prevent modification of a TF by 
another PTM. TFs can often control gene expression of unrelated genes in different cell 
types and so it is important they are not globally activated. Multiple PTMs of the same TF 
can help to produce tissue or cell specific effects, but studying the significance and 
frequency of these interdependent sequential modifications is still at an early stage (Filtz et 
al., 2014). 
 
E4bp4 is a key TF for a range of biological processes, many involving cells of the immune 
system (Male et al., 2012). In particular, E4bp4 has been identified as an essential regulator 
of NK cell and ILC development (Geiger et al., 2014) (Male et al., 2014) (Seillet et al., 
2014b). Despite its prominence, it is still not clear how E4bp4 functions on a molecular level 
to regulate the expression of different target genes, in different cell types. E4bp4 was first 
identified as a transcriptional repressor and has been shown to repress the expression of 
numerous target genes in vivo, including IL-13 in TH2 cells (Kashiwada et al., 2011a). 
Equally, E4bp4 has been found to transactivate the expression of various target genes, 
including Id2 and Eomes in NK cells (Male et al., 2014) and the immunoglobulin germ-line ε 
gene in B cells, required for IgE class switching (Kashiwada et al., 2010). Some evidence 
now suggests that E4bp4 is able to interact with a number of chromatin modifying enzymes 
that may help to influence the transcription of target genes (Keniry et al., 2013) (Motomura et 
al., 2011) (Tong et al., 2013). E4bp4 was observed to interact with the histone H2A 
ubiquitinase MYSM1, and this interaction was identified to be crucial for the expression of 
Id2 and ultimately the development of NK cells (Nandakumar et al., 2013). 
 





It is unclear how E4bp4 is able to influence transcriptional activation and repression of 
different target genes, and how the activities of this TF are regulated. In this study E4bp4 
was found to be post translationally modified by both SUMOylation and phosphorylation. 
Both of these PTMs appear to function in a similar manner, repressing the activity of E4bp4. 
When phosphorylation or SUMOylation sites of E4bp4 are mutated, the activity of the protein 
increased. This was observed by the greater number of NK cells produced from Lin- BM 
cells, grown in vitro and transduced with E4bp4 mutants, compared to WT E4bp4. However 
the underlying mechanism for this phenotype was not known, or whether the mechanism 
was the same for both phosphorylation and SUMOylation. 
 
This study aimed to establish the molecular mechanism underlying the post translational 
regulation of E4bp4 during NK cell development. In order to achieve this, the following 
objectives were set: 
 
1. Ascertain whether PTMs affect the stability of E4bp4. 
2. Determine whether the PTMs of E4bp4 influence its transcriptional activity using a 
luciferase reporter assay. 
3. Use quantitative PCR to determine whether the PTMs of E4bp4 are important for its 




5.2 The PTMs of E4bp4 do not affect its stability or proteasomal 
degradation 
SUMOylation and phosphorylation both influence the stability of TFs. Multi-site 
phosphorylation of the TF ATF4 affects its ubiquitination and ultimately its stability, which is 
essential for regulation of the cell cycle (Frank et al., 2010). Phosphorylation of ATF4 acts 
progressively to control its degradation, allowing for dose-dependent regulation of target 
genes during neurogenesis (Frank et al., 2010). Despite being similar in structure to 
ubiquitin, SUMOylation does not directly target proteins for proteasomal degradation, but it 
can promote ubiquitin-mediated degradation, which has been observed for the TF PML 
(Lallemand-Breitenbach et al., 2008). Arsenic trioxide, used to treat acute myeloid 
leukaemia, can induce SUMOylation of PML in leukemic cells and these SUMO 
modifications help to recruit the ubiquitin-ligase RNF4 (Lallemand-Breitenbach et al., 2008). 





This leads to polyubiquitination of PML, its subsequent proteasomal degradation and 
therefore a reduction in the oncogenic activity of PML in leukemic cells (Lallemand-
Breitenbach et al., 2008). Conversely, SUMOylation can stabilise target proteins by blocking 
ubiquitination at a particular lysine residue, which has been shown for IκBα (Desterro et al., 
1998). SUMO1 modification of IκBα at lysine 21 prevents ubiquitination and protects the 
protein from degradation, preventing signal-induced activation of NFκB-dependent 
transcription (Desterro et al., 1998). 
 
As both phosphorylation and SUMOylation negatively regulate the activity of E4bp4, it was 
hypothesised that both of these modifications could promote the proteasomal degradation of 
the protein. Alternatively, the Lys to Arg mutations that were made in the E4bp4 
SUMOylation mutants could prevent E4bp4 from being ubiquitinated if one of the mutated 
lysine residues was also a site of ubiquitination (Tatham et al., 2009). Doi et al. previously 
suggested the phosphorylation of E4bp4 induces its proteasomal degradation (Doi et al., 
2004). However, this was only inferred by the fact that, when E4bp4 was coexpressed with 
Casein kinase I, a small reduction in the production of E4bp4 was observed. This was 
subsequently abolished when the proteasome was chemically inhibited by MG132 (Doi et 
al., 2004). This experiment was also performed with transiently overexpressed protein which 
may not accurately represent how the protein functions in vivo. To determine whether 
SUMOylation and phosphorylation regulate the degradation of E4bp4, a cycloheximide time 
course assay was used to compare the half-life of E4bp4 in the presence and absence of its 
PTMs. 
 
Cycloheximide is an inhibitor of the mammalian translational machinery and once active 
inside cells new peptides cannot be synthesised (Schneider-Poetsch et al., 2010). To 
determine a protein’s stability, samples of cycloheximide treated cells can be analysed every 
few hours to establish the point at which the protein is no longer detectable (Schneider-
Poetsch et al., 2010). Cycloheximide assays have previously been used to analyse the 
stability of numerous TFs including the oncogene Myc (Yeh et al., 2011), the circadian clock 
protein Per2 (Asher et al., 2008) and the tumour suppressor p53 (Shen et al., 2014). 
 
To perform the cycloheximide time course assay a source of cells that expressed detectable 
levels of E4bp4 and the E4bp4 PTM mutants were required. It was important to have cells 
that expressed the E4bp4 mutants at close to endogenous levels so that if either PTM 
affected stability, it would be relevant to the situation in vivo. Therefore, murine 3T3 cells 
were stably transduced with retroviruses produced from the pMSCV-IRES-hCD2 construct 





(the same as was used in the NK cell development assay) to create stable cell lines that 
expressed WT E4bp4, E4bp4 S286-353A or E4bp4 5X SUMO (Figure 5.1). The S286-353A 
and 5X SUMO mutants were analysed as these had produced the strongest phenotypes in 
the NK cell development assays. 
 
Following transduction, all hCD2 positive cells in each sample were FACS sorted, 
maintained in culture and the level of hCD2 expression was checked using flow cytometry 
every 3 - 4 days (Figure 5.1). To confirm successful transduction, the cell lines were 
analysed by WB for their expression of E4bp4. Nuclear extracts were created from each cell 
line and E4bp4 was present in each of the nuclear extracts (Figure 5.1B). This confirmed 
that the SUMOylation and phosphorylation site mutations did not interfere with the ability of 
E4bp4 to translocate to the nucleus (Figure 5.1B). However, this was not unexpected as the 
mutants both have greater functionality than WT E4bp4. 
 
Each transduced cell line was subjected to 50 µg/ml cycloheximide for 0 - 16 hours, with 
samples lysed at regular time intervals. Nuclear extracts were prepared and compared by 
WB for E4bp4 expression (Figure 5.2). The 5X SUMO mutant, the S286-353A mutant and 
WT E4bp4 all had very similar half-lives; the protein level reduced by almost half after 8 
hours and after 12 hours of cycloheximide treatment, E4bp4 was undetectable in all samples 
(Figure 5.2). Neither SUMOylation nor phosphorylation affected the stability of E4bp4 and 
so it was concluded that these PTMs must use a different mechanism to influence the 
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5.3 PTMs of E4bp4 regulate its transcriptional activity 
5.3.1 Transcriptional repression of target genes by E4bp4 
There are many of reports of SUMOylation influencing the transcriptional activities of TFs 
and there appears to be a strong association between SUMOylation and enhanced 
transcriptional repression (Gill, 2005). There are suggestions that this may be due to SUMO 
promoting interactions between TFs and chromatin remodelling proteins that induce 
transcriptionally repressive chromatin structures (Lee and Muller, 2009) (Ouyang et al., 
2009). There are also reports of SUMOylation stimulating transcriptional activity, or at least 
dampening transcriptional repression, mediated by a number of TFs (Yan et al., 2010) 
(Zhang et al., 2012). Phosphorylation has also commonly been found to regulate TF function 
by influencing interactions with transcriptional cofactors, promoting transactivation through 
phosphorylation dependent activation domains and, in some cases, repression domains 
(Whitmarsh and Davis, 2000). 
 
To establish if SUMOylation or phosphorylation regulates the transcriptional activity of 
E4bp4, a transcription reporter gene assay was established (Figure 5.3). Using the pMSCV-
IRES-hCD2 construct, 3T3 cells were transfected and were able to express E4bp4. The 
expression of hCD2 allowed the levels of transfection to be analysed using flow cytometry, to 
ensure E4bp4 was expressed in all cells (Figure 5.3). The 3T3 cells were also transfected 
with a pGL3-Luc construct that contained a promoter controlling the expression of the Firefly 
Luciferase gene (Figure 5.3). Upstream of the promoter was either three copies of the 
E4bp4 DNA-binding consensus sequence, identified by Cowell et al. (Cowell et al., 1992) or 
the 2 kb region upstream of Eomes or Id2, in the murine genome, both of which contain 
E4bp4 binding sites (Male et al., 2014). As an additional control, the 3T3 cells were also 
transfected with a second luciferase construct containing the Renilla Luciferase gene, which 
acted as an internal control for luciferase activity (Figure 5.3). 3T3 cells were used in this 
assay system as they are of murine origin and they allowed consistent transfections of the 
three DNA constructs in each cell. Ideally the murine NK cell line MNK-1 (Allan et al., 2014) 
would have been used for this assay, but previous work from the Brady laboratory had 
shown transgene expression in these cell could only be achieved using lentiviral 
transduction.  
 
Initially the activity of E4bp4 in the luciferase assay was compared using the different pGL3-
Luc constructs (Figure 5.4A). The upstream genomic regions of Eomes and Id2 did not 
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The WT form of E4bp4, the K10-116-219R E4bp4 mutant and 5X SUMO mutant were 
transfected into 3T3 cells with pGL3-E4bp4-CS to compare their transcriptional activity. 
Forty-eight hours after transfection, the cells were analysed by flow cytometry, which 
demonstrated all cells were consistently transfected with the MSCV-IRES-hCD2 constructs, 
due to their expression of hCD2 (Figure 5.4B). Both the K10-116-219R and 5X SUMO 
mutants caused greater transcriptional repression of the luciferase gene than the WT E4bp4 
(Figure 5.4D). The 5X SUMO mutant, which lacked all SUMO modifications gave the 
strongest transcriptional repression and this was significantly lower than the empty vector 
and WT E4bp4 (Figure 5.4D). This transcriptional repression was only observed when the 
E4bp4 DNA-binding sites were present upstream of the luciferase gene promoter (Figure 
5.4).  
 
Five of the E4bp4 phosphorylation mutants were also analysed using this assay, in particular 
those that were previously found to affect NK cell development. The S286A, S286-353A and 
S286-301A mutants caused greater transcriptional repression than WT E4bp4, in a similar 
manner to the 5X SUMO mutant (Figure 5.5). However, the S210A, S301A and S353A 
mutants did not affect E4bp4’s ability to repress transcription of the luciferase gene (Figure 
5.5). Removing the phosphorylation and SUMOylation modifications from E4bp4 appeared 
to increase its transcriptional activity, making it a more potent transcriptional repressor. 
Additionally, the same E4bp4 mutants that affected NK cell development also affected the 
transcriptional activity of E4bp4, suggesting that this is a potential mechanism by which 
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5.3.2 Transcriptional activation of target genes by E4bp4 
As well as acting as a transcriptional repressor, E4bp4 has also been reported to activate 
the transcription of its target genes (Kashiwada et al., 2011a) (Male et al., 2014) (Zhang et 
al., 1995). As E4bp4 did not induce transcriptional activation of the luciferase gene in the 
presence of promoter regions from Eomes and Id2 (Figure 5.4A) an alternative approach 
was developed. Zhang et al. identified E4bp4 in human T cells as a regulator of IL-3 
expression and was the first to demonstrate that it could promote transcription of target 
genes (Zhang et al., 1995). In this study, Zhang et al. identified a minimal E4bp4 DNA-
binding consensus sequence that was required for transactivation of target genes (Zhang et 
al., 1995). Interestingly, this sequence differed slightly from the E4bp4 DNA-binding 
consensus sequence identified by Cowell et al. who discovered E4bp4 as a transcriptional 
repressor (Table 5.1). As SUMOylation and phosphorylation both affected E4bp4’s ability to 
repress transcription using the Cowell et al. binding sites (in pGL3-E4bp4-CS), it was 
postulated whether these would have a similar effect with transcriptional activation. 
 
 
Table 5.1 – E4bp4 DNA binding sequences 
Name Minimal DNA binding sequence Activity Reference 
E4bp4-CS TTATGTAAC Repression Cowell et al. (1992) 




To clone the Zhang et al. E4bp4 DNA-binding consensus sequence into the pGL3 Firefly 
Luciferase vector (pGL3-E4bp4-CS-ZH), an oligonucleotide was synthesised of the desired 
sequence which contained three copies of the minimal consensus DNA-binding sequence 
(Table 5.1) (Figure 5.6). The oligonucleotide was amplified by PCR, restriction digested and 
ligated into the pGL3 vector, upstream of the Luciferase promoter (Figure 5.6). The ligation 
product was transformed into competent E. coli and colony PCR was used to identify 
transformed bacterial colonies containing the correct DNA insert (Figure 5.6). Additionally, to 
confirm that the cloning was successful vector DNA was fully sequenced. The pGL3-E4bp4-
CS-ZH construct was identical to the previously used pGL3-E4bp4-CS construct except for 
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Using the lentiviral expression system it was possible to consistently achieve high levels of 
transduction of the MNK-1 cells. When analysing transduction by a GFP control construct, 
over 85% of the cells were GFP+ (Figure 5.11A). When MNK-1 cells were transduced with 
pCSGW-E4bp4 or mutant versions of E4bp4, high levels of E4bp4 were detectable in whole 
cell lysates of transduced cells when analysed by WB (Figure 5.11B). Analysis of the same 
WB with a long exposure also confirmed that WT E4bp4 expressed in these NK cells is 
SUMOylated and, as expected, the 5X SUMO mutant does not have any SUMO 
modifications, as determined by the presence of higher molecular weight forms of E4bp4 
(Figure 5.11B). This observation supported the findings in chapter 3, that SUMOylation of 
E4bp4 is important in NK cell development as it confirms that E4bp4 is SUMOylated in NK 
cells. The S286-353A mutant had the same higher molecular weight forms as WT E4bp4, 
suggesting that phosphorylation does not affect SUMOylation (Figure 5.11B). 
 
Using quantitative-PCR (qPCR), the expression of potential E4bp4 target genes were 
analysed in the transduced MNK-1 cells (Figure 5.12). WT E4bp4 effectively transactivated 
the expression of Id2 and Eomes, as previously reported (Male et al., 2014) and also Notch1 
and E2A (Figure 5.12). In comparison to WT E4bp4, the 5X SUMO and S286-353A mutants 
did not affect the transactivation of Eomes and Id2 (Figure 5.12). However, both mutants 
caused greater transcriptional activation of both Notch1 and E2A, when compared to WT 
E4bp4 (Figure 5.12). This provided evidence that the SUMOylation and phosphorylation of 
E4bp4 negatively regulate the transcriptional activity of E4bp4 in NK cells and, in the 
absence of these modifications, E4bp4 is a more potent transcriptional activator. Why the 
absence of PTMs on E4bp4 affected the transactivation of some genes and not others 
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The bZIP TF E4bp4 has multiple PTMs; it is phosphorylated on at least three serine residues 
and at least three lysine residues carry SUMO modifications. Both phosphorylation and 
SUMOylation regulate the activity of E4bp4 and suppress its functionality. When 
phosphorylation or SUMOylation sites are mutated, the activity of E4bp4 during NK cell 
development is dramatically increased, resulting in greater numbers of NK cells being 
produced in vitro. The inhibition of CK1ε, which is thought to modify E4bp4, was also able to 
promote an increase in NK cell production. However, the molecular mechanism underlying 
the regulation by PTMs is yet to be explored. As a TF E4bp4 is able to active and repress 
the transcription of target genes, in different cell types and in varying contexts (Male et al., 
2012). Here, the PTMs of E4bp4 were found to directly influence its ability to repress and 
activate target genes expression, but did not influence the stability of the protein.  
 
As the PTMs of E4bp4 were able to influence the activity of E4bp4 during NK cell 
development, it was important to establish if this was a direct effect of increased protein 
levels being present within the cell due to the PTMs influencing the stability of E4bp4. Both 
phosphorylation and SUMOylation have been reported to influence ubiquitin-mediated 
proteasomal degradation of TFs (Filtz et al., 2014). The stability of WT E4bp4, 5X SUMO 
E4bp4 and S286-353A E4bp4 were compared using a cycloheximide time course assay. 
Although this assay is only semi-quantitative, it clearly demonstrated that the PTMs of E4bp4 
do not affect its stability and both mutants and WT E4bp4 are degraded at the same rate. 
This finding contradicted the previous work of Doi et al. who had suggested that the 
phosphorylation of E4bp4 influenced its proteasomal degradation (Doi et al., 2004). 
However, their approach simply involved the overexpression of CK1ε and E4bp4 together 
and is unlikely to be indicative of what occurs endogenously. As the PTMs of E4bp4 did not 
affect the stability of the protein, they must influence its activity through another mechanism.  
 
E4bp4 is a TF which regulates the expression of numerous target genes. Using a reporter 
gene assay, with E4bp4 binding sites cloned upstream of the promoter for Firefly Luciferase, 
E4bp4 was able to repress transcriptional activity. Mutants lacking both SUMOylation and 
phosphorylation sites caused greater transcriptional repression than WT E4bp4, 
demonstrating that both modifications regulate E4bp4 activity in the same way. Different 
phosphorylation mutants were analysed in this assay and all containing the S286A mutation 
caused greater repression than WT E4bp4. The effects of the various mutants in this assay 
mirrored what was previously observed in the NK cell development assays, suggesting this 





is an important mechanism by which PTMs regulate E4bp4 and ultimately influence NK cell 
development. However, in the luciferase assay, the combination of S286A and S353A did 
not seem to increase the activity of E4bp4 further than the S286A mutant alone, as was the 
case in the NK cell development assay. This regulation of E4bp4 is very similar to what has 
been observed for other TFs such as FOG-2, a critical regulator of heart morphogenesis and 
coronary vessel formation (Perdomo et al 2012). The SUMOylation of FOG-2 negatively 
regulated its ability to repress transcription of target genes, as mutating FOG-2 SUMOylation 
sites resulted in stronger transcriptional repression activity (Perdomo et al., 2012). 
 
It was noted that more than one minimal consensus-DNA binding sequence had been 
discovered for E4bp4. The binding site identified by Cowell et al. varied slightly from the one 
later identified by Zhang et al. but both contained the consensus TTGA
T
CGTAA at the centre of 
the minimal consensus-DNA binding site. These different binding sequences caused E4bp4 
to induce opposing effects on transcription when used in reporter gene assays (Cowell et al., 
1992) (Zhang et al., 1995). Using the Zhang et al. sequence, it was possible to analyse the 
effect of PTMs on transactivation by E4bp4 (Zhang et al., 1995). Removing PTMs from 
E4bp4 increased its transactivation, in similar manner to what was observed with the 
transcriptional repression. Both the 5X SUMO and S286-353A mutants caused greater 
transactivation than WT E4bp4. However, the transactivation observed for WT E4bp4 in the 
assay was lower than previously reported by Chen et al., who showed that reporter gene 
activity was 4.8x higher in the presence of E4bp4 (Chen et al., 1995). Further optimisation of 
assay conditions may be required to achieve such high levels of transcriptional activation. 
 
These findings demonstrated that E4bp4 can recognise different DNA-binding sites and can 
cause differing effects on the expression of target genes. However, the regulation of E4bp4 
by phosphorylation and SUMOylation is the same, regardless of whether it is activating or 
repressing transcription. A number of other bZIP TFs can also recognise two distinct DNA-
binding sites, including XBP1 and CREB3 (Jolma et al., 2013). Comparison of 
experimentally verified E4bp4 binding sites, upstream of in vivo target genes, also 
demonstrates that E4bp4 can bind to varying DNA sequences (Table 5.2). The exact 
mechanism that determines if E4bp4 will activate or repress a particular target gene is not 
clear, but it is likely to be combination of the exact DNA binding site it identifies, the wider 
nucleotide sequence surrounding that binding site and the presence or absence of other 
interacting proteins and cell specific factors. The tumour suppressor TF, p53, has been 
extensively studied and has also been found to bind different DNA binding sites as well as 





having different transcriptional activity on its target genes (Riley et al., 2008). In fact, p53 
uses both direct and indirect methods to repress gene transcription (Riley et al., 2008). 
 
 
Table 5.2 – In vivo E4bp4 binding sites 
Gene Cell type E4bp4 binding site Transcriptional 
activity 
Reference 
Id2 NK cell GTGTGTATGTAAATGT Activation (Male et al., 2014) 
Eomes NK cell AAAATAATGTAAATTT Activation (Male et al., 2014) 
IL3 T cell CCACAGACGTAATTAA Activation (Zhang et al., 1995) 
Per2  Pineal gland TCACTTATGTAAAATG Repression (Doi et al., 2001)   
IL-12b Macrophages ATGATGATGTAAGAAA Repression (Smith et al., 2011) 
IL-13 T cells GGCCTTATGTAACGGG Repression (Kashiwada et al., 
2011a) 
 




As the PTMs of E4bp4 influenced its transcriptional activity in the reporter gene assay, it was 
postulated whether the same would occur for endogenous target genes in vivo. The 5X 
SUMO mutant, S286-353A mutant and WT E4bp4 were expressed in the newly developed 
MNK-1 murine NK cell line (Allan et al., 2014) using lentiviral transduction and then the 
expression of potential E4bp4 target genes was analysed by qPCR. The MNK-1 cells did not 
express detectable levels of endogenous E4bp4, had a clear NK cell phenotype and could 
be transduced to high levels, so was ideal for this analysis. Expression of E4bp4 in the MNK-
1 cells caused the transactivation of a number of genes, but interestingly the transactivation 
of Notch1 and E2A was significantly higher with the 5X SUMO and S286-353A mutants 
compared to WT E4bp4. These observations supported the findings from the reporter gene 
assay and demonstrated that SUMOylation and phosphorylation are key regulators of E4bp4 
activity, influencing its transcriptional activity in vivo and specifically in NK cells. 
 
Notch1 and E2A have not previously been suggested as transcriptional targets for E4bp4 
and are more commonly associated with T cell development, but there is evidence to 
suggest that they play a role in NK cell development. Carotta et al. demonstrated that Notch 
signalling can directly induce NK cell development in murine Pax5-/- pro-B cells (Carotta et 





al., 2006). Specifically, Notch signalling was required at the earliest stages of NK cell 
development, as prolonged signalling decreased the number of NK cells produced and 
promoted the development of T cells (Carotta et al., 2006). A separate study also showed 
that the Notch ligand, Jagged 2, was able to induce NK cell development in vitro from murine 
HSCs (DeHart et al., 2005). 
 
Similar observations have also been made for the development of human NK cells, as the 
activation of Notch at an early point in NK cell development can promote the appearance of 
NK cells (Bachanova et al., 2009) (Haraguchi et al., 2009) (Schotte et al., 2010). The 
interruption of Notch signalling, at an early stage of development, also resulted in the loss of 
human NK cell development from HSCs in vitro (Haraguchi et al., 2009). Human umbilical 
cord blood CD34+ progenitors have also been developed into CD7+ lymphoid precursors and 
functional NK cells in the absence of both stromal cells and IL-15, when sustained Notch1 
signalling was present (Bachanova et al., 2009). However, for NK cells to fully mature, 
produce a full range of cytokines and acquire all NK cell receptors required for effector 
functions, they do require stromal cells as well as IL-15 and cannot simply rely on Notch1 
signalling (Bachanova et al., 2009). 
 
These findings demonstrate that Notch is required at the early stages of NK cell 
development, which is strikingly similar to what is observed for E4bp4 which is indispensable 
for the early stages of NK cell development but it is not required for NK cell maturation and 
functionality (Firth et al., 2013). Boos et al. also demonstrated that Id2, which is required to 
suppress E-proteins in developing NK cells, does not target E2A in developing NK cells, 
suggesting that this too could be involved in this process (Boos et al., 2007). E2A expression 
is essential for the production of LTi cells (Boos et al., 2007), a close relative of NK cells and 
E4bp4 is also required for their development (Geiger et al., 2014). Finally, promoter regions 
of both Notch1 and E2A (Tcf3) genes in the mouse genome, were discovered to contain 
predicted E4bp4 binding sites, in particular five sites were found in different promoter regions 
of the Notch1 gene (Table 5.3).  
 
E4bp4 was found to transactivate a number of genes in the MNK-1 cells, but Eomes and Id2 
transactivation was not influenced by the lack of SUMOylation or phosphorylation. Therefore, 
the regulation of E4bp4 transcriptional activity by its PTMs may be more complex, with only 
the transcription of a subset of E4bp4 target genes being regulated by its PTMs. The MNK-1 
experiment did not reveal any transcriptional repression by E4bp4 in vivo, however only a 
small number of potential target genes were tested. As both phosphorylation and 
SUMOylation had a significant effect on transcriptional repression in the Luciferase reporter 





assay, it would be interesting to determine if this also occurred in vivo. Analysing the effects 
of the E4bp4 PTM mutants during the development of ex vivo NK cells would also be of 
interest. However, to analyse changes in developing cells would require large numbers of 
FACS-sorted CLP cells to be transduced in order to see clear differences in gene activation 
between E4bp4 mutants, making this experiment technically and financially impractical. An 
alternative approach could involve FACS-sorting NK cells that develop from the transduced 
ex vivo Lin- BM cells and analysing global changes in gene expression by microarray. Gene 
expression patterns could be compared between cells transduced with the WT form of 
E4bp4 or those transduced with a mutant form. However, E4bp4 functions at the earliest 
stages of NK cell development, so analysing gene expression in fully mature NK cells may 
not reveal important changes caused by the presence/absence of PTMs on E4bp4 that lead 
to increased levels of NK cell production. 
 
 
Table 5.3 – Predicted E4bp4 binding sites in the promoter regions of Notch1 and E2A (Tcf3) 






26477525 - 26477545 
 
CTACGGTCATGTAACTCATC 
Notch1 GXP_164006  26477509 - 26477529 TCAGGCTGAGGTAAAGCTGG 
Notch1 GXP_164007  26458924 – 26458944 TCACACTTCTGTAACCACCA 
Notch1 GXP_164010  26468217 – 26468237 GTGCAAGTAAGTAAGGCTGA 
Notch1 GXP_3078977  26466245 – 26466265 TAAAAAATATGTAATGTGTAT 














As well as E4bp4, other bZIP TFs are known to be able to transactivate and repress different 
target genes. The bZIP transcription factor, MafA, which is responsible for β-islet cell 
maturation in the pancreas, has also been identified as a transcriptional activator and 
repressor (Hang and Stein, 2011) (Pouponnot et al., 2006). MafA activity is tightly controlled 
by phosphorylation and changes to specific phosphorylation sites are associated with 





pathologies including Type 1 Diabetes Mellitus (Hang and Stein, 2011). MafA is also 
SUMOylated and, like E4bp4, SUMOylation negatively regulates MafA transcriptional activity 
and ultimately β-islet cell function (Shao and Cobb, 2009). The TF Ets1, which, like E4bp4, 
is essential for NK cell development, is also negatively regulated by both SUMOylation and 
phosphorylation. Ets1 has two SUMOylation sites at K15 and K227 and modification of these 
sites reduced transactivation of target genes by Ets1, but did not affect its stability (Ji et al., 
2007). Additionally, Ets1 can be phosphorylated by calmodulin-dependent protein kinase II 
near its DNA binding domain and this influences it ability to bind DNA and activate target 
gene expression (Pufall et al., 2005). 
 
Both the SUMOylation and phosphorylation mutants displayed the same phenotypes 
throughout this study. Mutants lacking both PTMs were able to promote a greater level of 
transcription repression and transcriptional activation. Therefore, it is possible that these two 
PTMs work together to regulate the transcriptional activity of E4bp4. A number of studies 
have reported that phosphorylation can influence SUMOylation, through a phosphorylation-
dependent consensus motif ΨKxExxS/T, so the phosphorylated serine or threonine is in 
close proximity to the SUMOylated lysine (Hietakangas et al., 2006) (Shalizi et al., 2006) (Su 
et al., 2012). The TF, MEF2A, which is required for myogenesis and neuronal 
morphogenesis, is regulated by phosphorylation dependent SUMOylation at one of these 
consensus sites (Shalizi et al., 2006). Dephosphorylation of Ser408, which is catalysed by 
neuronal activity and calcium-dependent phosphatases, promotes the desumoylation of 
Lys403, resulting in the activation of MEF2A and the subsequent expression of target genes 
(Shalizi et al., 2006). However, a similar process is unlikely to occur with E4bp4 because 
none of the phosphorylation and SUMOylation sites identified in this study are in close 
proximity and E4bp4 does not contain any ΨKxExxS/T consensus motifs for 
phosphorylation-dependent SUMOylation. The E4bp4 S286-353A mutant also appeared to 
have the same SUMO modifications as WT E4bp4, suggesting that phosphorylation does 
not influence the SUMOylation of E4bp4. However, analysing whether the phosphorylation 
and SUMOylation of E4bp4 influence each other should be part of future studies into the 
regulation of E4bp4.  
 
Phosphorylation and SUMOylation are both potent regulators of E4bp4’s activity during NK 
cell development and both PTMs directly influence its transcriptional activity, without 
affecting its stability. The activity of E4bp4 during NK cell development is therefore likely to 
be controlled by PTMs, allowing it to activate and repress different target genes to different 
extents. In the absence of phosphorylation or SUMOylation E4bp4 can be more active as a 
TF, causing greater levels of transcriptional activation or repression, both of which will help 





to drive an NK cell specific genetic programme. In particular it was observed that in the 
absence of PTMs E4bp4 promoted transcriptional activation of Notch1 and E2A in NK cells, 
which may help to influence NK cell development. The full relationship between E4bp4 
PTMs remains to be explored as it could have alternative modification states in vivo that may 

























6.1 Conclusions  
NK cells are innate lymphocytes that are capable of producing inflammatory cytokines and 
can spontaneously kill infected, stressed or malignant cells. NK cells develop in the BM from 
HSCs and lymphoid progenitor cells by a tightly regulated process, requiring the expression 
of numerous TFs as well as the presence of cytokines and other signal molecules 
(Vosshenrich and Di Santo, 2013). Of the TFs identified as essential for NK cell development 
so far, E4bp4 is the only one required for commitment to the NK lineage and must be 
expressed in CLPs in order for the earliest pre-NKPs to develop (Male et al., 2014). During 
this process, E4bp4 regulates the expression of other important TFs that control NK cell 
development, such as Eomes and Id2 (Male et al., 2014). This is a highly specialised 
function as E4bp4 activity is expendable for the maintenance, homeostasis and anti-viral 
responses of mature NK cells (Firth et al., 2013). E4bp4 is also essential for other 
immunological processes including the cytokine production by TH1 and TH2 T helper cells 
(Kashiwada et al., 2011a) (Kobayashi et al., 2014) (Motomura et al., 2011), class switching 
to IgE in B cells (Kashiwada et al., 2010) and the development of TH17 T helper cells (Yu et 
al., 2013b). 
 
The research presented here demonstrates that the E4bp4 protein is multiply SUMOylated 
and multiply phosphorylated in vivo and both function in a similar manner to negatively 
regulate its transcriptional activity. This influence on transcriptional activity affected the 
function of E4bp4 during NK cell development. The expression of E4bp4 lacking either 
SUMOylation or phosphorylation sites in E4bp4-/- Lin- BM cells caused a dramatic increase in 
NK cell production, compared with cells expressing WT E4bp4. An almost identical 
phenotype was observed when the mutant versions of E4bp4 were expressed in WT Lin- BM 
cells. This negative regulation of E4bp4 by phosphorylation and SUMOylation is similar to 
what has been reported for a number of other TFs, for example transcriptional repression of 
target genes by FOG-2 is negatively regulated by SUMOylation (Perdomo et al., 2012). The 
activity of Ets1, which is important for NK cell development, is also regulated by both 
phosphorylation and SUMOylation (Ji et al., 2007) (Tootle and Rebay, 2005). However, until 
this study very few have demonstrated that the SUMOylation of a single TF can have such a 
significant impact on a complex, dynamic biological process. Additionally, mutation of a 
single phosphorylation site, S286, was found to have a profound effect on E4bp4 activity and 
ultimately NK cell development. 





6.2 Signals that influence the PTMs and activity of E4bp4 
The signals required to induce E4bp4 expression and activity in NK cells, as well as the 
signals that influence its PTMs, are largely unknown. IL-15, the critical cytokine for NK cell 
production, was originally proposed to function ‘upstream’ of E4bp4 in NK cell development 
as IL-15 signalling promoted its expression (Gascoyne et al., 2009). Ectopic expression of 
E4bp4 also promoted NK cell development even in the absence of IL-15 signalling 
(Gascoyne et al., 2009). However, the relationship between E4bp4 and IL-15 now appears 
more complex; in the absence of E4bp4, IL-15 responsive NKPs expressing the IL-2Rβ 
receptor (CD122) do not develop (Male et al., 2014). This suggests that E4bp4 may also act 
upstream of IL-15 signalling and may function in some form of self-reinforcing positive feed-
back loop that drives cells to commit to the NK lineage (Male et al., 2014). IL-15 signalling 
involves the phosphorylation of JAK3, which in turn phosphorylate STATs, such as STAT5, 
causing its dimerisation and translocation to the nucleus (Orr et al., 2010). It is possible that 
this signalling influences the PTMs of E4bp4 as well as its transcription.  
 
The evolutionarily conserved serine-threonine kinase, mTOR (‘mammalian target of 
rapamycin’), is a central component in many metabolic and inflammatory pathways and 
recent work by Marcais et al. has revealed that its activation is important for proliferation of 
NK cells in the BM (Marcais et al., 2014). mTOR activation was found to be an important 
component of IL-15 signalling and therefore it is possible that it too could influence the PTMs 
and activity of E4bp4. Identifying whether or not these signalling pathways influence the 
modifications of E4bp4 will be challenging, as modified forms of endogenous E4bp4 are very 
low in abundance. However, analysis could be made possible through the development of 
specific antibodies that recognise the phosphorylated/SUMOylated isoforms of E4bp4. 
 
E4bp4 is a circadian protein; its expression fluctuates in an overt diurnal manner and is 
opposite to that of numerous PAR proteins, which form part of the mammalian circadian 
clock (Mitsui et al., 2001) (Ueda et al., 2005). The differentiation of TH17 cells is controlled by 
E4bp4 and the circadian clock, with the expression of RORγt being repressed in a diurnal 
manner by E4bp4 (Yu et al., 2013b). In the absence of the primary circadian activator 
CLOCK, naïve CD4+ T cells had higher expression of E4bp4 and a reduced capacity for 
TH17 cell differentiation (Yu et al., 2013b). Whether E4bp4 expression, its activity or its 
PTMs are controlled by the circadian clock in developing NK cells has yet to be determined, 
however this could be an important mechanism by which NK cell production and immune 





responses are coordinated. To establish if this regulatory mechanism exists, NK cell 
populations and their E4bp4 expression should be analysed in CLOCK-/- mice and in other 
mice that lack key circadian rhythm genes.  
 
 
6.3 E4bp4 and human NK cell development 
The regulation of E4bp4 by its PTMs has significant implications for the production of human 
NK cells for use in various forms of immunotherapy. NK cells spontaneous cytotoxicity 
against a wide variety of tumour cells means there is intense interest in using NK cells in 
various forms of anti-cancer treatment (Knorr et al., 2014). NK cells exist at fairly low 
numbers in the blood so, after isolation from volunteers, these cells must be expanded in 
vitro to produce enough cells to give to each patient (Rujkijyanont et al., 2013). However, 
this process can lead to NK cell exhaustion meaning they become less effective at killing 
target cells and do not survive more than a few days in a recipient (Knorr et al., 2014). 
Alternative strategies have now been developed with the aim of generating large numbers of 
cytotoxic NK cells from embryonic stem cells (Woll et al., 2005), induced-pluripotent stem 
cells (Kaufman, 2009) (Knorr et al., 2013) (Ni et al., 2011) and umbilical cord blood (UCB) 
(Luevano et al., 2014) (Pinho et al., 2012) (Spanholtz et al., 2010). The production of NK 
cells from these different sources involves the use of cytokines and ‘feeder layer’ stromal 
cells to commit stem cells to the NK cell lineage (Luevano et al., 2012). Influencing E4bp4 
activity, potentially via its PTMs, in developing human NK cells could be an important step 
towards increasing NK cell production.  
 
Both previous research (Gascoyne et al., 2009) (Male et al., 2014) and this study have 
shown that the overexpression of E4bp4 in developing murine NK cells leads to an increase 
in NK cell production, demonstrating that E4bp4 is a limiting factor for this process. E4bp4 is 
expressed in human NK cells developed from UCB and its expression significantly increases 
as the NK cells mature (Luevano et al., 2014). It is highly likely that E4bp4 is important for 
this process, but this has yet to be studied in detail. However, a recent report by Ning et al. 
has begun to suggest the potential impact that E4bp4 can have on developing human NK 
cells (Ning et al., 2014). NK cells were developed from adipose tissue-derived stem cells and 
one strategy used to do this involved the lentiviral transduction of the stem cells with a virus 
expressing E4bp4 (Ning et al., 2014). These E4bp4 expressing NK cells were more cytotoxic 
than NK cells produced with just cytokines and ‘feeder layer’ stromal cells and they 
significantly delayed tumour progression when injected into nude mice with induced prostate 





or breast cancer (Ning et al., 2014). The manipulation of E4bp4 expression levels is likely to 
have an important role in producing future NK cell immunotherapeutic products. Influencing 
the PTMs of E4bp4, for example through the use of a specific kinase inhibitors, could be the 
simplest and most effective way to help boost the development of large numbers of highly 
cytotoxic NK cells. 
 
To determine if the activity of E4bp4 and its PTMs are important for the production of human 
NK cells, the Brady laboratory has established a human NK cell development assay, based 
on the work of the Saudemont laboratory (Anthony Nolan Institute, London) (Luevano et al., 
2014), to allow genes of interest to be ectopically expressed in developing human NK cells. 
Using an in vitro culture system NK cells can be produced from UBC CD34+ progenitor cells 
and a lentiviral expression vector can be used to stably and efficiently transduce them with a 
cDNA of interest (Figure 6.1). The pCSGW lentiviral vector has been adapted to drive 
expression of a gene of interest linked to an IRES sequence upstream of a cDNA for the 
tandem Tomato Red fluorescent protein. Following transduction of CD34+ cells and 
subsequent culture, more than 70% of cells were stably transduced and more than 20% 
were CD56+ mature human NK cells (Figure 6.1). Future studies should involve the 
transduction of these cells with genes of interest, in particular E4bp4 and E4bp4 mutants 
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This analysis may also reveal other dysfunctional mutations that are carried in their E4bp4 
alleles. E4bp4-/- mice have almost no detectable cNK cells, but strikingly the E4bp4+/- mice 
have almost exactly half the number of NK cells of a WT mouse (Gascoyne et al., 2009). As 
the heterozygote mice display haploinsufficiency for NK cell production, it would be 
interesting if SNP analysis could identify E4bp4 heterozygote humans, who have a 
dysfunctional mutation in one of their E4bp4 alleles. Analysis of the NK cell populations and 
wider immune system of these individuals may demonstrate they have a similar phenotype 
to the heterozygote mice. An initial cohort of 38 blood samples has been acquired and 
analysis of the peripheral blood NK cell numbers showed the large variability in the number 
of NK cells in each person (Figure 6.2). The percentage of NK cells of all the lymphocytes in 
the blood varied greaterly from 3 – 20% (Figure 6.2). Age and acute or chronic viral infection 
are known to influence the numbers of peripheral blood NK cells populations in vivo (Zhang 
et al., 2007). However, E4bp4 expression and the presence of mutations in E4bp4 alleles 
may also contribute to this high level of variablity in human NK cell populations, which could 
have implications for human health. 
 
The 1000 Genomes Project (Genomes Project et al., 2010) and the NHLBI Exome 
Sequencing Project (Tennessen et al 2012) have provided unprecedented resources for 
studying the genetic variation of human genes and the data from these projects contains 
information on the variability of the E4bp4 gene. To date, 43 missense variants, two frame 
shift variants and three stop gain variants have been identified in the E4bp4 ORF. The data 
showed that 13 missense variants may damage the structure and/or function of the E4bp4 
protein, meaning an individual with any of these mutations could effectively be E4bp4 
heterozygous. Most interestingly a SNP was identified that caused a mutation is serine 286, 
changing it to a phenylalanine. The results presented in Chapter 4 demonstrate that this 
residue is phosphorylated and is important for NK cell development. If individuals carrying 
this polymorphism could be identified, then analysis of their NK cell populations and wider 
immune system would be of great interest. However, the NHLBI Exome Sequencing 
database states that this polymorphism was only found in one individual of the 6500 
analysed (Exome Variant Server, NHLBI GO Exome Sequencing Project, Seattle, WA (URL: 














Figure 6.2 – Variations in the number of NK cells in human peripheral blood 
Blood donated by 38 healthy volunteers was analysed by flow cytometry for the presence of human NK cells 
(CD3- CD19- CD16+ CD56bright/dim). The absolute number of NK cells was quantified and compared to the overall 




6.4 E4bp4 SUMOylation and infection 
Some intracellular pathogens influence SUMOylation of host cells during infection (Fritah et 
al., 2014) (Ribet et al., 2010). Listeria monocytogenes produces the virulence factor, 
Listeriolysin O (LLO), which attacks the Ubc9 enzyme central to the SUMOylation pathway in 
all cells (Ribet et al., 2010). By targeting this enzyme L. monocytogenes can use the LLO 
toxin to simultaneously modify the activity of many proteins within a host cell, which may 
help to dampen host immune responses (Ribet et al., 2010). NK cells and other innate 
lymphoid cells are important for controlling L. monocytogenes infections (Naper et al., 2011), 
however these cells can become sites of infection and may also serve as reservoirs for L. 
monocytogenes growth (McElroy et al., 2009). As E4bp4 is a prominent molecule for the 
function of NK cells, it is possible that it is targeted by L. monocytogenes and LLO as part of 
the mechanism of infection. 
 
In an attempt to establish whether LLO affected E4bp4, 6His-SUMO2 HeLa cells were 
transfected and exposed to purified LLO (Figure 6.3). LLO clearly affected the SUMOylation 
of E4bp4 in the 6His-SUMO2 cells (Figure 6.3). The global SUMO2 level within these cells 
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6.5 Interactions between E4bp4 PTMs 
Both SUMOylation and phosphorylation function to repress the transcriptional activity of 
E4bp4 as the protein is more active once these modifications are removed. E4bp4 is crucial 
for many biological processes; therefore, it is important that its function is tightly regulated by 
multiple mechanisms because aberrant activity could have damaging consequences. As the 
phenotypes observed for the phosphorylation and SUMOylation site mutants were so similar 
this suggests that the two PTMs may work together to regulate the activity of E4bp4.  
 
Some studies suggest that some PTMs occur progressively; SUMOylation can affect 
acetylation (Wu and Chiang, 2009), SUMOylation can lead to ubiquitination (Guo et al., 
2012) and phosphorylation may increase (or decrease) levels of SUMOylation (Mohideen et 
al., 2009) (Hietakangas et al., 2006). Other reports have demonstrated how PTMs function 
reciprocally to promote specific functions of a TF. This was observed by Zhang et al. who 
found that phosphorylation and SUMOylation act to reduce the activities of Bcl11b and 
prevent it from binding to target DNA sites (Zhang et al., 2012). The interplay between 
E4bp4’s PTMs is yet to be explored in detail, but the S286-353A mutant expressed in the 
MNK-1 cells was observed to have the same SUMO modifications as WT E4bp4, suggesting 
that phosphorylation does not influence SUMOylation. MS experiments involving various 
E4bp4 PTM mutants will reveal if the absence of a particular modification impacts on the 
presence of another. Additionally, in vitro sequential modification assays can also be used to 
help reveal if some modifications are dependent on others. 
 
Further MS analysis will also establish if E4bp4 has other PTMs such as acetylation, 
methylation or glycosylation, which may also be important for regulating its activity. 
Knowledge of the three-dimensional structure of E4bp4 would supplement this study and is 













This study has demonstrated that SUMOylation and phosphorylation both control the 
transcriptional activity of E4bp4 and its function during NK cell development. In the absence 
of these modifications the transcriptional activation and repression of target genes by E4bp4 
was significantly increased and this heightened functional activity caused greater levels of 
NK cell production, compared to WT E4bp4. Determining what signals influence these 
modifications in vivo, should now be ascertained as this may provide a simple mechanism by 
which the activity of E4bp4 can be modulated. The findings of this study have immediate 
application in the production of human NK cells for use in various forms of immunotherapy. 
Modulation of E4bp4 activity in developing human NK cells may prove to be a key tool in 
producing large numbers of highly cytotoxic cells to treat patients with various malignancies 
and viral infections. 
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